BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 992] [Article Influence: 194.3] [Reference Citation Analysis]
Number Citing Articles
1 Gu L, Li S, He Y, Chen Y, Jiang Y, Peng Y, Liu X, Yang H. Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line Helicobacter pylori therapy in clinical practice: A pilot study. Helicobacter 2019. [DOI: 10.1111/hel.12594] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Tucker RM, Augustin AD, Hayee BH, Bjarnason I, Taylor D, Weller C, Charlett A, Dobbs SM, Dobbs RJ. Role of Helicobacters in Neuropsychiatric Disease: A Systematic Review in Idiopathic Parkinsonism. J Clin Med 2020;9:E2159. [PMID: 32650535 DOI: 10.3390/jcm9072159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Zhou A, Li L, Zhao G, Min L, Liu S, Zhu S, Guo Q, Liu C, Zhang S, Li P. Vitamin D3 Inhibits Helicobacter pylori Infection by Activating the VitD3/VDR-CAMP Pathway in Mice. Front Cell Infect Microbiol 2020;10:566730. [PMID: 33194806 DOI: 10.3389/fcimb.2020.566730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Doorakkers E, Lagergren J, Gajulapuri VK, Callens S, Engstrand L, Brusselaers N. Helicobacter pylori eradication in the Swedish population. Scandinavian Journal of Gastroenterology 2017;52:678-85. [DOI: 10.1080/00365521.2017.1303844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
5 Choi YI, Jeong SH, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, So S, Lee JH, Jeong JY, Lee SM. Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-Resistant H. pylori in Korea. Can J Infect Dis Med Microbiol. 2019;2019:9351801. [PMID: 31360270 DOI: 10.1155/2019/9351801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
6 Ortigão R, Pimentel-Nunes P, Dinis-Ribeiro M, Libânio D. Gastrointestinal Microbiome - What We Need to Know in Clinical Practice. GE Port J Gastroenterol 2020;27:336-51. [PMID: 32999906 DOI: 10.1159/000505036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ji Y, Liang X, Lu H. Analysis of by high-throughput sequencing: Helicobacter pylori infection and salivary microbiome. BMC Oral Health 2020;20:84. [PMID: 32197614 DOI: 10.1186/s12903-020-01070-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 Chey WD, Howden CW, Leontiadis GI. Clarifying the Houston Consensus on Helicobacter pylori. Clin Gastroenterol Hepatol 2018;16:2003-4. [PMID: 30454936 DOI: 10.1016/j.cgh.2018.07.024] [Reference Citation Analysis]
9 Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [DOI: 10.1111/apt.14597] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
10 Guo CG, Jiang F, Cheung KS, Li B, Ooi PH, Leung WK. Timing of prior exposure to antibiotics and failure of Helicobacter pylori eradication: a population-based study. J Antimicrob Chemother 2021:dkab415. [PMID: 34791274 DOI: 10.1093/jac/dkab415] [Reference Citation Analysis]
11 Byambajav TO, Bira N, Choijamts G, Davaadorj D, Gantuya B, Sarantuya T, Sarantuya G, Enkhtsetseg A, Erdenetsogt D, Battulga A, Tserentogtokh T, Matsuhisa T, Yamaoka Y, Oyuntsetseg K. Initial Trials With Susceptibility-Based and Empiric Anti-H. pylori Therapies in Mongolia. Front Pharmacol 2019;10:394. [PMID: 31040783 DOI: 10.3389/fphar.2019.00394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Saranathan R, Levi MH, Wattam AR, Malek A, Asare E, Behin DS, Pan DH, Jacobs WR Jr, Szymczak WA. Helicobacter pylori Infections in the Bronx, New York: Surveying Antibiotic Susceptibility and Strain Lineage by Whole-Genome Sequencing. J Clin Microbiol 2020;58:e01591-19. [PMID: 31801839 DOI: 10.1128/JCM.01591-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, Levi Z, Boltin D. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34114673 DOI: 10.1111/jgh.15575] [Reference Citation Analysis]
14 Arévalo A, Otero WA, Trespalacios AA. Helicobacter pylori: Multiple resistance in patients from Bogotá, Colombia. Biomedica 2019;39:125-34. [PMID: 31529855 DOI: 10.7705/biomedica.v39i3.4437] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Shuto M, Fujioka T, Matsunari O, Okamoto K, Mizukami K, Okimoto T, Kodama M, Takigami S, Seguchi C, Nonaka Y, Sato R, Yamaoka Y, Murakami K. Association between Gastric Cancer Risk and Serum Helicobacter pylori Antibody Titers. Gastroenterol Res Pract 2017;2017:1286198. [PMID: 28690637 DOI: 10.1155/2017/1286198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
16 Atilgan CU, Kosekahya P, Yozgat A, Sen E, Berker N, Caglayan M, Sendul SY, Altiparmak E, Yilmazbas P. Are optic nerve heads of patients with helicobacter pylori infection more susceptible to glaucomatous damage? Helicobacter 2017;22:e12443. [DOI: 10.1111/hel.12443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
17 Robotis J, Tsiodras S, Rokkas T. Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma. Helicobacter 2018;23:e12499. [PMID: 29897650 DOI: 10.1111/hel.12499] [Reference Citation Analysis]
18 Guo C, Cheung KS, Zhang F, Chan EW, Chen L, Wong IC, Leung WK. Incidences, temporal trends and risks of hospitalisation for gastrointestinal bleeding in new or chronic low-dose aspirin users after treatment for Helicobacter pylori : a territory-wide cohort study. Gut 2020;69:445-52. [DOI: 10.1136/gutjnl-2019-318352] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
19 Savarino V, Tosetti C, Benedetto E, Compare D, Nardone G. Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) - Study section "Digestive Diseases in Primary Care". Dig Liver Dis 2018;50:894-902. [PMID: 30093304 DOI: 10.1016/j.dld.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
20 Boltin D, Levi Z, Perets TT, Schmilovitz-Weiss H, Gingold-Belfer R, Dickman R, Dotan I. Correlation between Quantitative 13C-Urea Breath Test and Helicobacter pylori Treatment Success in a Population-Based Cohort. Gastroenterol Res Pract 2018;2018:5439539. [PMID: 30538739 DOI: 10.1155/2018/5439539] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Alihosseini S, Ghotaslou R, Heravi FS, Ahmadian Z, Leylabadlo HE. Management of antibiotic-resistant Helicobacter pylori infection: current perspective in Iran. J Chemother 2020;32:273-85. [PMID: 32657237 DOI: 10.1080/1120009X.2020.1790889] [Reference Citation Analysis]
22 Kim SY, Lee SW, Choe JW, Jung SW, Hyun JJ, Jung YK, Koo JS, Yim HJ. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017;22. [PMID: 28940815 DOI: 10.1111/hel.12441] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
23 Huh CW, Kim B. Diagnosis of Helicobacter pylori Infection. Korean J Gastroenterol 2018;72:229. [DOI: 10.4166/kjg.2018.72.5.229] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021;160:1831-41. [PMID: 33524402 DOI: 10.1053/j.gastro.2020.11.059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
25 Butorova LI, Ardatskaya MD, Osadchuk MA, Kadnikova NG, Lukianova EI, Plavnik RG, Sayutina EV, Topchiy TB, Tuayeva EM. [Comparison of clinical-metabolic efficacy of pre- and probiotics in the conducted optimized protocols of eradication therapy of Helicobacter pylori infection]. Ter Arkh 2020;92:64-9. [PMID: 32598700 DOI: 10.26442/00403660.2020.04.000647] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Chen MJ, Chen CC, Chen YN, Fang YJ, Lin JT, Wu MS, Liou JM;  Taiwan Gastrointestinal Disease Helicobacter Consortium. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2018;113:1444-1457. [PMID: 30171216 DOI: 10.1038/s41395-018-0217-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
27 Bordin DS, Voynovan IN, Andreev DN, Maev IV. Current Helicobacter pylori Diagnostics. Diagnostics (Basel) 2021;11:1458. [PMID: 34441392 DOI: 10.3390/diagnostics11081458] [Reference Citation Analysis]
28 Ponzetto A, Figura N, Ciancio A. Containing the Costs of Recurrent Gastro-Duodenal Ulcer Bleeding. Dig Dis 2018;36:269. [PMID: 29791892 DOI: 10.1159/000488874] [Reference Citation Analysis]
29 Na'amnih W, Ben Tov A, Bdair-Amsha A, Cohen S, Tsamir J, Chodick G, Muhsen K. Physicians' adherence to management guidelines for H. pylori infection and gastroesophageal reflux disease: a cross-sectional study. Isr J Health Policy Res 2020;9:28. [PMID: 32527326 DOI: 10.1186/s13584-020-00389-y] [Reference Citation Analysis]
30 Zarzecka U, Matkowska D, Backert S, Skorko-Glonek J. Importance of two PDZ domains for the proteolytic and chaperone activities of Helicobacter pylori serine protease HtrA. Cell Microbiol 2021;23:e13299. [PMID: 33277762 DOI: 10.1111/cmi.13299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Tuan VP, Narith D, Tshibangu-Kabamba E, Dung HDQ, Viet PT, Sokomoth S, Binh TT, Sokhem S, Tri TD, Ngov S, Tung PH, Thuan NPM, Truc TC, Phuc BH, Matsumoto T, Fauzia KA, Akada J, Trang TTH, Yamaoka Y. A Next-Generation Sequencing-Based Approach to Identify Genetic Determinants of Antibiotic Resistance in Cambodian Helicobacter pylori Clinical Isolates. J Clin Med 2019;8:E858. [PMID: 31208076 DOI: 10.3390/jcm8060858] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
32 Alhalabi M, Alassi MW, Alaa Eddin K, Cheha K. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial. BMC Infect Dis 2021;21:642. [PMID: 34218802 DOI: 10.1186/s12879-021-06356-5] [Reference Citation Analysis]
33 Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: Current status and rational treatment options. North Clin Istanb 2020;7:87-94. [PMID: 32232212 DOI: 10.14744/nci.2019.62558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
34 Ozturk A. Periodontal Treatment Is Associated With Improvement in Gastric Helicobacter pylori Eradication: An Updated Meta-analysis of Clinical Trials. Int Dent J 2021;71:188-96. [PMID: 34024329 DOI: 10.1111/idj.12616] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kim BJ, Yang CH, Song HJ, Jeon SW, Kim GH, Kim HS, Kim TH, Shim KN, Chung IK, Park MI, Choi IJ, Kim JH, Kim BW, Baik GH, Han SW, Seo HE, Jung WT, Hwan Oh J, Kim SG, Lee JH, Park SK, Park BJ, Yang BR, Lee J, Kim JG. Online registry for nationwide database of Helicobacter pylori eradication in Korea: Correlation of antibiotic use density with eradication success. Helicobacter. 2019;24:e12646. [PMID: 31368629 DOI: 10.1111/hel.12646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
36 Shah T, Baloch Z, Shah Z, Cui X, Xia X. The Intestinal Microbiota: Impacts of Antibiotics Therapy, Colonization Resistance, and Diseases. Int J Mol Sci 2021;22:6597. [PMID: 34202945 DOI: 10.3390/ijms22126597] [Reference Citation Analysis]
37 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Reference Citation Analysis]
38 Budzyński J. Helicobacter pylori eradication: Not only early consequences. EBioMedicine 2018;35:8-9. [PMID: 30174279 DOI: 10.1016/j.ebiom.2018.08.051] [Reference Citation Analysis]
39 Arenas A, Serrano C, Quiñones L, Harris P, Sandoval M, Lavanderos M, Sepúlveda R, Maquilón S, Echeverría A, Ríos C, Fuentes-López E, Rojas L, Jorquera A, Pizarro M, Camargo MC, Riquelme A. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Sci Rep 2019;9:20070. [PMID: 31882676 DOI: 10.1038/s41598-019-56399-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
40 Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS;  Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19:1109-1120. [PMID: 31559966 DOI: 10.1016/s1473-3099(19)30272-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 21.5] [Reference Citation Analysis]
41 Sebastián Domingo JJ. Inhibidores de la bomba de protones y carcinogénesis gástrica. Medicina Clínica 2018;151:400-1. [DOI: 10.1016/j.medcli.2018.03.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Hirata Y, Yamada A, Niikura R, Shichijo S, Hayakawa Y, Koike K. Efficacy and safety of a new rifabutin‐based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single‐arm study. Helicobacter 2020;25. [DOI: 10.1111/hel.12719] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
43 Argueta EA, Moss SF. Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment. Aliment Pharmacol Ther 2019;50:331-2. [DOI: 10.1111/apt.15302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
44 Depoorter L, Vandenplas Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients 2021;13:2176. [PMID: 34202742 DOI: 10.3390/nu13072176] [Reference Citation Analysis]
45 Goldenring JR. The AGA/Funderburg Award in Gastric Cancer: Twenty-five Years of Advances in Gastric Cancer Research. Gastroenterology 2017;152:1262-6. [PMID: 28327368 DOI: 10.1053/j.gastro.2017.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Krzyżek P, Biernat MM, Gościniak G. Intensive formation of coccoid forms as a feature strongly associated with highly pathogenic Helicobacter pylori strains. Folia Microbiol (Praha) 2019;64:273-81. [PMID: 30449016 DOI: 10.1007/s12223-018-0665-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
47 Jehanne Q, Bénéjat L, Mégraud F, Bessède E, Lehours P. Evaluation of the Allplex™ H pylori and ClariR PCR Assay for Helicobacter pylori detection on gastric biopsies. Helicobacter 2020;25:e12702. [PMID: 32426894 DOI: 10.1111/hel.12702] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
48 Barchi A, Miraglia C, Violi A, Cambiè G, Nouvenne A, Capasso M, Leandro G, Meschi T, De' Angelis GL, Di Mario F. A non-invasive method for the diagnosis of upper GI diseases. Acta Biomed 2018;89:40-3. [PMID: 30561417 DOI: 10.23750/abm.v89i8-S.7917] [Reference Citation Analysis]
49 Parra-Sepúlveda C, Merino JS, Sáez-Carrillo K, González C, García-Cancino A. ANTIBIOTIC RESISTANCE SURVEILLANCE OF HELICOBACTER PYLORI AT THE BIOBÍO REGION (CHILE) IN A DECADE. Arq Gastroenterol 2019;56:361-6. [PMID: 31721972 DOI: 10.1590/S0004-2803.201900000-72] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Ierardi E, Losurdo G, Fortezza RFL, Principi M, Barone M, Leo AD. Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness. World J Gastroenterol 2019; 25(34): 5097-5104 [PMID: 31558859 DOI: 10.3748/wjg.v25.i34.5097] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
51 Nicholson BD, Abel LM, Turner PJ, Price CP, Heneghan C, Hayward G, Plüddemann A. Point-of-care Helicobacter pylori testing: primary care technology update. Br J Gen Pract 2017;67:576-7. [PMID: 29192118 DOI: 10.3399/bjgp17X693881] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
52 Coumes S, Froissart B, Wion N, Reche F, Arvieux C, Borel AL. Prevalence and Factors Associated with Helicobacter Pylori in Patients Undergoing Bariatric Surgery: the SOON Cohort. Obes Surg 2018;28:3958-64. [PMID: 30076561 DOI: 10.1007/s11695-018-3440-4] [Reference Citation Analysis]
53 Kamboj AK, Cotter TG, Oxentenko AS. Helicobacter pylori. Mayo Clinic Proceedings 2017;92:599-604. [DOI: 10.1016/j.mayocp.2016.11.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
54 Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
55 Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter 2019;24:e12584. [PMID: 30990575 DOI: 10.1111/hel.12584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
56 Hu Y, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Front Cell Infect Microbiol 2017;7:168. [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
57 Tursi A, Di Mario F, Franceschi M, De Bastiani R, Elisei W, Baldassarre G, Ferronato A, Grillo S, Landi S, Zamparella M, De Polo M, Boscariolo L, Picchio M. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori : A first Italian experience in clinical practice. Helicobacter 2017;22:e12371. [DOI: 10.1111/hel.12371] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
58 Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori Infection in Geriatric Patients: Current Situation and Treatment Regimens. Front Med (Lausanne) 2021;8:713908. [PMID: 34660627 DOI: 10.3389/fmed.2021.713908] [Reference Citation Analysis]
59 Chen L, He J, Wang L, Ge Q, Chu H, Chen Y, Chen X, Long Y, Deng Y, He H, Li A, Chen S. Efficacies of different proton pump inhibitor-based 14-day bismuth–furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clin Exp Med 2018;18:569-76. [DOI: 10.1007/s10238-018-0510-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
60 Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Lanas A, Dumonceau JM, Hunt RH, Fujishiro M, Scheiman JM, Gralnek IM, Campbell HE, Rostom A, Villanueva C, Sung JJY. Non-variceal upper gastrointestinal bleeding. Nat Rev Dis Primers 2018;4:18020. [PMID: 29671413 DOI: 10.1038/nrdp.2018.20] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
62 Mcnicholl AG, Amador J, Ricote M, Cañones‐garzón PJ, Gene E, Calvet X, Gisbert JP; the Spanish Primary Care Societies SEMFyC, SEMERGEN and SEMG, the Spanish Association of Gastroenterology, the OPTICARE Long‐Term Educational Project. Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions. Helicobacter 2019. [DOI: 10.1111/hel.12593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
63 Ignatius R, Berg C, Weiland C, Darmer A, Wenzel T, Lorenz M, Fuhrmann J, Müller M. Accurate Detection of Helicobacter pylori Antigen in Human Stool Specimens by Two Novel Immunoassays. Eur J Microbiol Immunol (Bp) 2019;9:29-31. [PMID: 31223492 DOI: 10.1556/1886.2019.00008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
64 Niu ZY, Li SZ, Shi YY, Xue Y. Effect of gastric microbiota on quadruple Helicobacter pylori eradication therapy containing bismuth. World J Gastroenterol 2021; 27(25): 3913-3924 [PMID: 34321854 DOI: 10.3748/wjg.v27.i25.3913] [Reference Citation Analysis]
65 Lee JW, Kim SJ, Choi CW, Kim HJ, Kang DH, Kim HW, Park SB, Nam HS, Ryu DG. Seven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation. Medicine (Baltimore) 2021;100:e26133. [PMID: 34032763 DOI: 10.1097/MD.0000000000026133] [Reference Citation Analysis]
66 Zhang L, Lan Y, Wang Q, Zhang Y, Si X. Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori. Gastroenterol Res Pract 2019;2019:9251879. [PMID: 31933634 DOI: 10.1155/2019/9251879] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
67 Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, Furnari M, Marabotto E, Plaz Torres MC, Zentilin P, Savarino V. Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Dig Liver Dis 2020;52:862-8. [PMID: 32505566 DOI: 10.1016/j.dld.2020.05.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Cheng Y, Kou F, Liu J, Dai Y, Li X, Li J. Systematic assessment of environmental factors for gastroesophageal reflux disease: An umbrella review of systematic reviews and meta-analyses. Dig Liver Dis 2021;53:566-73. [PMID: 33339748 DOI: 10.1016/j.dld.2020.11.022] [Reference Citation Analysis]
69 Miendje Deyi VY, Lare MS, Burette A, Ntounda R, Elkilic O, Cadranel S, Bontems P, Hallin M. Update of primary Helicobacter pylori resistance to antimicrobials in Brussels, Belgium. Diagnostic Microbiology and Infectious Disease 2019;95:114875. [DOI: 10.1016/j.diagmicrobio.2019.114875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
70 Öztürk K, Kurt Ö, Çelebi G, Şarlak H, Karakaya MF, Demirci H, Kılınç A, Uygun A. High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection. Turk J Gastroenterol 2020;31:234-8. [PMID: 32343235 DOI: 10.5152/tjg.2020.18974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
71 Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354-361. [PMID: 29138921 DOI: 10.1007/s00535-017-1407-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 12.2] [Reference Citation Analysis]
72 Marrero Rolon R, Cunningham SA, Mandrekar JN, Polo ET, Patel R. Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool. J Clin Microbiol 2021;59:e03040-20. [PMID: 33536295 DOI: 10.1128/JCM.03040-20] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Losurdo G, Giorgio F, Pricci M, Girardi B, Russo F, Riezzo G, Martulli M, Piazzolla M, Cocomazzi F, Abbruzzi F, Parente E, Paolillo R, Mileti A, Iannone A, Principi M, Ierardi E, Leo AD. Helicobacter pylori Primary and Secondary Genotypic Resistance to Clarithromycin and Levofloxacin Detection in Stools: A 4-Year Scenario in Southern Italy. Antibiotics (Basel) 2020;9:E723. [PMID: 33096925 DOI: 10.3390/antibiotics9100723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
74 Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2020;7:CD005583. [PMID: 32628791 DOI: 10.1002/14651858.CD005583.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
75 Toyoshima O, Nishizawa T, Sakitani K, Yamakawa T, Takahashi Y, Yamamichi N, Hata K, Seto Y, Koike K, Watanabe H, Suzuki H. Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age: A cross-sectional study. World J Gastroenterol 2018; 24(35): 4061-4068 [PMID: 30254410 DOI: 10.3748/wjg.v24.i35.4061] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
76 Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856 [PMID: 32921961 DOI: 10.3748/wjg.v26.i32.4846] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Salillas S, Galano-Frutos JJ, Mahía A, Maity R, Conde-Giménez M, Anoz-Carbonell E, Berlamont H, Velazquez-Campoy A, Touati E, Mamat U, Schaible UE, Gálvez JA, Díaz-de-Villegas MD, Haesebrouck F, Aínsa JA, Sancho J. Selective Targeting of Human and Animal Pathogens of the Helicobacter Genus by Flavodoxin Inhibitors: Efficacy, Synergy, Resistance and Mechanistic Studies. Int J Mol Sci 2021;22:10137. [PMID: 34576300 DOI: 10.3390/ijms221810137] [Reference Citation Analysis]
78 Cho JH, Jeon SR, Jin SY, Park S. Analysis of factors associated with recovery of the serum pepsinogen ratio after Helicobacter pylori eradication: a long-term follow-up study in Korea. Scand J Gastroenterol 2019;54:1306-14. [PMID: 31702966 DOI: 10.1080/00365521.2019.1686058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
79 Cosme A, Montes M, Ibarra B, Tamayo E, Alonso H, Mendarte U, Lizasoan J, Herreros-Villanueva M, Bujanda L. Antimicrobial susceptibility testing before first-line treatment for Helicobacter pylori infection in patients with dual or triple antibiotic resistance. World J Gastroenterol 2017; 23(18): 3367-3373 [PMID: 28566898 DOI: 10.3748/wjg.v23.i18.3367] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
80 Sugimoto M, Yasuda H, Andoh A. Nutrition status and Helicobacter pylori infection in patients receiving hemodialysis. World J Gastroenterol 2018; 24(15): 1591-1600 [PMID: 29686466 DOI: 10.3748/wjg.v24.i15.1591] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
81 Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Toward population specific and personalized treatment of Helicobacter pylori infection. J Biomed Sci 2018;25:70. [PMID: 30285834 DOI: 10.1186/s12929-018-0471-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
82 Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017; 23(16): 2854-2869 [PMID: 28522904 DOI: 10.3748/wjg.v23.i16.2854] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
83 Su DJ, Chang MH, Yang JC, Ni YH, Hsu HY, Wu JF. Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. J Formos Med Assoc 2021:S0929-6646(21)00106-6. [PMID: 33745813 DOI: 10.1016/j.jfma.2021.03.001] [Reference Citation Analysis]
84 Morilla A, Melón S, Álvarez-Argüelles ME, Armesto E, Villar H, de Oña M. Utility of normalized genome quantification of Helicobacter pylori in gastric mucosa using an in-house real-time polymerase chain reaction. PLoS One 2017;12:e0178674. [PMID: 28575047 DOI: 10.1371/journal.pone.0178674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
85 Calvet X. Dealing with uncertainty in the treatment of Helicobacter pylori. Ther Adv Chronic Dis 2018;9:93-102. [PMID: 29623181 DOI: 10.1177/2040622318758240] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
86 Marchesi F, Tartamella F, De Sario G, Forlini C, Caleffi A, Riccò M, Di Mario F. The Sleeping Remnant. Effect of Roux-En-Y Gastric Bypass on Plasma Levels of Gastric Biomarkers in Morbidly Obese Women: A Prospective Longitudinal Study. Obes Surg 2017;27:1901-5. [PMID: 28508274 DOI: 10.1007/s11695-017-2724-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
87 Katsurahara M, Imoto I, Umeda Y, Miura H, Tsuboi J, Yamada R, Yasuma T, Nakamura M, Hamada Y, Inoue H, Tanaka K, Horiki N, Gabazza EC, Takei Y. Increased Reflux Esophagitis after Helicobacter pylori Eradication Therapy in Cases Undergoing Endoscopic Submucosal Dissection for Early Gastric Cancer. Cancers (Basel) 2021;13:1779. [PMID: 33917861 DOI: 10.3390/cancers13081779] [Reference Citation Analysis]
88 Iannone A, Giorgio F, Russo F, Riezzo G, Girardi B, Pricci M, Palmer SC, Barone M, Principi M, Strippoli GF, Di Leo A, Ierardi E. New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study. World J Gastroenterol 2018; 24(27): 3021-3029 [PMID: 30038469 DOI: 10.3748/wjg.v24.i27.3021] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
89 Lim H, Bang CS, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ. Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial. Medicine (Baltimore) 2018;97:e13245. [PMID: 30431605 DOI: 10.1097/MD.0000000000013245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Li H, Tang H, Debowski AW, Stubbs KA, Marshall BJ, Benghezal M. Lipopolysaccharide Structural Differences between Western and Asian Helicobacter pylori Strains. Toxins (Basel) 2018;10:E364. [PMID: 30205541 DOI: 10.3390/toxins10090364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
91 Xiao FK, Yang JX, Li XM, Zhao XK, Zheng PY, Wang LD. Interaction of 22 risk SNPs with Helicobacter pylori infection and risk of gastric cardia adenocarcinoma. Future Oncol. 2019;15:3579-3585. [PMID: 31650851 DOI: 10.2217/fon-2019-0319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
92 Song C, Xie C, Zhu Y, Liu W, Zhang G, He S, Zheng P, Lan C, Zhang Z, Hu R, Du Q, Xu J, Chen Y, Zeng Z, Cheng H, Wang X, Zuo X, Lu H, Guo T, Chen Z, Xie Y, Lu N. Management of Helicobacter pylori infection by clinicians: A nationwide survey in a developing country. Helicobacter 2019;24:e12656. [PMID: 31571330 DOI: 10.1111/hel.12656] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
93 Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, Kanno T, Sugimoto M, Chiba T, Nomura S, Mieda M, Hiraishi H, Yoshino J, Takagi A, Watanabe S, Koike K. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol 2021;56:303-22. [PMID: 33620586 DOI: 10.1007/s00535-021-01769-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
94 Cho JH, Jin SY, Park S. Comparison of tailored Helicobacter pylori eradication versus modified bismuth quadruple therapy in Korea: a randomized controlled trial. Expert Rev Anti Infect Ther 2021;:1-7. [PMID: 34883037 DOI: 10.1080/14787210.2022.2017280] [Reference Citation Analysis]
95 Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol 2020;7:e000472. [PMID: 32883715 DOI: 10.1136/bmjgast-2020-000472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Kountouras J, Doulberis M, Papaefthymiou A, Polyzos SA, Vardaka E, Tzivras D, Dardiotis E, Deretzi G, Giartza‐taxidou E, Grigoriadis S, Katsinelos P. A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection. Ann N Y Acad Sci 2019;1452:12-7. [DOI: 10.1111/nyas.14168] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
97 Miftahussurur M, Aftab H, Shrestha PK, Sharma RP, Subsomwong P, Waskito LA, Doohan D, Fauzia KA, Yamaoka Y. Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. Antimicrob Resist Infect Control 2019;8:40. [PMID: 30815255 DOI: 10.1186/s13756-019-0482-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
98 Luu MN, Quach DT, Hiyama T. Screening and surveillance for gastric cancer: Does family history play an important role in shaping our strategy? Asia Pac J Clin Oncol 2021. [PMID: 34811928 DOI: 10.1111/ajco.13704] [Reference Citation Analysis]
99 Siupsinskiene N, Katutiene I, Jonikiene V, Janciauskas D, Vaitkus S. Intranasal Helicobacter pylori infection in patients with chronic rhinosinusitis with polyposis. J Laryngol Otol 2018;132:816-21. [DOI: 10.1017/s0022215118001299] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Kumar S, Metz DC, Kaplan DE, Goldberg DS. Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection. Am J Gastroenterol 2020;115:716-22. [PMID: 32356953 DOI: 10.14309/ajg.0000000000000626] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Cha B, Bang BW, Shin JB, Ko EJ, Ko W, Kwon KS, Shin YW, Suh YJ, Kim H. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area. Scand J Gastroenterol 2021;56:1017-22. [PMID: 34369255 DOI: 10.1080/00365521.2021.1948606] [Reference Citation Analysis]
102 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
103 Santos MLC, de Brito BB, da Silva FAF, Sampaio MM, Marques HS, Oliveira e Silva N, de Magalhães Queiroz DM, de Melo FF. Helicobacter pylori infection: Beyond gastric manifestations. World J Gastroenterol 2020; 26(28): 4076-4093 [PMID: 32821071 DOI: 10.3748/wjg.v26.i28.4076] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
104 Guillemard E, Poirel M, Schäfer F, Quinquis L, Rossoni C, Keicher C, Wagner F, Szajewska H, Barbut F, Derrien M, Malfertheiner P. A Randomised, Controlled Trial: Effect of a Multi-Strain Fermented Milk on the Gut Microbiota Recovery after Helicobacter pylori Therapy. Nutrients 2021;13:3171. [PMID: 34579049 DOI: 10.3390/nu13093171] [Reference Citation Analysis]
105 Hu Y, Ouyang Y, Zhu Y, Lu NH. Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Helicobacter 2021;26:e12784. [PMID: 33534148 DOI: 10.1111/hel.12784] [Reference Citation Analysis]
106 Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019-1026. [PMID: 31915235 DOI: 10.1136/gutjnl-2019-319954] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 16.0] [Reference Citation Analysis]
107 Megraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y; European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut 2021:gutjnl-2021-324032. [PMID: 33837118 DOI: 10.1136/gutjnl-2021-324032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
108 Auttajaroon J, Chotivitayatarakorn P, Yamaoka Y, Vilaichone RK. CYP2C19 Genotype, CagA Genotype and Antibiotic Resistant Strain of Helicobacter pylori Infection. Asian Pac J Cancer Prev 2019;20:1243-7. [PMID: 31030500 DOI: 10.31557/APJCP.2019.20.4.1243] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
109 Zullo A, Germanà B, Galliani E, Iori A, de Pretis G, Manfredi G, Buscarini E, Buonocore MR, Monica F. Optimizing the searching for H. pylori in clinical practice with EndoFaster. Dig Liver Dis 2021;53:772-5. [PMID: 33676857 DOI: 10.1016/j.dld.2021.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Guo C, Cheung KS, Zhang F, Chan EW, Chen L, Wong IC, Leung WK. Delay in Retreatment of Helicobacter pylori Infection Increases Risk of Upper Gastrointestinal Bleeding. Clinical Gastroenterology and Hepatology 2021;19:314-322.e2. [DOI: 10.1016/j.cgh.2020.03.071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
111 Mansour-Ghanaei F, Samadi A, Joukar F, Tirgar Fakheri H, Hassanipour S, Ashoobi MT, Soltanipour S, Alizadeh A, Rezamand G, Fathalipour M. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of Helicobacter pylori: a randomized, double-blind clinical trial. EXCLI J 2019;18:644-52. [PMID: 31611747 DOI: 10.17179/excli2019-1613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Vianna JS, Ramis IB, Ramos DF, Gastal OL, Silva RAD, Gonçalves CV, Silva PEAD. The interplay between mutations in cagA, 23S rRNA, gyrA and drug resistance in Helicobacter pylori. Rev Inst Med Trop Sao Paulo 2018;60:e25. [PMID: 29972462 DOI: 10.1590/s1678-9946201860025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
113 Kahramanoğlu Aksoy E, Pirinçci Sapmaz F, Göktaş Z, Uzman M, Nazlıgül Y. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Med Princ Pract 2017;26:523-9. [PMID: 29131124 DOI: 10.1159/000484930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
114 Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med 2019;8:E1498. [PMID: 31546909 DOI: 10.3390/jcm8091498] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
115 Magni A, Agostoni P, Bonezzi C, Massazza G, Menè P, Savarino V, Fornasari D. Management of Osteoarthritis: Expert Opinion on NSAIDs. Pain Ther 2021. [PMID: 33876393 DOI: 10.1007/s40122-021-00260-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
116 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
117 Zhao JB, Yuan L, Yu XC, Shao QQ, Ma J, Yu M, Wu Y, Qi YB, Hu RB, Wei PR, Jia BL, Zhang LZ, Zhang YR, Ding SZ. Whole family-based Helicobacter pylori eradication is a superior strategy to single-infected patient treatment approach: A systematic review and meta-analysis. Helicobacter 2021;26:e12793. [PMID: 33675089 DOI: 10.1111/hel.12793] [Reference Citation Analysis]
118 Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, Lee JH, Yang HJ, Cho YK, Bang CS, Kim BJ, Jung HK, Kim BW, Lee YC; Korean College of Helicobacter and Upper Gastrointestinal Research. [Clinical Guidelines for Drug-induced Peptic Ulcer, 2020 Revised Edition]. Korean J Gastroenterol 2020;76:108-33. [PMID: 32969360 DOI: 10.4166/kjg.2020.76.3.108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
119 O’morain N, O’morain C. The burden of digestive disease across Europe: Facts and policies. Digestive and Liver Disease 2019;51:1-3. [DOI: 10.1016/j.dld.2018.10.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Akar M, Aydın F, Kayman T, Abay S, Karakaya E. Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing? Turk J Med Sci 2021;51:1445-64. [PMID: 33631868 DOI: 10.3906/sag-2101-69] [Reference Citation Analysis]
121 Huang X, Sun X, Yu X, Qian H. WITHDRAWN: Efficacy and safety of Sijunzi decoction for peptic ulcers: a systematic review and meta-analysis. Journal of Traditional Chinese Medical Sciences 2018. [DOI: 10.1016/j.jtcms.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Mégraud F, Alix C, Charron P, Bénéjat L, Ducournau A, Bessède E, Lehours P. Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years. Helicobacter 2021;26:e12767. [PMID: 33090614 DOI: 10.1111/hel.12767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Hu Y, Zhu Y, Lu NH. Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci. 2017;62:1146-1154. [PMID: 28315035 DOI: 10.1007/s10620-017-4536-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
124 Feng ZH, Fan L, Yang J, Huo XY, Guo Y, Zhang Y, Lan CH. Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori. BMC Microbiol 2019;19:176. [PMID: 31382897 DOI: 10.1186/s12866-019-1558-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157:44-53. [PMID: 30998990 DOI: 10.1053/j.gastro.2019.04.011] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 30.0] [Reference Citation Analysis]
126 Domșa AT, Lupușoru R, Gheban D, Șerban R, Borzan CM. Helicobacter pylori Gastritis in Children-The Link between Endoscopy and Histology. J Clin Med 2020;9:E784. [PMID: 32183130 DOI: 10.3390/jcm9030784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Gudra D, Pupola D, Skenders G, Leja M, Radovica-Spalvina I, Gorskis H, Vangravs R, Fridmanis D. Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 years after a single eradication event. Helicobacter 2020;25:e12748. [PMID: 32776403 DOI: 10.1111/hel.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
128 Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM. Precision medicine in gastric cancer. World J Gastrointest Oncol 2019; 11(10): 804-829 [PMID: 31662821 DOI: 10.4251/wjgo.v11.i10.804] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 34] [Article Influence: 9.7] [Reference Citation Analysis]
129 Poonyam P, Chotivitayatarakorn P, Vilaichone RK. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev 2019;20:2859-64. [PMID: 31554388 DOI: 10.31557/APJCP.2019.20.9.2859] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
130 Lu HH, Lai FP, Lo HY, Sheu BS, Yang YJ. Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two decades. Helicobacter 2019;24:e12633. [PMID: 31295754 DOI: 10.1111/hel.12633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
131 Tran LTC, Gueutin C, Frebourg G, Burucoa C, Faivre V. Erythromycin encapsulation in nanoemulsion-based delivery systems for treatment of Helicobacter pylori infection: Protection and synergy. Biochem Biophys Res Commun 2017;493:146-51. [PMID: 28917836 DOI: 10.1016/j.bbrc.2017.09.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
132 Zhou Y, Ye Z, Wang Y, Zhang Y, Tang Z, Yan W, Jiang Y, Huang Y. Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children. Helicobacter 2020;25:e12679. [PMID: 31958193 DOI: 10.1111/hel.12679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
133 Oh JH, Kwon JG, Jung HK, Tae CH, Song KH, Kang SJ, Kim SE, Jung K, Kim JS, Park JK, Bang KB, Baeg MK, Shin JE, Shin CM, Lee JY, Lim HC; Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil 2020;26:29-50. [PMID: 31917913 DOI: 10.5056/jnm19209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
134 Xiang W, Wang R, Bai D, Yu T, Chen X; on behalf of the SIGES Research Groups. Helicobacter Pylori Related Gastric Cancer Screening and Cost-Effectiveness Analysis: A Hospital-Based Cross-Sectional Study (SIGES). Nutrition and Cancer. [DOI: 10.1080/01635581.2021.2022168] [Reference Citation Analysis]
135 Lee SW, Moon SJ, Kim SH, Jung SH, Song KH, Kim SM, Sung JK, Lee DS. The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori. Medicine (Baltimore) 2020;99:e22137. [PMID: 32957336 DOI: 10.1097/MD.0000000000022137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
136 Pouw RE, Barret M, Biermann K, Bisschops R, Czakó L, Gecse KB, de Hertogh G, Hucl T, Iacucci M, Jansen M, Rutter M, Savarino E, Spaander MCW, Schmidt PT, Vieth M, Dinis-Ribeiro M, van Hooft JE. Endoscopic tissue sampling - Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:1174-88. [PMID: 34535035 DOI: 10.1055/a-1611-5091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Raaf N, Amhis W, Saoula H, Abid A, Nakmouche M, Balamane A, Ali Arous N, Ouar-Korichi M, Vale FF, Bénéjat L, Mégraud F. Prevalence, antibiotic resistance, and MLST typing of Helicobacter pylori in Algiers, Algeria. Helicobacter 2017;22. [PMID: 29035009 DOI: 10.1111/hel.12446] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
138 Vasapolli R, Venerito M, Schirrmeister W, Thon C, Weigt J, Wex T, Malfertheiner P, Link A. Inflammatory microRNAs in gastric mucosa are modulated by Helicobacter pylori infection and proton-pump inhibitors but not by aspirin or NSAIDs. PLoS One 2021;16:e0249282. [PMID: 33857171 DOI: 10.1371/journal.pone.0249282] [Reference Citation Analysis]
139 Sholeh M, Maleki F, Krutova M, Bavari S, Golmoradi R, Sadeghifard N, Amiriani T, Kouhsari E. The increasing antimicrobial resistance of Helicobacter pylori in Iran: A systematic review and meta-analysis. Helicobacter 2020;25:e12730. [PMID: 32705749 DOI: 10.1111/hel.12730] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Boyanova L, Gergova G, Markovska R, Kandilarov N, Davidkov L, Spassova Z, Mitov I. Primary Helicobacter pylori resistance in elderly patients over 20 years: A Bulgarian study. Diagn Microbiol Infect Dis. 2017;88:264-267. [PMID: 28506722 DOI: 10.1016/j.diagmicrobio.2017.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
141 Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, Das R, Lu H, Lin JT, Tu YK. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:707-715. [PMID: 28781119 DOI: 10.1016/s2468-1253(17)30219-4] [Cited by in Crossref: 96] [Cited by in F6Publishing: 39] [Article Influence: 19.2] [Reference Citation Analysis]
142 Tergast TL, Wranke A, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B. Dose‐dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. Liver Int 2018;38:1602-13. [DOI: 10.1111/liv.13862] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
143 Varon C, Azzi-Martin L, Khalid S, Seeneevassen L, Ménard A, Spuul P. Helicobacters and cancer, not only gastric cancer? Semin Cancer Biol 2021:S1044-579X(21)00219-4. [PMID: 34425210 DOI: 10.1016/j.semcancer.2021.08.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice. Infect Drug Resist 2021;14:1239-46. [PMID: 33790594 DOI: 10.2147/IDR.S304711] [Reference Citation Analysis]
145 Yeh JY, Lin HJ, Kuo CJ, Feng CL, Chou CH, Lin CD, Wu HY, Li CY, Chiu CH, Lai CH. Campylobacter jejuni Cytolethal Distending Toxin C Exploits Lipid Rafts to Mitigate Helicobacter pylori-Induced Pathogenesis. Front Cell Dev Biol 2020;8:617419. [PMID: 33708766 DOI: 10.3389/fcell.2020.617419] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Mescoli C, Gallo Lopez A, Taxa Rojas L, Jove Oblitas W, Fassan M, Rugge M. Gastritis staging as a clinical priority. Eur J Gastroenterol Hepatol. 2018;30:125-129. [PMID: 29215433 DOI: 10.1097/meg.0000000000001015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Li H, Yang T, Tang H, Tang X, Shen Y, Benghezal M, Tay A, Marshall B. Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed. Precision Clinical Medicine 2019;2:77-80. [DOI: 10.1093/pcmedi/pbz009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
148 Hays C, Delerue T, Lamarque D, Burucoa C, Collobert G, Billöet A, Kalach N, Raymond J. Molecular diagnosis of Helicobacter pylori infection in gastric biopsies: Evaluation of the Amplidiag ®H. pylori  + ClariR assay. Helicobacter 2019;24:e12560. [DOI: 10.1111/hel.12560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
149 Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017;14:383-384. [PMID: 28465548 DOI: 10.1038/nrgastro.2017.57] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 12.4] [Reference Citation Analysis]
150 Zhao J, Zou Y, Li K, Huang X, Niu C, Wang Z, Zhao S, Zhang Y, Song C, Xie Y. Doxycycline and minocycline in Helicobacter pylori treatment: A systematic review and meta-analysis. Helicobacter 2021;:e12839. [PMID: 34318971 DOI: 10.1111/hel.12839] [Reference Citation Analysis]
151 Charitos IA, D’agostino D, Topi S, Bottalico L. 40 Years of Helicobacter pylori: A Revolution in Biomedical Thought. Gastroenterology Insights 2021;12:111-35. [DOI: 10.3390/gastroent12020011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
152 Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest. 2018;48. [PMID: 29144559 DOI: 10.1111/eci.12857] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
153 Perkovic N, Mestrovic A, Bozic J, Ivelja MP, Vukovic J, Kardum G, Sundov Z, Tonkic M, Puljiz Z, Vukojevic K, Tonkic A. Randomized Clinical Trial Comparing Concomitant and Tailored Therapy for Eradication of Helicobacter pylori Infection. J Pers Med 2021;11:534. [PMID: 34207870 DOI: 10.3390/jpm11060534] [Reference Citation Analysis]
154 Liu DS, Wang YH, Zhu ZH, Zhang SH, Zhu X, Wan JH, Lu NH, Xie Y. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations. Antimicrob Resist Infect Control 2019;8:192. [PMID: 31798838 DOI: 10.1186/s13756-019-0632-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
155 Yang J, Zhou X, Liu X, Ling Z, Ji F. Role of the Gastric Microbiome in Gastric Cancer: From Carcinogenesis to Treatment. Front Microbiol 2021;12:641322. [PMID: 33790881 DOI: 10.3389/fmicb.2021.641322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
156 Kaźmierczak-Siedlecka K, Ruszkowski J, Skonieczna-Żydecka K, Jędrzejczak J, Folwarski M, Makarewicz W. Gastrointestinal cancers: the role of microbiota in carcinogenesis and the role of probiotics and microbiota in anti-cancer therapy efficacy. Cent Eur J Immunol 2020;45:476-87. [PMID: 33658894 DOI: 10.5114/ceji.2020.103353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Yuan L, Zhao JB, Zhou YL, Qi YB, Guo QY, Zhang HH, Khan MN, Lan L, Jia CH, Zhang YR, Ding SZ. Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area. World J Gastroenterol 2020; 26(25): 3673-3685 [PMID: 32742135 DOI: 10.3748/wjg.v26.i25.3673] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Wojtyś MI, Jaźwiec R, Kazazić S, Leščić Ašler I, Knežević P, Aleksić Sabo V, Luić M, Jagusztyn-Krynicka EK, Bzowska A. A comprehensive method for determining cellular uptake of purine nucleoside phosphorylase and adenylosuccinate synthetase inhibitors by H. pylori. Appl Microbiol Biotechnol 2021;105:7949-67. [PMID: 34562116 DOI: 10.1007/s00253-021-11510-9] [Reference Citation Analysis]
159 Bayati S, Alebouyeh M, Amirmozafari N, Ebrahimi Daryani N, Talebi M, Zali MR. Histological changes in refractory Helicobacter pylori infection and its relationship with increased levels of resistance to antibiotics and therapeutic regimens: one-year follow-up. APMIS 2020;128:25-34. [PMID: 31628820 DOI: 10.1111/apm.13001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Huang CC, Tsai KW, Tsai TJ, Hsu PI. Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy. Biomark Res 2017;5:23. [PMID: 28702193 DOI: 10.1186/s40364-017-0103-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
161 Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
162 Muhsen K, Sinnreich R, Beer-Davidson G, Nassar H, Cohen D, Kark JD. Sero-prevalence of Helicobacter pylori CagA immunoglobulin G antibody, serum pepsinogens and haemoglobin levels in adults. Sci Rep 2018;8:17616. [PMID: 30514858 DOI: 10.1038/s41598-018-35937-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
163 Ribaldone DG, Fagoonee S, Astegiano M, Durazzo M, Morgando A, Sprujevnik T, Giordanino C, Baronio M, De Angelis C, Saracco GM, Pellicano R. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. J Clin Med. 2019;8. [PMID: 30736338 DOI: 10.3390/jcm8020199] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
164 Chang YW, Park YM, Oh CH, Oh SJ, Cho JH, Kim JW, Jang JY. Effects of probiotics or broccoli supplementation on Helicobacter pylori eradication with standard clarithromycin-based triple therapy. Korean J Intern Med 2020;35:574-81. [PMID: 31830776 DOI: 10.3904/kjim.2019.139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
165 Parreira P, Monteiro C, Graça V, Gomes J, Maia S, Gomes P, Gonçalves IC, Martins MCL. Surface Grafted MSI-78A Antimicrobial Peptide has High Potential for Gastric Infection Management. Sci Rep 2019;9:18212. [PMID: 31796755 DOI: 10.1038/s41598-019-53918-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
166 Huh KY, Chung H, Kim YK, Lee S, Bhatia S, Takanami Y, Nakaya R, Yu KS. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. Br J Clin Pharmacol 2021. [PMID: 34080718 DOI: 10.1111/bcp.14934] [Reference Citation Analysis]
167 Azzaya D, Gantuya B, Oyuntsetseg K, Davaadorj D, Matsumoto T, Akada J, Yamaoka Y. High Antibiotic Resistance of Helicobacter pylori and Its Associated Novel Gene Mutations among the Mongolian Population. Microorganisms 2020;8:E1062. [PMID: 32708761 DOI: 10.3390/microorganisms8071062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
168 Oikawa R, Watanabe Y, Miyamoto S, Sato Y, Ono S, Mabe K, Yamamoto H, Kato M, Itoh F. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. Tumour Biol 2017;39:1010428317734865. [PMID: 28990461 DOI: 10.1177/1010428317734865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
169 Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol 2021;21:95. [PMID: 33653284 DOI: 10.1186/s12876-021-01680-1] [Reference Citation Analysis]
170 Kotilea K, Cadranel S, Salame A, Nguyen J, Mahler T, Miendje Deyi VY, Verset L, Bontems P. Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children. Helicobacter 2021;26:e12825. [PMID: 34101296 DOI: 10.1111/hel.12825] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Bénéjat L, Buissonnière A, Ducournau A, Mégraud F, Bessède E, Lehours P. Evaluation of RIDASCREEN® and RIDA®QUICK Helicobacter kits for Helicobacter pylori detection in stools. Eur J Clin Microbiol Infect Dis 2020;39:1941-3. [PMID: 32519216 DOI: 10.1007/s10096-020-03943-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Cardos IA, Zaha DC, Sindhu RK, Cavalu S. Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies. Molecules 2021;26:6078. [PMID: 34641620 DOI: 10.3390/molecules26196078] [Reference Citation Analysis]
173 Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera ® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22:e12423. [DOI: 10.1111/hel.12423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
174 Kim YJ, Lee SY, Yang H, Kim JH, Sung IK, Park HS. [Nodular Gastritis as a Precursor Lesion of Atrophic and Metaplastic Gastritis]. Korean J Gastroenterol 2019;73:332-40. [PMID: 31234623 DOI: 10.4166/kjg.2019.73.6.332] [Reference Citation Analysis]
175 Beckman E, Saracino I, Fiorini G, Clark C, Slepnev V, Patel D, Gomez C, Ponaka R, Elagin V, Vaira D. A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. J Clin Microbiol. 2017;55:2400-2405. [PMID: 28515219 DOI: 10.1128/jcm.00506-17] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
176 Bartels LE, Pedersen AB, Kristensen NR, Vilstrup H, Stengaard-Pedersen K, Dahlerup JF. A positive Helicobacter pylori test is associated with low spondylarthritis incidence in a Danish historical cohort study. Rheumatol Int 2020;40:359-66. [PMID: 31802207 DOI: 10.1007/s00296-019-04487-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
177 Wise MJ, Lamichhane B, Webberley KM. A Longitudinal, Population-Level, Big-Data Study of Helicobacter pylori-Related Disease across Western Australia. J Clin Med 2019;8:E1821. [PMID: 31683830 DOI: 10.3390/jcm8111821] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
178 Chen Y, Liu Q, Hu F, Ma J. Identifying the best regimen for primary eradication of Helicobacter pylori: analysis of 240 cases. Microbiologyopen 2020;9:e1120. [PMID: 33026166 DOI: 10.1002/mbo3.1120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
179 Matta AJ, Zambrano DC, Pazos AJ. Punctual mutations in 23S rRNA gene of clarithromycin-resistant Helicobacter pylori in Colombian populations. World J Gastroenterol 2018; 24(14): 1531-1539 [PMID: 29662291 DOI: 10.3748/wjg.v24.i14.1531] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
180 Lee JH, Ahn JY, Choi KD, Jung HY, Kim JM, Baik GH, Kim BW, Park JC, Jung HK, Cho SJ, Shin CM, Choi YJ, Lee SH, Kim JH, Lee WS, Sung JK, Chung JW, Cheung DY, Lee H, Min YW, Kim JJ, Kim SY;  Korean College of Helicobacter;  Upper Gastrointestinal Research. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study. Helicobacter. 2019;24:e12592. [PMID: 31111572 DOI: 10.1111/hel.12592] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
181 Marcos P, Brito-gonçalves G, Libânio D, Pita I, Castro R, Sá I, Dinis-ribeiro M, Pimentel-nunes P. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West? Gut 2020;69:1762-8. [DOI: 10.1136/gutjnl-2019-320091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
182 Long X, Chen Q, Yu L, Liang X, Liu W, Lu H. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter 2018;23:e12485. [DOI: 10.1111/hel.12485] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
183 Nyssen OP, Perez-Aisa A, Rodrigo L, Castro M, Mata Romero P, Ortuño J, Barrio J, Huguet JM, Modollel I, Alcaide N, Lucendo A, Calvet X, Perona M, Gomez B, Gomez Rodriguez BJ, Varela P, Jimenez-Moreno M, Dominguez-Cajal M, Pozzati L, Burgos D, Bujanda L, Hinojosa J, Molina-Infante J, Di Maira T, Ferrer L, Fernández-Salazar L, Figuerola A, Tito L, de la Coba C, Gomez-Camarero J, Fernandez N, Caldas M, Garre A, Resina E, Puig I, O'Morain C, Megraud F, Gisbert JP. Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg). Helicobacter 2020;25:e12722. [PMID: 32656898 DOI: 10.1111/hel.12722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
184 Gatta L, Scarpignato C. Editorial: Helicobacter pylori resistance and sequential therapy-authors’ reply. Aliment Pharmacol Ther 2018;48:96-7. [DOI: 10.1111/apt.14676] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
185 Arj A, Mollaei M, Razavizadeh M, Moraveji A. The Comparison of Levofloxacin- and Clarithromycin-Based Bismuth Quadruple Therapy Regimens in Helicobacter pylori Eradication. J Res Pharm Pract 2020;9:101-5. [PMID: 33102384 DOI: 10.4103/jrpp.JRPP_19_86] [Reference Citation Analysis]
186 Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 [PMID: 30386104 DOI: 10.3748/wjg.v24.i40.4548] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
187 Sharara AI. Confirmatory Testing for Eradication of Helicobacter pylori: Challenges and Opportunities. Clin Gastroenterol Hepatol 2021;19:232-4. [PMID: 32492481 DOI: 10.1016/j.cgh.2020.05.051] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
188 Chen Q, Zhou X, Tan W, Zhang M. Association between Helicobacter pylori infection and Sjögren syndrome: A meta-analysis. Medicine (Baltimore) 2018;97:e13528. [PMID: 30544455 DOI: 10.1097/MD.0000000000013528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
189 Hsu P, Tsay F, Graham DY, Tsai T, Tsai K, Kao JY, Peng N, Kuo C, Kao S, Wang H, Lin T, Wu D. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology 2018;16:1427-33. [DOI: 10.1016/j.cgh.2018.03.031] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
190 Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z] [Cited by in Crossref: 148] [Cited by in F6Publishing: 123] [Article Influence: 24.7] [Reference Citation Analysis]
191 Nkuize M, Vanderpas J, Buset M, Delforge M, Cadière GB, De Wit S. Failure to eradicate Helicobacter pylori infection is more frequent among HIV-positive patients. HIV Med 2021;22:547-56. [PMID: 33765332 DOI: 10.1111/hiv.13083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Yu Y, Cai J, Song Z, Wang J, Wu L. Association of Helicobacter pylori infection with metabolic syndrome in aged Chinese females. Exp Ther Med 2019;17:4403-8. [PMID: 31105780 DOI: 10.3892/etm.2019.7509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
193 Steiner TM, Lettl C, Schindele F, Goebel W, Haas R, Fischer W, Eisenreich W. Substrate usage determines carbon flux via the citrate cycle in Helicobacter pylori. Mol Microbiol 2021. [PMID: 34164854 DOI: 10.1111/mmi.14775] [Reference Citation Analysis]
194 Tang X, Shen Y, Hu R, Yang T, Benghezal M, Li H, Tang H. Re-assessment of the disk diffusion technique for routine antimicrobial susceptibility testing for Helicobacter pylori. Helicobacter 2020;25:e12703. [PMID: 32453910 DOI: 10.1111/hel.12703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
195 Nyssen OP, McNicholl AG, Gisbert JP. Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori. Helicobacter. 2019;24:e12570. [PMID: 30767339 DOI: 10.1111/hel.12570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
196 Erkut M, Uzun DY, Kaklıkkaya N, Fidan S, Yoğun Y, Coşar AM, Akyıldız E, Topbaş M, Özgür O, Arslan M. Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turk J Gastroenterol 2020;31:221-33. [PMID: 32343234 DOI: 10.5152/tjg.2020.18631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Seyyedmajidi M, Abbasi L, Seyedmajidi S, Hosseini SA, Ahmadi A, Hajiebrahimi S, Vafaeimanesh J. Levofloxacin-containing triple therapy versus bismuth-based quadruple therapy as regimens for second line anti- Helicobacter pylori. Caspian J Intern Med 2019;10:211-6. [PMID: 31363400 DOI: 10.22088/cjim.10.2.211] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
198 Dinis-Ribeiro M, Kuipers EJ. How to Manage a Patient With Gastric Intestinal Metaplasia: An International Perspective. Gastroenterology 2020;158:1534-7. [PMID: 31926996 DOI: 10.1053/j.gastro.2020.01.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
199 Wu MC, Wang YK, Liu CJ, Yu FJ, Kuo FC, Liu ML, Kuo CH, Wu DC, Huang YK, Wu IC. Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori. Gastroenterol Res Pract 2017;2017:5320180. [PMID: 28791044 DOI: 10.1155/2017/5320180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
200 Mosso E, Bonetto S, Longobardi G, Abenavoli L, Ribaldone DG, Saracco GM, Pellicano R. Management of functional dyspepsia in 2020: a clinical point of view. Minerva Gastroenterol Dietol 2020;66:331-42. [PMID: 32623872 DOI: 10.23736/S1121-421X.20.02732-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
201 Wärme J, Sundqvist M, Mars K, Aladellie L, Pawelzik SC, Erlinge D, Jernberg T, James S, Hofmann R, Bäck M. Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction. Am Heart J 2021;231:105-9. [PMID: 33144087 DOI: 10.1016/j.ahj.2020.10.072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Zhang W, Lian Y, Li Q, Sun L, Chen R, Lai X, Lai Z, Yuan E, Sun S. Preventative and Therapeutic Potential of Flavonoids in Peptic Ulcers. Molecules 2020;25:E4626. [PMID: 33050668 DOI: 10.3390/molecules25204626] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Seddik H, Boutallaka H, Elkoti I, Nejjari F, Berraida R, Berrag S, Loubaris K, Sentissi S, Benkirane A. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol 2019;75:639-45. [DOI: 10.1007/s00228-019-02625-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
204 Pih GY, Choi KD, Gong EJ, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY. Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter 2021;26:e12759. [PMID: 33113240 DOI: 10.1111/hel.12759] [Reference Citation Analysis]
205 McNicholl AG, Garre A, Llorca L, Bujanda L, Molina-Infante J, Barenys M, Perez J, Guerrero-Torres MD, Tamayo E, Montes M, Prados-Manzano R, Sanchez-Garcia A, Ramas M, Valdez Blanco VB, Montoro M, Calvet X, Figuerola A, Lario S, Quilez E, Lanas A, Silva-Pomarino P, Perez-Aisa A, Donday MG, Belloc B, Montserrat-Torres A, Fernandez-Moreno N, Ramírez MJ, Alarcon T, Gisbert JP. Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection. Gastroenterol Hepatol 2020;43:117-25. [PMID: 31810793 DOI: 10.1016/j.gastrohep.2019.09.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Smith S, Fowora M, Pellicano R. Infections with Helicobacter pylori and challenges encountered in Africa. World J Gastroenterol 2019; 25(25): 3183-3195 [PMID: 31333310 DOI: 10.3748/wjg.v25.i25.3183] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
207 Loor A, Dumitrascu DL, Surdea-Blaga T, Leucuta DC, David L. Helicobacter pylori infection and positive Rome IV criteria for functional dyspepsia in Romanian medical students. J Med Life 2021;14:492-7. [PMID: 34621372 DOI: 10.25122/jml-2021-0163] [Reference Citation Analysis]
208 Peng C, Hu Y, Ge ZM, Zou QM, Lyu NH. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations. Chronic Dis Transl Med 2019;5:243-51. [PMID: 32055783 DOI: 10.1016/j.cdtm.2019.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
209 Chen MJ, Chen CC, Huang YC, Tseng CC, Hsu JT, Lin YF, Fang YJ, Wu MS, Liou JM; Taiwan Gastrointestinal Disease, Helicobacter Consortium. The efficacy of Lactobacillus acidophilus and rhamnosus in the reduction of bacterial load of Helicobacter pylori and modification of gut microbiota-a double-blind, placebo-controlled, randomized trial. Helicobacter 2021;26:e12857. [PMID: 34708471 DOI: 10.1111/hel.12857] [Reference Citation Analysis]
210 Zhang S, Wang X, Wise MJ, He Y, Chen H, Liu A, Huang H, Young S, Tay CY, Marshall BJ, Li X, Chua EG. Mutations of Helicobacter pylori RdxA are mainly related to the phylogenetic origin of the strain and not to metronidazole resistance. J Antimicrob Chemother 2020;75:3152-5. [PMID: 32676634 DOI: 10.1093/jac/dkaa302] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Negovan A, Pantea M, Banescu C, Mocan S. Response to: Comment on "Factors Associated with Recurrent Ulcers in Patients with Gastric Surgery after More Than 15 Years: A Cross-Sectional Single-Center Study". Gastroenterol Res Pract 2019;2019:9214597. [PMID: 30918517 DOI: 10.1155/2019/9214597] [Reference Citation Analysis]
212 Egli K, Wagner K, Keller PM, Risch L, Risch M, Bodmer T. Comparison of the Diagnostic Performance of qPCR, Sanger Sequencing, and Whole-Genome Sequencing in Determining Clarithromycin and Levofloxacin Resistance in Helicobacter pylori. Front Cell Infect Microbiol 2020;10:596371. [PMID: 33392106 DOI: 10.3389/fcimb.2020.596371] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
213 Rezaei S, Talebi Bezmin Abadi A, Mohabatti Mobarez A. Metronidazole-resistant Helicobacter pylori isolates without rdxA mutations obtained from Iranian dyspeptic patients. New Microbes New Infect 2020;34:100636. [PMID: 31993205 DOI: 10.1016/j.nmni.2019.100636] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
214 Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, Zhang X, Cheng H. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. Helicobacter 2020;25:e12717. [PMID: 32548932 DOI: 10.1111/hel.12717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
215 Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter. 2017;22. [PMID: 28066960 DOI: 10.1111/hel.12368] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
216 Malfertheiner P, Venerito M, Schulz C. Helicobacter pylori Infection: New Facts in Clinical Management. Curr Treat Options Gastroenterol. 2018;16:605-615. [PMID: 30415359 DOI: 10.1007/s11938-018-0209-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
217 Bang CS, Lee JJ, Baik GH. The most influential articles in Helicobacter pylori research: A bibliometric analysis. Helicobacter 2019;24:e12589. [PMID: 31033071 DOI: 10.1111/hel.12589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
218 Lee JH, Choi KD, Jung HY, Baik GH, Park JK, Kim SS, Kim BW, Hong SJ, Lim H, Shin CM, Lee SH, Jeon SW, Kim JH, Choi CW, Jung HK, Kim JH, Choi SC, Cho JW, Lee WS, Na SY, Sung JK, Song KH, Chung JW, Yun SC; Korean College of Helicobacter and Upper Gastrointestinal Research. Seroprevalence of Helicobacter pylori in Korea: A multicenter, nationwide study conducted in 2015 and 2016. Helicobacter 2018;23:e12463. [PMID: 29345022 DOI: 10.1111/hel.12463] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
219 Ning L, Liu R, Lou X, Du H, Chen W, Zhang F, Li S, Chen X, Xu G. Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systemic review and meta-analysis. European Journal of Gastroenterology & Hepatology 2019;31:735-42. [DOI: 10.1097/meg.0000000000001398] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 4.7] [Reference Citation Analysis]
220 Kim SJ, Chung JW, Woo HS, Kim SY, Kim JH, Kim YJ, Kim KO, Kwon KA, Park DK. Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial. World J Gastroenterol 2019; 25(46): 6790-6798 [PMID: 31857780 DOI: 10.3748/wjg.v25.i46.6790] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
221 Lee JY, Kim N, Nam RH, In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter. 2019;24:e12660. [PMID: 31507036 DOI: 10.1111/hel.12660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
222 Cremon C, Barbaro MR, Ventura M, Barbara G. Pre- and probiotic overview. Curr Opin Pharmacol. 2018;43:87-92. [PMID: 30219638 DOI: 10.1016/j.coph.2018.08.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 10.8] [Reference Citation Analysis]
223 Buckley M, Lacey S, Doolan A, Goodbody E, Seamans K. The effect of Lactobacillus reuteri supplementation in Helicobacter pylori infection: a placebo-controlled, single-blind study. BMC Nutr 2018;4:48. [PMID: 32153909 DOI: 10.1186/s40795-018-0257-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
224 Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, Palla E, Kanesa-thasan N, Scharschmidt B, Rappuoli R, Graham DY, Schiavetti F, Del Giudice G. Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. The Lancet Gastroenterology & Hepatology 2018;3:698-707. [DOI: 10.1016/s2468-1253(18)30125-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 5.8] [Reference Citation Analysis]
225 Khasag O, Boldbaatar G, Tegshee T, Duger D, Dashdorj A, Uchida T, Matsuhisa T, Yamaoka Y. The prevalence of Helicobacter pylori infection and other risk factors among Mongolian dyspeptic patients who have a high incidence and mortality rate of gastric cancer. Gut Pathog 2018;10:14. [PMID: 29636824 DOI: 10.1186/s13099-018-0240-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
226 Bénéjat L, Ducournau A, Lehours P, Mégraud F. Real‐time PCR for Helicobacter pylori diagnosis. The best tools available. Helicobacter 2018;23:e12512. [DOI: 10.1111/hel.12512] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
227 Losurdo G, Cubisino R, Barone M, Principi M, Leandro G, Ierardi E, Di Leo A. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol 2018; 24(1): 139-149 [PMID: 29358890 DOI: 10.3748/wjg.v24.i1.139] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
228 Santambrogio E, Orsucci L. Helicobacter pylori and hematological disorders. Minerva Gastroenterol Dietol 2019;65. [DOI: 10.23736/s1121-421x.19.02580-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
229 Spada C, Piccirelli S. Real-Time Diagnosis of Helicobacter pylori During Endoscopy by Gastric Juice Analysis. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 21-7. [DOI: 10.1007/978-1-0716-1302-3_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Yu ML. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Am J Gastroenterol 2020;115:1226-35. [PMID: 32221162 DOI: 10.14309/ajg.0000000000000606] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
231 Sakitani K, Nishizawa T, Arita M, Yoshida S, Kataoka Y, Ohki D, Yamashita H, Isomura Y, Toyoshima A, Watanabe H, Iizuka T, Saito Y, Fujisaki J, Yahagi N, Koike K, Toyoshima O. Early detection of gastric cancer after Helicobacter pylori eradication due to endoscopic surveillance. Helicobacter. 2018;23:e12503. [PMID: 29924436 DOI: 10.1111/hel.12503] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
232 Hsieh M, Liu C, Hsu W, Li C, Tsai P, Hu H, Shih H, Lu C, Yu F, Kuo F, Wu D, Kuo C. Gastric juice‐based PCR assay: An alternative testing method to aid in the management of previously treated Helicobacter pylori infection. Helicobacter 2019;24:e12568. [DOI: 10.1111/hel.12568] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
233 Chi TY, Zhu HM, Zhang M. Risk factors associated with nonsteroidal anti-inflammatory drugs (NSAIDs)-induced gastrointestinal bleeding resulting on people over 60 years old in Beijing. Medicine (Baltimore) 2018;97:e0665. [PMID: 29718891 DOI: 10.1097/MD.0000000000010665] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
234 Munteanu D, Etzion O, Ben-Yakov G, Halperin D, Eidelman L, Schwartz D, Novack V, Abufreha N, Krugliak P, Rozenthal A, Gaspar N, Moshkalo A, Dizingof V, Fich A. Efficacy and safety of sequential versus quadruple therapy as second-line treatment for helicobacter pylori infection-A randomized controlled trial. PLoS One. 2017;12:e0183302. [PMID: 28957341 DOI: 10.1371/journal.pone.0183302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
235 Zhou C, Fang J. Several aspects in study design need further consideration. Gut 2018;67:2070-1. [DOI: 10.1136/gutjnl-2017-315692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
236 Park JY, Kim JG. [New Helicobacter pylori Eradication Therapies]. Korean J Gastroenterol 2018;72:237-44. [PMID: 30642139 DOI: 10.4166/kjg.2018.72.5.237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
237 Jonaityte IR, Ciupkeviciene E, Jonaitis P, Kupcinskas J, Petkeviciene J, Jonaitis L. Changes in the Seroprevalence of Helicobacter pylori among the Lithuanian Medical Students over the Last 25 Years and Its Relation to Dyspeptic Symptoms. Medicina (Kaunas) 2021;57:254. [PMID: 33803389 DOI: 10.3390/medicina57030254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci. 2021;. [PMID: 33755825 DOI: 10.1007/s10620-021-06938-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
239 Ribaldone DG, Zurlo C, Fagoonee S, Rosso C, Armandi A, Caviglia GP, Saracco GM, Pellicano R. A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy. Life (Basel) 2021;11:650. [PMID: 34357021 DOI: 10.3390/life11070650] [Reference Citation Analysis]
240 Zhao Y, Yang Y, Aruna, Xiao J, Song J, Huang T, Li S, Kou J, Huang L, Ji D, Xiong S, Peng W, Xu S, Cheng B. Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial. Front Med (Lausanne) 2021;8:776955. [PMID: 34869495 DOI: 10.3389/fmed.2021.776955] [Reference Citation Analysis]
241 Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacotherapy 2019;39:1012-22. [DOI: 10.1002/phar.2318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
242 Li B, Lan X, Wang L, Zhao J, Ding J, Ding H, Lei J, Wei Y, Zhang W. Proton-pump inhibitor and amoxicillin-based triple therapy containing clarithromycin versus metronidazole for Helicobacter pylori: A meta-analysis. Microb Pathog 2020;142:104075. [PMID: 32074497 DOI: 10.1016/j.micpath.2020.104075] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
243 Siavoshi F, Saniee P, Malekzadeh R. Effective antimicrobial activity of rifabutin against multidrug-resistant Helicobacter pylori. Helicobacter 2018;23:e12531. [PMID: 30230637 DOI: 10.1111/hel.12531] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
244 Ding SZ. Global whole family based-Helicobacter pylori eradication strategy to prevent its related diseases and gastric cancer. World J Gastroenterol 2020; 26(10): 995-1004 [PMID: 32205991 DOI: 10.3748/wjg.v26.i10.995] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
245 Bjorkman DJ, Steenblik M. Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol 2017;15:648-59. [PMID: 28932965 DOI: 10.1007/s11938-017-0157-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
246 Selgrad M, Malfertheiner P. Management of Helicobacter pylori Infection: What Should the Surgeon Know? Visc Med 2017;33:216-9. [PMID: 28785571 DOI: 10.1159/000477977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
247 Ennkaa A, Shaath N, Salam A, Mohammad RM. Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study. Turk J Gastroenterol 2018;29:549-54. [PMID: 30260776 DOI: 10.5152/tjg.2018.17707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
248 Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci 2020;65:1917-31. [PMID: 32170476 DOI: 10.1007/s10620-020-06193-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
249 Pichon M, Pichard B, Barrioz T, Plouzeau C, Croquet V, Fotsing G, Chéron A, Vuillemin É, Wangermez M, Haineaux PA, Vasseur P, Thiebault Q, Lefèvre C, de Singly A, Cremniter J, Broutin L, Michaud A, Silvain C, Burucoa C. Diagnostic Accuracy of a Noninvasive Test for Detection of Helicobacter pylori and Resistance to Clarithromycin in Stool by the Amplidiag H. pylori+ClariR Real-Time PCR Assay. J Clin Microbiol 2020;58:e01787-19. [PMID: 31996442 DOI: 10.1128/JCM.01787-19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
250 Russo M, Miraglia C, Nouvenne A, Leandro G, Meschi T, De' Angelis GL, Di Mario F. Approach to gastroenterological diseases in primary care. Acta Biomed 2018;89:5-11. [PMID: 30561411 DOI: 10.23750/abm.v89i8-S.7973] [Reference Citation Analysis]
251 Buzás GM. Benign and malignant gastroduodenal diseases associated with Helicobacter pylori: a narrative review and personal remarks in 2018. Minerva Gastroenterol Dietol 2018;64:280-96. [PMID: 29458240 DOI: 10.23736/S1121-421X.18.02481-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
252 Yang X, Li Y, Sun Y, Zhang M, Guo C, Mirza IA, Li Y. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Dig Dis Sci 2018;63:302-11. [DOI: 10.1007/s10620-017-4866-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
253 Bae HJ, Kim JS, Kim BW, Nam YJ. Concomitant or Sequential Therapy as the First-line Therapy for Eradication of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis. Korean J Gastroenterol. 2018;71:31-37. [PMID: 29361811 DOI: 10.4166/kjg.2018.71.1.31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
254 Wang S, Ye F, Sheng Y, Yu W, Liu Y, Liu D, Zhang K. Development and Validation of Nomograms to Predict Operative Link for Gastritis Assessment Any-Stage and Stages III-IV in the Chinese High-Risk Gastric Cancer Population. Front Med (Lausanne) 2021;8:724566. [PMID: 34447771 DOI: 10.3389/fmed.2021.724566] [Reference Citation Analysis]
255 Lucero Y, Lagomarcino AJ, Torres JP, Roessler P, Mamani N, George SA, Huerta N, González M, O'Ryan G M. Effect of Helicobacter pylori eradication therapy on clinical and laboratory biomarkers associated with gastric damage in healthy school-aged children: A randomized non-blinded trial. Helicobacter 2021;26:e12853. [PMID: 34528337 DOI: 10.1111/hel.12853] [Reference Citation Analysis]
256 Yang Q, Yasuda T, Choi E, Toyoda T, Roland JT, Uchida E, Yoshida H, Seto Y, Goldenring JR, Nomura S. MEK Inhibitor Reverses Metaplasia and Allows Re-Emergence of Normal Lineages in Helicobacter pylori-Infected Gerbils. Gastroenterology 2019;156:577-581.e4. [PMID: 30391471 DOI: 10.1053/j.gastro.2018.10.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
257 Signal V, Gurney J, Inns S, Mcleod M, Sika-paotonu D, Sowerbutts S, Teng A, Sarfati D. Helicobacter pylori , stomach cancer and its prevention in New Zealand. Journal of the Royal Society of New Zealand 2020;50:397-417. [DOI: 10.1080/03036758.2019.1650081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
258 Mladenova I. Helicobacter pylori and cardiovascular disease: update 2019. Minerva Cardioangiol 2019;67:425-32. [PMID: 31343146 DOI: 10.23736/S0026-4725.19.04986-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
259 Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E. The appropriate use of proton-pump inhibitors. Minerva Med 2018;109. [DOI: 10.23736/s0026-4806.18.05705-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 6] [Article Influence: 5.8] [Reference Citation Analysis]
260 Saito H, Nishikawa Y, Masuzawa Y, Tsubokura M, Mizuno Y. Helicobacter pylori Infection Mass Screening for Children and Adolescents: a Systematic Review of Observational Studies. J Gastrointest Cancer 2021;52:489-97. [PMID: 33761050 DOI: 10.1007/s12029-021-00630-0] [Reference Citation Analysis]
261 Leja M, Kortelainen JM, Polaka I, Turppa E, Mitrovics J, Padilla M, Mochalski P, Shuster G, Pohle R, Kashanin D, Klemm R, Ikonen V, Mezmale L, Broza YY, Shani G, Haick H; SniffPhone Project Research Group. Sensing gastric cancer via point-of-care sensor breath analyzer. Cancer 2021;127:1286-92. [PMID: 33739456 DOI: 10.1002/cncr.33437] [Reference Citation Analysis]
262 Muresan IAP, Pop LL, Dumitrascu DL. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia. Med Pharm Rep 2019;92:352-5. [PMID: 31750434 DOI: 10.15386/mpr-1375] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Xu H, Wang W, Ma X, Feng R, Su Y, Cheng L, Yang Y, Zhang D. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis. European Journal of Gastroenterology & Hepatology 2021;33:775-86. [DOI: 10.1097/meg.0000000000001835] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
264 Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernanadez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. United European Gastroenterol J 2021;9:38-46. [PMID: 33176617 DOI: 10.1177/2050640620972615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
265 Yu L, Luo L, Long X, Liang X, Ji Y, Chen Q, Song Y, Li X, Graham DY, Lu H. Susceptibility-guided therapy for Helicobacter pylori infection treatment failures. Therap Adv Gastroenterol 2019;12:1756284819874922. [PMID: 31523279 DOI: 10.1177/1756284819874922] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
266 Hu Y, Liu JP, Li XY, Cai Y, He C, Li NS, Xie C, Xiong ZJ, Ge ZM, Lu NH, Zhu Y. Downregulation of tumor suppressor RACK1 by Helicobacter pylori infection promotes gastric carcinogenesis through the integrin β-1/NF-κB signaling pathway. Cancer Lett 2019;450:144-54. [PMID: 30849478 DOI: 10.1016/j.canlet.2019.02.039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
267 Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW; Taiwan Acid-related Disease (TARD) Study Group. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter 2018;23:e12498. [PMID: 29897654 DOI: 10.1111/hel.12498] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
268 Molina-infante J, Gutierrez-junquera C, Savarino E, Penagini R, Modolell I, Bartolo O, Prieto-garcía A, Mauro A, Alcedo J, Perelló A, Guarner-argente C, Alcaide N, Vegas AM, Barros-garcía P, Murzi-pulgar M, Perona M, Gisbert JP, Lucendo AJ. Helicobacter Pylori Infection Does Not Protect Against Eosinophilic Esophagitis: Results From a Large Multicenter Case-Control Study. American Journal of Gastroenterology 2018;113:972-9. [DOI: 10.1038/s41395-018-0035-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
269 Veliev AM, Maev IV, Andreev DN, Dicheva DT, Zaborovskii AV, Lobanova EG, Bektemirova LG. [The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease]. Ter Arkh 2019;91:28-33. [PMID: 32598751 DOI: 10.26442/00403660.2019.08.000382] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
270 Wang YH, Wang FF, Gong XL, Yan LL, Zhao QY, Song YP, Zhao RL, He YJ, Zhou L, Liu DS, Xie Y. Genotype profiles of Helicobacter pylori from gastric biopsies and strains with antimicrobial-induced resistance. Therap Adv Gastroenterol 2020;13:1756284820952596. [PMID: 33029198 DOI: 10.1177/1756284820952596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
271 Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: A systematic review and network meta-analysis. Helicobacter. 2017;22. [PMID: 28425141 DOI: 10.1111/hel.12389] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
272 Alcedo J, Gracia M, García-cámara P, Palacín C, Gallego S, Jimeno-ayllon C, Frago S, Aured I, Luzón L. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterología y Hepatología 2020;43:301-9. [DOI: 10.1016/j.gastrohep.2019.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
273 Xie Y, Shi L, He X, Luo Y. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterol Rep (Oxf) 2021;9:91-104. [PMID: 34026216 DOI: 10.1093/gastro/goab010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
274 Siddique O, Moss SF. Editorial: Helicobacter pylori resistance and sequential therapy. Aliment Pharmacol Ther 2018;48:95-6. [DOI: 10.1111/apt.14643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
275 Boltin D, Schmilovitz-weiss  H, Gingold-belfer R, Leibovitzh  H, Snir Y, Perets  T, Dickman R, Levi Z, Niv Y. Temporal Trends in <b><i>Helicobacter pylori</i></b> Eradication Success in a Test-and-Treat Population. Digestion 2018;98:169-74. [DOI: 10.1159/000488448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
276 Pohl D, Keller PM, Bordier V, Wagner K. Review of current diagnostic methods and advances in Helicobacter pylori diagnostics in the era of next generation sequencing. World J Gastroenterol 2019; 25(32): 4629-4660 [PMID: 31528091 DOI: 10.3748/wjg.v25.i32.4629] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
277 Migone De Amicis M, Rimondi A, Elli L, Motta I. Acquired Refractory Iron Deficiency Anemia. Mediterr J Hematol Infect Dis 2021;13:e2021028. [PMID: 34007416 DOI: 10.4084/MJHID.2021.028] [Reference Citation Analysis]
278 Perets TT, Gingold-Belfer R, Leibovitzh H, Itskoviz D, Schmilovitz-Weiss H, Snir Y, Dickman R, Dotan I, Levi Z, Boltin D. Optimization of 13 C-urea breath test threshold levels for the detection of Helicobacter pylori infection in a national referral laboratory. J Clin Lab Anal 2019;33:e22674. [PMID: 30221401 DOI: 10.1002/jcla.22674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
279 Steinbuss G, Kriegsmann K, Kriegsmann M. Identification of Gastritis Subtypes by Convolutional Neuronal Networks on Histological Images of Antrum and Corpus Biopsies. Int J Mol Sci. 2020;21. [PMID: 32932860 DOI: 10.3390/ijms21186652] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
280 Vohlonen IJ, Hakama M, Härkönen M, Malila N, Pukkala E, Koistinen V, Sipponen P. Oesophageal cancer incidence in 20-year follow-up in a population-based sample of 12 000 middle-age men with or without Helicobacter pylori infection in Finland. Gut 2018;67:1201-2. [PMID: 28860351 DOI: 10.1136/gutjnl-2017-314913] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
281 Llorca-otero L, Toro-rueda C. Diagnosis of Helicobacter pylori infection: Progress and challenges. Enfermedades Infecciosas y Microbiología Clínica 2020;38:407-9. [DOI: 10.1016/j.eimc.2020.09.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
282 Beresniak A, Malfertheiner P, Franceschi F, Liebaert F, Salhi H, Gisbert JP. Helicobacter pylori "Test-and-Treat" strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative. Helicobacter 2020;25:e12693. [PMID: 32285569 DOI: 10.1111/hel.12693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
283 O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter 2018;23 Suppl 1:e12519. [PMID: 30203585 DOI: 10.1111/hel.12519] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
284 Yang H, Wei B, Hu B. Chronic inflammation and long-lasting changes in the gastric mucosa after Helicobacter pylori infection involved in gastric cancer. Inflamm Res 2021;70:1015-26. [PMID: 34549319 DOI: 10.1007/s00011-021-01501-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
285 Abrignani MG, Gatta L, Gabrielli D, Milazzo G, De Francesco V, De Luca L, Francese M, Imazio M, Riccio E, Rossini R, Scotto di Uccio F, Soncini M, Zullo A, Colivicchi F, Di Lenarda A, Gulizia MM, Monica F. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med 2021;85:1-13. [PMID: 33279389 DOI: 10.1016/j.ejim.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
286 Li WQ, Zhang JY, Ma JL, Li ZX, Zhang L, Zhang Y, Guo Y, Zhou T, Li JY, Shen L, Liu WD, Han ZX, Blot WJ, Gail MH, Pan KF, You WC. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ 2019;366:l5016. [PMID: 31511230 DOI: 10.1136/bmj.l5016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 14.7] [Reference Citation Analysis]
287 Zhang C, Cao M, Lv T, Wang H, Liu X, Xie Y, Lv N, Chen H, Cram DS, Zhong J, Zhou L. Molecular testing for H. pylori clarithromycin and quinolone resistance: a prospective Chinese study. Eur J Clin Microbiol Infect Dis 2021;40:1599-608. [PMID: 33646449 DOI: 10.1007/s10096-021-04188-4] [Reference Citation Analysis]
288 He XJ, Zeng XP, Jiang CS, Liu G, Li DZ, Wang W. Antofloxacin-based bismuth quadruple therapy is safe and effective in Helicobacter pylori eradication: A prospective, open-label, randomized trial. Arab J Gastroenterol 2021;22:47-51. [PMID: 33551347 DOI: 10.1016/j.ajg.2020.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 [DOI: 10.1101/2021.01.14.21249458] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
290 Reyes D, Ortiz J, Fuentes-López E, Budnik S, Gandara V, Gallardo A, Seydewitz MF, Candia R, Ignacio Vargas J, Rollan MP, Godoy J, Rollan A, Mansilla R, Arenas A, Chahuán J, Espino A, Pizarro M, Riquelme A. Quadruple therapies are superior to standard triple therapy for Helicobacter pylori first-line eradication in Chile. Gastroenterol Hepatol 2021:S0210-5705(21)00320-4. [PMID: 34890721 DOI: 10.1016/j.gastrohep.2021.11.010] [Reference Citation Analysis]
291 Wennerström ECM, Simonsen J, Camargo MC, Rabkin CS. Acid-suppressing therapies and subsite-specific risk of stomach cancer. Br J Cancer 2017;116:1234-8. [PMID: 28350791 DOI: 10.1038/bjc.2017.84] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
292 Khan S, Sharaf M, Ahmed I, Khan TU, Shabana S, Arif M, Kazmi SSUH, Liu C. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther 2021;:1-18. [PMID: 34658307 DOI: 10.1080/14787210.2022.1990041] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Beales IL. Advances in the Therapy of Bleeding Peptic Ulcer. Clinical Medicine Insights: Therapeutics 2018;10:1179559X1879025. [DOI: 10.1177/1179559x18790258] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
294 Wang ZJ, Chen XF, Zhang ZX, Li YC, Deng J, Tu J, Song ZQ, Zou QH. Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humans. Microb Pathog 2017;109:156-61. [PMID: 28552806 DOI: 10.1016/j.micpath.2017.05.035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
295 Seo SI, Park CH, You SC, Kim JY, Lee KJ, Kim J, Kim Y, Yoo JJ, Seo WW, Lee HS, Shin WG. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut 2021:gutjnl-2020-323845. [PMID: 33975868 DOI: 10.1136/gutjnl-2020-323845] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
296 Zhang Q, Wu W, Zhang J, Xia X. Eradication of Helicobacter pylori: the power of nanosized formulations. Nanomedicine (Lond) 2020;15:527-42. [PMID: 32028847 DOI: 10.2217/nnm-2019-0329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
297 Kocazeybek B, Sakli MK, Yuksel P, Demirci M, Caliskan R, Sarp TZ, Saribas S, Demiryas S, Kalayci F, Cakan H, Uysal HK, Gareayaghi N, Ergin S, Erzin YZ, Bal K, Tascı İ, Tokman HB. Comparison of new and classical point mutations associated with clarithromycin resistance in Helicobacter pylori strains isolated from dyspeptic patients and their effects on phenotypic clarithromycin resistance. J Med Microbiol 2019;68:566-73. [PMID: 30724729 DOI: 10.1099/jmm.0.000944] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
298 Kalach N, Bontems P, Raymond J. Helicobacter pylori infection in children. Helicobacter 2017;22 Suppl 1. [PMID: 28891139 DOI: 10.1111/hel.12414] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
299 Mori H, Suzuki H. Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J Neurogastroenterol Motil. 2019;25:6-14. [PMID: 30504527 DOI: 10.5056/jnm18139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
300 Valean S, Chira R, Dumitrascu D. Epidemiological trends in digestive cancers in Romania, 1955-2012, compared to alcohol consumption. Correlation or coincidence? Clujul Med 2018;91:376-86. [PMID: 30564012 DOI: 10.15386/cjmed-1067] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
301 Sia R, Plouzeau C, Godonou HSM, Guingané A, Coulibaly A, Somda S, Sermé AK, Burucoa C. Low-level primary clarithromycin resistance of Helicobacter pylori in Burkina Faso: A prospective molecular study. Helicobacter 2019;24:e12551. [PMID: 30417953 DOI: 10.1111/hel.12551] [Reference Citation Analysis]
302 Han C, Ni Z, Yuan T, Zhang J, Wang C, Wang X, Ning HB, Liu J, Sun N, Liu CF, Shi M, Lu WQ, Shi YQ. Influence of serum vitamin D level on Helicobacter pylori eradication: A multi-center, observational, prospective and cohort study. J Dig Dis 2019;20:421-6. [PMID: 31145549 DOI: 10.1111/1751-2980.12793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
303 Maev IV, Andreev DN, Govorun VM, Ilina EN, Kucheryavyy YA, Oganesian TS, Melnikova EV, Zayratyants OV, Parfenova TV, Dzhedzheia LV, Kirillova NV, Maevskaya EA, Fomenko AK, Lobanova EG, Zaborovskii AV, Kriukov KA. [Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results]. Ter Arkh 2020;92:24-8. [PMID: 33346458 DOI: 10.26442/00403660.2020.08.000761] [Reference Citation Analysis]
304 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Reference Citation Analysis]
305 Tan B, Luo HQ, Xu H, Lv NH, Shi RH, Luo HS, Li JS, Ren JL, Zou YY, Li YQ, Ji F, Fang JY, Qian JM. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLoS One 2017;12:e0175625. [PMID: 28407007 DOI: 10.1371/journal.pone.0175625] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
306 Virili C, Antonelli A, Santaguida MG, Benvenga S, Centanni M. Gastrointestinal Malabsorption of Thyroxine. Endocr Rev 2019;40:118-36. [PMID: 30476027 DOI: 10.1210/er.2018-00168] [Cited by in Crossref: 49] [Cited by in F6Publishing: 35] [Article Influence: 16.3] [Reference Citation Analysis]
307 Kuo CJ, Lee CH, Chang ML, Lin CY, Lin WR, Su MY, Chiu CH, Tseng CN, Wu YS, Chiu CT, Lai CH. Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection. J Microbiol Immunol Infect 2021:S1684-1182(21)00059-1. [PMID: 33840604 DOI: 10.1016/j.jmii.2021.03.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
308 Merino JS, García A, Pastene E, Salas A, Saez K, González CL. Lactobacillus fermentum UCO-979C strongly inhibited Helicobacter pylori SS1 in Meriones unguiculatus. Benef Microbes 2018;9:625-7. [PMID: 29633633 DOI: 10.3920/BM2017.0160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
309 Khien VV, Thang DM, Hai TM, Duat NQ, Khanh PH, Ha DT, Binh TT, Dung HDQ, Trang TTH, Yamaoka Y. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13:483-97. [PMID: 31009957 DOI: 10.5009/gnl18137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
310 Li XH, Huang YY, Lu LM, Zhao LJ, Luo XK, Li RJ, Dai YY, Qin C, Huang YQ, Chen H. Early genetic diagnosis of clarithromycin resistance in Helicobacter pyloriWorld J Gastroenterol 2021; 27(24): 3595-3608 [PMID: 34239272 DOI: 10.3748/wjg.v27.i24.3595] [Reference Citation Analysis]
311 Yamaoka Y, Graham DY. Empiric H. pylori therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best. Transl Cancer Res 2016;5:S1476-8. [PMID: 28819587 DOI: 10.21037/tcr.2016.12.39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
312 Doohan D, Fauzia KA, Rathnayake J, Lamawansa MD, Waskito LA, Tuan VP, Dashdorj A, Kabamba ET, Phuc BH, Ansari S, Akada J, Matsumoto T, Uchida T, Matsuhisa T, Yamaoka Y. Pepsinogen and Serum IgG Detection Is a Valuable Diagnostic Method for Helicobacter pylori Infection in a Low-Prevalence Country: A Report from Sri Lanka. Diagnostics (Basel) 2021;11:1364. [PMID: 34441303 DOI: 10.3390/diagnostics11081364] [Reference Citation Analysis]
313 Iqbal U, Khara HS, Akhtar D, Hu Y, Anwar H, Haq KF, Siddiqui HU, Bergenstock MK, Shellenberger MJ. Safety and Efficacy of Nitazoxanide-Based Regimen for the Eradication of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Gastroenterology Res 2020;13:260-8. [PMID: 33447305 DOI: 10.14740/gr1342] [Reference Citation Analysis]
314 Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
315 Kamiya S, Yonezawa H, Osaki T. Role of Probiotics in Eradication Therapy for Helicobacter pylori Infection. Adv Exp Med Biol 2019;1149:243-55. [PMID: 31016634 DOI: 10.1007/5584_2019_369] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
316 Yang T, Hu R, Tang X, Shen Y, Tay A, Pi X, Wang G, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020;3:127-35. [DOI: 10.1093/pcmedi/pbaa010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
317 Walker MM, Talley NJ. Functional Dyspepsia in the Elderly. Curr Gastroenterol Rep 2019;21:54. [PMID: 31720909 DOI: 10.1007/s11894-019-0722-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
318 Sarajlic P, Simonsson M, Jernberg T, Bäck M, Hofmann R. Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2021:pvab059. [PMID: 34423350 DOI: 10.1093/ehjcvp/pvab059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
319 Nikbazm R, Rahimi Z, Moradi Y, Alipour M, Shidfar F. The effect of cranberry supplementation on Helicobacter pylori eradication in H. pylori positive subjects: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2021;:1-10. [PMID: 34670631 DOI: 10.1017/S0007114521004256] [Reference Citation Analysis]
320 Quach DT, Nguyen TT, Hiyama T. Abnormal Gastroesophageal Flap Valve Is Associated With High Gastresophageal Reflux Disease Questionnaire Score and the Severity of Gastroesophageal Reflux Disease in Vietnamese Patients With Upper Gastrointestinal Symptoms. J Neurogastroenterol Motil 2018;24:226-32. [PMID: 29605978 DOI: 10.5056/jnm17088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
321 Sugimoto M, Murata M, Kawai T. How long should patients be surveyed for gastric cancer risk after Helicobacter pylori eradication therapy? 10 years is no longer enough. J Gastroenterol 2020;55:577-8. [DOI: 10.1007/s00535-020-01674-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
322 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Reference Citation Analysis]
323 Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics (Basel) 2020;9:E26. [PMID: 31941121 DOI: 10.3390/antibiotics9010026] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
324 Huang X, Liu Y, Lin Z, Wu B, Nong G, Chen Y, Lu Y, Ji X, Zhou X, Suo B, Chen Q, Wei J. Minimum inhibitory concentrations of commonly used antibiotics against Helicobacter Pylori: A multicenter study in South China. PLoS One 2021;16:e0256225. [PMID: 34473713 DOI: 10.1371/journal.pone.0256225] [Reference Citation Analysis]
325 Bhakta D, Graham DY, Chan J, El-Serag HB. Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. Clin Gastroenterol Hepatol 2018;16:1531-2. [PMID: 29306045 DOI: 10.1016/j.cgh.2017.12.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
326 Pereira V, Abraham P, Nallapeta S, Shetty A. Gastric bacterial Flora in patients Harbouring Helicobacter pylori with or without chronic dyspepsia: analysis with matrix-assisted laser desorption ionization time-of-flight mass spectroscopy. BMC Gastroenterol 2018;18:20. [PMID: 29373960 DOI: 10.1186/s12876-018-0744-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
327 Sánchez-Alonzo K, Silva-Mieres F, Arellano-Arriagada L, Parra-Sepúlveda C, Bernasconi H, Smith CT, Campos VL, García-Cancino A. Nutrient Deficiency Promotes the Entry of Helicobacter pylori Cells into Candida Yeast Cells. Biology (Basel) 2021;10:426. [PMID: 34065788 DOI: 10.3390/biology10050426] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
328 Mera RM, Bravo LE, Camargo MC, Bravo JC, Delgado AG, Romero-Gallo J, Yepez MC, Realpe JL, Schneider BG, Morgan DR, Peek RM, Correa P, Wilson KT, Piazuelo MB. Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial. Gut. 2018;67:1239-1246. [PMID: 28647684 DOI: 10.1136/gutjnl-2016-311685] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 14.2] [Reference Citation Analysis]
329 Joo MK, Park CH, Kim JS, Park JM, Ahn JY, Lee BE, Lee JH, Yang HJ, Cho YK, Bang CS, Kim BJ, Jung HK, Kim BW, Lee YC; Korean College of Helicobacter Upper Gastrointestinal Research. Clinical Guidelines for Drug-Related Peptic Ulcer, 2020 Revised Edition.Gut Liver. 2020;14:707-726. [PMID: 33191311 DOI: 10.5009/gnl20246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Lopo I, Libânio D, Pita I, Dinis-ribeiro M, Pimentel-nunes P. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and meta-analysis. Helicobacter 2018;23:e12493. [DOI: 10.1111/hel.12493] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
331 Dore MP, Pes GM. What Is New in Helicobacter pylori Diagnosis. An Overview. J Clin Med 2021;10:2091. [PMID: 34068062 DOI: 10.3390/jcm10102091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
332 Biernat MM, Wróbel T. Bacterial Infection and Non-Hodgkin B-Cell Lymphoma: Interactions between Pathogen, Host and the Tumor Environment. Int J Mol Sci 2021;22:7372. [PMID: 34298992 DOI: 10.3390/ijms22147372] [Reference Citation Analysis]
333 Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, Choi IJ, Yoon SM, Kim SW, Baik GH, Lee JY, Kim JI, Kim SG, Kim J, Lee J, Kim JG, Kim JJ;  Korean College of Helicobacter Upper Gastrointestinal Research. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13:531-540. [PMID: 31505907 DOI: 10.5009/gnl19136] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
334 Schulz C, Kalali B, Link A, Gerhard M, Malfertheiner P. New rapid Helicobacter pylori blood test based on dual detection of FliD and CagA antibodies for on-site testing. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01220-9. [PMID: 34793965 DOI: 10.1016/j.cgh.2021.11.008] [Reference Citation Analysis]
335 Yang C, Liang L, Lv P, Liu L, Wang S, Wang Z, Chen Y. Effects of non-viable Lactobacillus reuteri combining with 14-day standard triple therapy on Helicobacter pylori eradication: A randomized double-blind placebo-controlled trial. Helicobacter 2021;26:e12856. [PMID: 34628695 DOI: 10.1111/hel.12856] [Reference Citation Analysis]
336 Xie M, Li Q, Zhang B, Zhang Q, Tian QJ, Liu H, Zang YJ, Rao W. Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients. Helicobacter 2021;26:e12791. [PMID: 33600067 DOI: 10.1111/hel.12791] [Reference Citation Analysis]
337 Mascellino MT, Oliva A, Miele MC, De Angelis M, Bruno G, Severi C. Secondary Antibiotic Resistance, Correlation between Genotypic and Phenotypic Methods and Treatment in Helicobacter pylori Infected Patients: A Retrospective Study. Antibiotics (Basel) 2020;9:E549. [PMID: 32872117 DOI: 10.3390/antibiotics9090549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
338 Graham DY. Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics (Basel) 2020;9:E671. [PMID: 33023041 DOI: 10.3390/antibiotics9100671] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
339 Jukic I, Rusic D, Vukovic J, Zivkovic PM, Bukic J, Leskur D, Seselja Perisin A, Luksic M, Modun D. Correlation of registered drug packs with Maastricht V/Florence Consensus Report and national treatment guidelines for management of Helicobacter pylori infection. Basic Clin Pharmacol Toxicol 2020;126:212-25. [DOI: 10.1111/bcpt.13322] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
340 Wauters L, Dickman R, Drug V, Mulak A, Serra J, Enck P, Tack J, Accarino A, Barbara G, Bor S, Coffin B, Corsetti M, De Schepper H, Dumitrascu D, Farmer A, Gourcerol G, Hauser G, Hausken T, Karamanolis G, Keszthelyi D, Malagelada C, Milosavljevic T, Muris J, O'Morain C, Papathanasopoulos A, Pohl D, Rumyantseva D, Sarnelli G, Savarino E, Schol J, Sheptulin A, Smet A, Stengel A, Storonova O, Storr M, Törnblom H, Vanuytsel T, Velosa M, Waluga M, Zarate N, Zerbib F; ESNM FD Consensus Group. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United European Gastroenterol J 2021;9:307-31. [PMID: 33939891 DOI: 10.1002/ueg2.12061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
341 Sato Y, Sato T, Matsushima J, Fujii A, Ono Y, Suda T, Katayama Y, Ban S. Histopathologic Change of a Case of Gastric Oxyntic Neoplasm (Gastric Adenocarcinoma of Fundic Gland Mucosa Type) Through 5 Years With Concurrent Other Oxyntic Gland Lesions. Int J Surg Pathol 2021;29:557-64. [PMID: 33030084 DOI: 10.1177/1066896920962574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
342 Menchicchi B, Savvaidou E, Thöle C, Hensel A, Goycoolea FM. Low-Molecular-Weight Dextran Sulfate Nanocapsules Inhibit the Adhesion of Helicobacter pylori to Gastric Cells. ACS Appl Bio Mater 2019;2:4777-89. [DOI: 10.1021/acsabm.9b00523] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
343 Hsieh MS, Kuo FC, Wu MC, Wang JW, Liu CJ, Chu NS, Tsai PY, Hsu PI, Wu IC, Wu JY, Wu DC, Yu FJ, Kuo CH. Tailored susceptibility-guided therapy via gastric juice PCR for the first-line H. pylori eradication, a randomized controlled trial. J Formos Med Assoc 2021:S0929-6646(21)00483-6. [PMID: 34836662 DOI: 10.1016/j.jfma.2021.10.011] [Reference Citation Analysis]
344 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.7] [Reference Citation Analysis]
345 Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol 2020;104:9891-905. [PMID: 33052519 DOI: 10.1007/s00253-020-10945-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
346 Fang YJ, Chen MJ, Chen CC, Lee JY, Yang TH, Yu CC, Chiu MC, Kuo CC, Weng YJ, Bair MJ, Wu MS, Luo JC, Liou JM. Accuracy of rapid Helicobacter pylori antigen tests for the surveillance of the updated prevalence of H. pylori in Taiwan. J Formos Med Assoc 2020;119:1626-33. [PMID: 31926791 DOI: 10.1016/j.jfma.2019.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
347 Mcnicholl AG, Gisbert JP. Reply. Clin Gastroenterol Hepatol 2019;17:2822-3. [PMID: 31757363 DOI: 10.1016/j.cgh.2019.05.054] [Reference Citation Analysis]
348 Fiorini G, Saracino IM, Zullo A, Gatta L, Pavoni M, Vaira D. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains. Helicobacter 2017;22:e12448. [DOI: 10.1111/hel.12448] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
349 Lu B, Wang J, Li J, Liu L, Chen Y. Half‐dose clarithromycin‐containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single‐center, open‐label, randomized trial. Helicobacter 2019;24:e12566. [DOI: 10.1111/hel.12566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
350 Yun CY, Kim N, Lee J, Lee JY, Hwang YJ, Lee HS, Yoon H, Shin CM, Park YS, Kim JW, Lee DH. Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors. Helicobacter. 2018;23:e12542. [PMID: 30303591 DOI: 10.1111/hel.12542] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
351 Boltin D, Ashorov O, Benejat L, Hamouda D, Belfer RG, Niv Y, Dickman R, Perets TT. Novel high resolution melt curve assay for the analysis of predominance of Helicobacter pylori clarithromycin resistance. Pathogens and Disease 2019;77:ftz042. [DOI: 10.1093/femspd/ftz042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
352 Kabakambira JD, Hategeka C, Page C, Ntirenganya C, Dusabejambo V, Ndoli J, Ngabonziza F, Hale D, Bayingana C, Walker T. Efficacy of Helicobacter pylori eradication regimens in Rwanda: A randomized controlled trial. BMC Gastroenterol. 2018;18:134. [PMID: 30165823 DOI: 10.1186/s12876-018-0863-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
353 Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036. [PMID: 28569272 DOI: 10.1038/nrdp.2017.36] [Cited by in Crossref: 178] [Cited by in F6Publishing: 184] [Article Influence: 35.6] [Reference Citation Analysis]
354 Kuo CJ, Lin CY, Le PH, Chang PY, Lai CH, Lin WR, Chang ML, Hsu JT, Cheng HT, Tseng CN, Lin CJ, Su MY, Hsieh SY, Chiu CT. Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains. BMC Gastroenterol 2020;20:218. [PMID: 32650737 DOI: 10.1186/s12876-020-01370-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
355 Park JY, Forman D, Waskito LA, Yamaoka Y, Crabtree JE. Epidemiology of Helicobacter pylori and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins (Basel). 2018;10:pii: E163. [PMID: 29671784 DOI: 10.3390/toxins10040163] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 14.3] [Reference Citation Analysis]
356 Romano M, Gravina AG, Nardone G, Federico A, Dallio M, Martorano M, Mucherino C, Romiti A, Avallone L, Granata L, Priadko K, Compare D, Tuccillo C, Romito MR, Sgambato D, Miranda A, Romano L, Loguercio C, Bazzoli F, Zagari RM. Non‐bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real‐life study. Helicobacter 2020;25. [DOI: 10.1111/hel.12694] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
357 Gisbert JP, McNicholl AG. Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies. Helicobacter. 2017;22. [PMID: 28464347 DOI: 10.1111/hel.12392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 7.4] [Reference Citation Analysis]
358 Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes 2020;11:1314-23. [PMID: 32362221 DOI: 10.1080/19490976.2020.1754118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
359 Shetty V, Lamichhane B, Tay CY, Pai GC, Lingadakai R, Balaraju G, Shetty S, Ballal M, Chua EG. High primary resistance to metronidazole and levofloxacin, and a moderate resistance to clarithromycin in Helicobacter pylori isolated from Karnataka patients. Gut Pathog. 2019;11:21. [PMID: 31110563 DOI: 10.1186/s13099-019-0305-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
360 El-assaad F, Gong L, Gia A, Yim HCH, El-omar EM. Helicobacter pylori, Peptic Ulcer Disease and Gastric Cancer. Gastrointestinal Diseases and their Associated Infections. Elsevier; 2019. pp. 17-29. [DOI: 10.1016/b978-0-323-54843-4.00002-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
361 Cui R, Song Z, Suo B, Tian X, Xue Y, Meng L, Niu Z, Jin Z, Zhang H, Zhou L. Correlation Analysis Among Genotype Resistance, Phenotype Resistance and Eradication Effect of Helicobacter pylori. Infect Drug Resist 2021;14:1747-56. [PMID: 34012273 DOI: 10.2147/IDR.S305996] [Reference Citation Analysis]
362 Ludvigsson JF, Ciacci C, Green PH, Kaukinen K, Korponay-Szabo IR, Kurppa K, Murray JA, Lundin KEA, Maki MJ, Popp A, Reilly NR, Rodriguez-Herrera A, Sanders DS, Schuppan D, Sleet S, Taavela J, Voorhees K, Walker MM, Leffler DA. Outcome measures in coeliac disease trials: the Tampere recommendations. Gut. 2018;67:1410-1424. [PMID: 29440464 DOI: 10.1136/gutjnl-2017-314853] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 13.3] [Reference Citation Analysis]
363 Glover B, Teare J, Ashrafian H, Patel N. The endoscopic predictors of Helicobacter pylori status: a meta-analysis of diagnostic performance. Ther Adv Gastrointest Endosc 2020;13:2631774520950840. [PMID: 33150333 DOI: 10.1177/2631774520950840] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
364 Lee JW, Kim N, Nam RH, Lee SM, Soo In C, Kim JM, Lee DH. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2019;34:666-72. [DOI: 10.1111/jgh.14625] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
365 Wang Z, Ren R, Yang Y. Mucosa microbiome of gastric lesions: Fungi and bacteria interactions. Prog Mol Biol Transl Sci 2020;171:195-213. [PMID: 32475522 DOI: 10.1016/bs.pmbts.2020.03.004] [Reference Citation Analysis]
366 Li J, Deng J, Wang Z, Li H, Wan C. Antibiotic Resistance of Helicobacter pylori Strains Isolated From Pediatric Patients in Southwest China. Front Microbiol 2020;11:621791. [PMID: 33574804 DOI: 10.3389/fmicb.2020.621791] [Reference Citation Analysis]
367 Gravina AG, Priadko K, Ciamarra P, Granata L, Facchiano A, Miranda A, Dallio M, Federico A, Romano M. Extra-Gastric Manifestations of Helicobacter pylori Infection. J Clin Med 2020;9:E3887. [PMID: 33265933 DOI: 10.3390/jcm9123887] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
368 Barbuti RC, Schiavon LL, Oliveira CP, Alvares-DA-Silva MR, Sassaki LY, Passos MDCF, Farias AQ, Barros LL, Barreto BP, Albuquerque GBML, Alves AM, Navarro-Rodriguez T, Bittencourt PL. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). Arq Gastroenterol 2020;57:381-98. [PMID: 33331485 DOI: 10.1590/S0004-2803.202000000-72] [Reference Citation Analysis]
369 Kim J, Wang TC. Helicobacter pylori and Gastric Cancer. Gastrointest Endosc Clin N Am 2021;31:451-65. [PMID: 34053633 DOI: 10.1016/j.giec.2021.03.003] [Reference Citation Analysis]
370 Ford AC, Tsipotis E, Yuan Y, Leontiadis GI, Moayyedi P. Efficacy of Helicobacter pylori eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. Gut 2022:gutjnl-2021-326583. [PMID: 35022266 DOI: 10.1136/gutjnl-2021-326583] [Reference Citation Analysis]
371 Spurnic AR, Bukumiric Z, Jevtovic D, Brmbolic B, Pekmezovic T, Salemovic D, Pesic Pavlovic I, Milosevic I, Ranin J, Korac M. Helicobacter pylori infection rates in dyspeptic Serbian HIV-infected patients compared to HIV-negative controls. PLoS One 2021;16:e0248041. [PMID: 33690620 DOI: 10.1371/journal.pone.0248041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Olekhnovich EI, Manolov AI, Samoilov AE, Prianichnikov NA, Malakhova MV, Tyakht AV, Pavlenko AV, Babenko VV, Larin AK, Kovarsky BA, Starikova EV, Glushchenko OE, Safina DD, Markelova MI, Boulygina EA, Khusnutdinova DR, Malanin SY, Abdulkhakov SR, Abdulkhakov RA, Grigoryeva TV, Kostryukova ES, Govorun VM, Ilina EN. Shifts in the Human Gut Microbiota Structure Caused by Quadruple Helicobacter pylori Eradication Therapy. Front Microbiol 2019;10:1902. [PMID: 31507546 DOI: 10.3389/fmicb.2019.01902] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
373 Ouyang Y, Liu G, Xu W, Yang Z, Li N, Xie C, Zhou C, Chen J, Zhu Y, Hong J, Lu N. Helicobacter pylori induces epithelial-mesenchymal transition in gastric carcinogenesis via the AKT/GSK3β signaling pathway. Oncol Lett 2021;21:165. [PMID: 33552283 DOI: 10.3892/ol.2021.12426] [Reference Citation Analysis]
374 Ghoshal UC, Gwee K, Holtmann G, Li Y, Park SJ, Simadibrata M, Sugano K, Wu K, Quigley EMM, Cohen H. The role of the microbiome and the use of probiotics in gastrointestinal disorders in adults in the Asia-Pacific region - background and recommendations of a regional consensus meeting: Gut microbiome/probiotics in Asia-Pacific. Journal of Gastroenterology and Hepatology 2018;33:57-69. [DOI: 10.1111/jgh.13840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
375 Hamidi S, Badmasti F, Sadeghpour Heravi F, Safapoor MH, Mohammad Ali Tabrizi A, Ghorbani M, Azizi O. Antibiotic resistance and clonal relatedness of Helicobacter pylori strains isolated from stomach biopsy specimens in northeast of Iran. Helicobacter 2020;25:e12684. [PMID: 32074664 DOI: 10.1111/hel.12684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
376 Resina E, Gisbert JP. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiotics (Basel) 2021;10:1028. [PMID: 34572610 DOI: 10.3390/antibiotics10091028] [Reference Citation Analysis]
377 Cameron D, Hock QS, Kadim M, Mohan N, Ryoo E, Sandhu B, Yamashiro Y, Jie C, Hoekstra H, Guarino A. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. World J Gastroenterol 2017; 23(45): 7952-7964 [PMID: 29259371 DOI: 10.3748/wjg.v23.i45.7952] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
378 Di Palma A, Alhabdan S, Maeda A, Chetty R, Serra S, Quereshy F, Jackson T, Okrainec A. Preoperative Helicobacter pylori Screening and Treatment in Patients Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg 2020;30:2816-20. [PMID: 32030613 DOI: 10.1007/s11695-020-04436-0] [Reference Citation Analysis]
379 Abadi ATB, Ierardi E. Vonoprazan and Helicobacter pylori Treatment: A Lesson From Japan or a Limited Geographic Phenomenon? Front Pharmacol. 2019;10:316. [PMID: 31024299 DOI: 10.3389/fphar.2019.00316] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
380 Auttajaroon J, Vilaichone R, Chotivitayatarakorn P, Mahachai V. Once‐daily rabeprazole, levofloxacin, clarithromycin‐MR, and bismuth for Helicobacter pylori eradication: A randomized study of 7 or 14 days (ONCE study). Helicobacter 2019;24. [DOI: 10.1111/hel.12615] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
381 Xie Y, Pan X, Li Y, Wang H, Du Y, Xu J, Wang J, Zeng Z, Chen Y, Zhang G, Wu K, Liu D, Lv N. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial. Journal of Antimicrobial Chemotherapy 2018;73:1681-7. [DOI: 10.1093/jac/dky056] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
382 Chen M, Liu C, Huan H, Hu RW, Wu H, Deng K. A comparative study on Helicobacter pylori infection in Tibetan and Han people from Tibet and Sichuan province. Shijie Huaren Xiaohua Zazhi 2018; 26(23): 1402-1407 [DOI: 10.11569/wcjd.v26.i23.1402] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
383 Feng XY, Zhang Y, Deng B. Progress in research of high-dose dual therapy as an eradication protocol for Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2020; 28(17): 847-851 [DOI: 10.11569/wcjd.v28.i17.847] [Reference Citation Analysis]
384 Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS, Pérez-Pérez G, Torres-López J, Abdo-Francis JM, Bielsa-Fernandez MV, Camargo MC, Esquivel-Ayanegui F, Garza-González E, Hernández-Guerrero AI, Herrera-Goepfert R, Huerta-Iga FM, Leal-Herrera Y, Lopéz-Colombo A, Ortiz-Olvera NX, Riquelme-Pérez A, Sampieri CL, Uscanga-Domínguez LF, Velarde-Ruiz Velasco JA. The fourth Mexican consensus on Helicobacter pylori. Rev Gastroenterol Mex (Engl Ed) 2018;83:325-41. [PMID: 29941237 DOI: 10.1016/j.rgmx.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
385 Bornschein J, Rugge M. Bright future for endoscopy: the new frontier of gastric cancer secondary prevention. Gut 2020;69:1723-4. [PMID: 32532892 DOI: 10.1136/gutjnl-2020-321570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
386 Klesiewicz K, Karczewska E, Nowak P, Skiba-kurek I, Sito E, Pańczyk K, Koczurkiewicz P, Żelaszczyk D, Pękala E, Waszkielewicz AM, Budak A, Marona H, Gunia-krzyżak A. Anti-Helicobacter pylori activities of selected N-substituted cinnamamide derivatives evaluated on reference and clinical bacterial strains. J Antibiot 2018;71:543-8. [DOI: 10.1038/s41429-018-0027-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
387 Li L, Jing J, Gao H, Zhang C, Lou H, Pan W. Regular arrangement of collecting venules under endoscopy for predicting a Helicobacter pylori-negative stomach: A systematic review and meta-analysis. Gastroenterol Hepatol 2021;44:286-92. [PMID: 33097281 DOI: 10.1016/j.gastrohep.2020.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
388 Murata M, Sugimoto M, Ban H, Otsuka T, Nakata T, Fukuda M, Inatomi O, Bamba S, Kushima R, Andoh A. Cap polyposis refractory to Helicobacter pylori eradication treated with endoscopic submucosal dissection. World J Gastrointest Endosc 2017; 9(10): 529-534 [PMID: 29085564 DOI: 10.4253/wjge.v9.i10.529] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
389 Boyanova L, Markovska R, Hadzhiyski P, Kandilarov N, Mitov I. Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data. Future Microbiol 2020;15:1185-96. [PMID: 32954842 DOI: 10.2217/fmb-2020-0084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
390 Marques AT, Vítor JMB, Santos A, Oleastro M, Vale FF. Trends in Helicobacter pylori resistance to clarithromycin: from phenotypic to genomic approaches. Microb Genom 2020;6. [PMID: 32118532 DOI: 10.1099/mgen.0.000344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
391 Ponzetto A, Holton J. Risk of Rebleeding After Hemostasis for Peptic Ulcer. Dig Dis Sci 2019;64:281-2. [PMID: 30446930 DOI: 10.1007/s10620-018-5375-y] [Reference Citation Analysis]
392 Matysiak-Budnik T, Fabiani B, Hennequin C, Thieblemont C, Malamut G, Cadiot G, Bouché O, Ruskoné-Fourmestraux A. Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH). Dig Liver Dis 2018;50:124-31. [PMID: 29301732 DOI: 10.1016/j.dld.2017.12.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
393 Akriviadis E, Liava C. Proton pump inhibitors and risk for gastric cancer: Is it real? Turk J Gastroenterol 2019;30:309-10. [PMID: 30923034 DOI: 10.5152/tjg.2019.18674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
394 Georgopoulos SD, Xirouchakis E. Which Regimens Should Be Used and Which Rejected for the Treatment of Helicobacter pylori? Am J Gastroenterol 2017;112:1168-9. [PMID: 28725073 DOI: 10.1038/ajg.2017.90] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
395 Zhang J, Ge L, Hill M, Liang Y, Xie J, Cui D, Li X, Zheng W, He R. Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness Analysis. Front Pharmacol 2018;9:1512. [PMID: 30666204 DOI: 10.3389/fphar.2018.01512] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
396 Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, Bujanda L, Lucendo A, Jurecic NB, Perez-Lasala J, Shvets O, Fadeenko G, Huguet JM, Kikec Z, Bordin D, Voynovan I, Leja M, Machado JC, Areia M, Fernandez-Salazar L, Rodrigo L, Alekseenko S, Barrio J, Ortuño J, Perona M, Vologzhanina L, Romero PM, Zaytsev O, Rokkas T, Georgopoulos S, Pellicano R, Buzas GM, Modolell I, Gomez Rodriguez BJ, Simsek I, Simsek C, Lafuente MR, Ilchishina T, Camarero JG, Dominguez-Cajal M, Ntouli V, Dekhnich NN, Phull P, Nuñez O, Lerang F, Venerito M, Heluwaert F, Tonkic A, Caldas M, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol 2021;116:1220-9. [PMID: 33840725 DOI: 10.14309/ajg.0000000000001246] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
397 Kapizioni C, Koutoufaris G, Ntouli V, Makris K, Milioni K, Kourkoulis P, Giannelis P, Mellos A, Michalopoulos G, Vrakas S, Xourgias V. Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study. European Journal of Gastroenterology & Hepatology 2019;31:1206-10. [DOI: 10.1097/meg.0000000000001517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
398 Fontes LES, Martimbianco ALC, Zanin C, Riera R. N-acetylcysteine as an adjuvant therapy for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2019;2:CD012357. [PMID: 30746681 DOI: 10.1002/14651858.cd012357.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
399 Wang YH, Li Z, Wang L, Zhu-Ge LY, Zhao RL, Wu S, Wang Y, An Y, Xie Y. A systematic review and meta-analysis of genotypic methods for detecting antibiotic resistance in Helicobacter pylori. Helicobacter 2018;23:e12467. [PMID: 29405526 DOI: 10.1111/hel.12467] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
400 Ogata SK, Camorlinga-Ponce M, Granato CFH, Rohr MRDS, Artigiani Neto R, Kawakami E. Development and validation of a whole-cell ELISA for serologically diagnosing Helicobacter pylori infection in Brazilian children and adults: a diagnostic accuracy study. Sao Paulo Med J 2018;136:442-8. [PMID: 30570095 DOI: 10.1590/1516-3180.2018.0203310818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
401 Kotilea K, Bontems P, Touati E. Epidemiology, Diagnosis and Risk Factors of Helicobacter pylori Infection. Adv Exp Med Biol. 2019;1149:17-33. [PMID: 31016621 DOI: 10.1007/5584_2019_357] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
402 Öztekin M, Yılmaz B, Ağagündüz D, Capasso R. Overview of Helicobacter pylori Infection: Clinical Features, Treatment, and Nutritional Aspects. Diseases 2021;9:66. [PMID: 34698140 DOI: 10.3390/diseases9040066] [Reference Citation Analysis]
403 Dacoll C, Sánchez-delgado J, Balter H, Pazos X, Di Pace M, Sandoya G, Cohen H, Calvet X. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay. Gastroenterología y Hepatología 2017;40:447-54. [DOI: 10.1016/j.gastrohep.2017.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
404 Liu L, Gao H, Wang H, Yu W, Zhu K, Zhang Y, Guo J. Comparison of Esophageal Function Tests to Investigate the Effect of Helicobacter Pylori Infection on Gastroesophageal Reflux Disease (GERD). Med Sci Monit. 2018;24:4791-4797. [PMID: 29992917 DOI: 10.12659/msm.908051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
405 Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
406 Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020;13:1756284820976990. [PMID: 33354229 DOI: 10.1177/1756284820976990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
407 Ierardi E, Losurdo G, Iannone A, Piscitelli D, Amoruso A, Barone M, Principi M, Pisani A, Di Leo A. Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored? Ann Gastroenterol. 2017;30:380-392. [PMID: 28655974 DOI: 10.20524/aog.2017.0165] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
408 Costa L, Corre S, Michel V, Le Luel K, Fernandes J, Ziveri J, Jouvion G, Danckaert A, Mouchet N, Da Silva Barreira D, Torres J, Camorlinga M, D'Elios MM, Fiette L, De Reuse H, Galibert MD, Touati E. USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis. Gut 2020;69:1582-91. [PMID: 31822580 DOI: 10.1136/gutjnl-2019-318640] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
409 Seo JH, Park JS, Rhee KH, Youn HS. Diagnosis of Helicobacter pylori Infection in Children and Adolescents in Korea. Pediatr Gastroenterol Hepatol Nutr 2018;21:219-33. [PMID: 30345235 DOI: 10.5223/pghn.2018.21.4.219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
410 O'connor A, Furuta T, Gisbert JP, O'morain C. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25. [DOI: 10.1111/hel.12743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
411 Kori M, Le Thi TG, Werkstetter K, Sustmann A, Bontems P, Lopes AI, Oleastro M, Iwanczak B, Kalach N, Misak Z, Cabral J, Homan M, Cilleruelo Pascual ML, Pehlivanoglu E, Casswall T, Urruzuno P, Martinez Gomez MJ, Papadopoulou A, Roma E, Dolinsek J, Rogalidou M, Urbonas V, Chong S, Kindermann A, Miele E, Rea F, Cseh Á, Koletzko S; Helicobacter pylori Working Group of ESPGHAN. Helicobacter pylori Infection in Pediatric Patients Living in Europe: Results of the EuroPedHP Registry 2013 to 2016. J Pediatr Gastroenterol Nutr 2020;71:476-83. [PMID: 32541200 DOI: 10.1097/MPG.0000000000002816] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
412 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine 2020;81:50-3. [DOI: 10.1016/j.ejim.2020.06.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
413 Wu D, Sun Z, Li T, Tan Q, Sun Y, Chen T, Liu Y, Li J, Jiang H, Yuan Z, Zhao Y, Chen W. Efficacy of quadruple regimen with polaprezinc for gastric Helicobacter pylori infection eradication: protocol for a single-centre, single-blind, non-inferiority, randomised clinical trial. BMJ Open 2020;10:e037182. [PMID: 33203625 DOI: 10.1136/bmjopen-2020-037182] [Reference Citation Analysis]
414 Wang T, Yang X, Li Y, Li L, Liu J, Ji C, Sun Y, Li Y, Zuo X. Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study. Helicobacter. 2019;24:e12569. [PMID: 30848868 DOI: 10.1111/hel.12569] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
415 Xie S, Wang S, Xue L, Middleton DRS, Guan C, Hao C, Wang J, Li B, Chen R, Li X, Wei W. Helicobacter pylori Is Associated With Precancerous and Cancerous Lesions of the Gastric Cardia Mucosa: Results of a Large Population-Based Study in China. Front Oncol 2020;10:205. [PMID: 32195175 DOI: 10.3389/fonc.2020.00205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
416 Mousavi T, Nikfar S, Abdollahi M. The pharmacotherapeutic management of duodenal and gastric ulcers. Expert Opin Pharmacother 2021;:1-27. [PMID: 34435515 DOI: 10.1080/14656566.2021.1959914] [Reference Citation Analysis]
417 Sun L, Tu H, Chen T, Yuan Q, Liu J, Dong N, Yuan Y. Three-dimensional combined biomarkers assay could improve diagnostic accuracy for gastric cancer. Sci Rep 2017;7:11621. [PMID: 28912586 DOI: 10.1038/s41598-017-12022-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
418 Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155: 1372-1382. e17. [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007] [Cited by in Crossref: 274] [Cited by in F6Publishing: 238] [Article Influence: 68.5] [Reference Citation Analysis]
419 Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018;23:e12495. [PMID: 29873436 DOI: 10.1111/hel.12495] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
420 Hunt R, B Lazebnik L, C Marakhouski Y, Manuc M, Gn R, S Aye K, S Bordin D, V Bakulina N, S Iskakov B, A Khamraev A, M Stepanov Y, Ally R, Garg A. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Antiinflammatory Drugs Induced Gastropathy-ICON-G. Euroasian J Hepatogastroenterol 2018;8:148-60. [PMID: 30828557 DOI: 10.5005/jp-journals-10018-1281] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
421 Dekhnich N, Ivanchik N, Kozlov R, Alimov A, Steshits A, Kirsov P, Pandav K. Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation. Helicobacter 2018;23:e12545. [PMID: 30324756 DOI: 10.1111/hel.12545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
422 Coelho LG, Sant'Ana CR, Oliveira RB, Cezar RCE, Araujo ACC, Silva RCTD, Trindade OR, Coelho MC, Ferrioli E, Bendassolli JA. Performance of the 13C-urea breath test for the diagnosis of H. pylori infection using a substrate synthesized in Brazil: A preliminary study. Clinics (Sao Paulo). 2018;73:e16553. [PMID: 29898005 DOI: 10.6061/clinics/2018/e16-553] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
423 Kim YJ, Chung WC, Kim DB. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection. Helicobacter 2021;26:e12792. [PMID: 33650225 DOI: 10.1111/hel.12792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rescue Therapies for Helicobacter pylori Infection in Foreign Patients Treated in Italy. J Clin Gastroenterol 2021;55:865-8. [PMID: 33136782 DOI: 10.1097/MCG.0000000000001457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
425 Chapelle N, Jirka I, Péron M, Quénéhervé L, Cauchin E, Touchefeu Y, Coron E, Mosnier JF, Matysiak-Budnik T. Evaluation of a Phone Call Reminder Strategy in the Surveillance of Patients with Gastric Precancerous Lesions Lost to Follow-Up. Gastrointest Tumors 2020;7:110-6. [PMID: 33173774 DOI: 10.1159/000508873] [Reference Citation Analysis]
426 Mégraud F. Time to change approaches to Helicobacter pylori management. Lancet Gastroenterol Hepatol 2017;2:692-3. [PMID: 28781120 DOI: 10.1016/S2468-1253(17)30245-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
427 Hsu PI, Tsai FW, Kao SS, Hsu WH, Cheng JS, Peng NJ, Tsai KW, Hu HM, Wang YK, Chuah SK, Chen A, Wu DC. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Am J Gastroenterol. 2017;112:1374-1381. [PMID: 28719592 DOI: 10.1038/ajg.2017.195] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
428 Liou J, Chen P, Luo J, Lee J, Chen C, Fang Y, Yang T, Chang C, Bair M, Chen M, Hsu Y, Hsu W, Chang C, Lin J, Shun C, El-omar EM, Wu M, Liou J, Lee Y, Lin J, Wu C, Wu J, Chen C, Lin C, Fang Y, Bair M, Luo J, Wu M, Cheng T, Tseng P, Chiu H, Chang C, Yu C, Chiu M, Chen Y, Hu W, Chou C, Tai C, Lee C, Wang W, Chang W. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology 2018;155:1109-19. [DOI: 10.1053/j.gastro.2018.06.047] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
429 Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmański Ł, Migdał P, Gościniak G. In Vitro Activity of 3-Bromopyruvate, an Anticancer Compound, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains. Cancers (Basel) 2019;11:E229. [PMID: 30781380 DOI: 10.3390/cancers11020229] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
430 Fang J, Du YQ, Liu WZ, Ren JL, Li YQ, Chen XY, Lv NH, Chen YX, Lv B; Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on chronic gastritis (2017, Shanghai): 2017 Chinese consensus on CG. Journal of Digestive Diseases 2018;19:182-203. [DOI: 10.1111/1751-2980.12593] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
431 Krzyżek P, Grande R. Transformation of Helicobacter pylori into Coccoid Forms as a Challenge for Research Determining Activity of Antimicrobial Substances. Pathogens 2020;9:E184. [PMID: 32143312 DOI: 10.3390/pathogens9030184] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
432 Brito-Gonçalves G, Libânio D, Marcos P, Pita I, Castro R, Sá I, Dinis-Ribeiro M, Pimentel-Nunes P. Clinicopathologic Characteristics of Patients with Gastric Superficial Neoplasia and Risk Factors for Multiple Lesions after Endoscopic Submucosal Dissection in a Western Country. GE Port J Gastroenterol 2020;27:76-89. [PMID: 32266305 DOI: 10.1159/000501939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
433 Kim JL, Cho SJ, Chung SJ, Lee A, Choi J, Chung H, Kim SG. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial. Clin Transl Gastroenterol 2020;11:e00194. [PMID: 33094958 DOI: 10.14309/ctg.0000000000000194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Arévalo-Jaimes BV, Rojas-Rengifo DF, Jaramillo CA, de Molano BM, Vera-Chamorro JF, Del Pilar Delgado M. Genotypic determination of resistance and heteroresistance to clarithromycin in Helicobacter pylori isolates from antrum and corpus of Colombian symptomatic patients. BMC Infect Dis 2019;19:546. [PMID: 31226948 DOI: 10.1186/s12879-019-4178-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
435 Chen Q, Liang X, Long X, Yu L, Liu W, Lu H. Cost-effectiveness analysis of screen-and-treat strategy in asymptomatic Chinese for preventing Helicobacter pylori-associated diseases. Helicobacter. 2019;24:e12563. [PMID: 30672082 DOI: 10.1111/hel.12563] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
436 Rugge M, Meggio A, Pravadelli C, Barbareschi M, Fassan M, Gentilini M, Zorzi M, Pretis GD, Graham DY, Genta RM. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut 2018;68:11-7. [DOI: 10.1136/gutjnl-2017-314600] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 13.5] [Reference Citation Analysis]
437 Manu P, Rogozea LM, Sandor V, Dumitraşcu DL. Pharmacological Management of Peptic Ulcer: A Century of Expert Opinions in Cecil Textbook of Medicine. Am J Ther 2021;28:e552-9. [PMID: 34469923 DOI: 10.1097/MJT.0000000000001439] [Reference Citation Analysis]
438 Gökışık MT, Uyar S. The role of Helicobacter pylori in vitamin-B12 deficiency due to metformin use. Helicobacter 2020;25:e12718. [PMID: 32559822 DOI: 10.1111/hel.12718] [Reference Citation Analysis]
439 Choi IJ. [Helicobacter pylori Eradication Therapy and Gastric Cancer Prevention]. Korean J Gastroenterol 2018;72:245-51. [PMID: 30642140 DOI: 10.4166/kjg.2018.72.5.245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
440 Sugimoto M, Murata M, Yamaoka Y. Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis. World J Gastroenterol 2020; 26(15): 1820-1840 [PMID: 32351296 DOI: 10.3748/wjg.v26.i15.1820] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
441 Garcia-Castillo V, Marín-Vega AM, Ilabaca A, Albarracín L, Marcial G, Kitazawa H, Garcia-Cancino A, Villena J. Characterization of the immunomodulatory and anti-Helicobacter pylori properties of the human gastric isolate Lactobacillus rhamnosus UCO-25A. Biofouling 2019;35:922-37. [PMID: 31646895 DOI: 10.1080/08927014.2019.1675153] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
442 Romstad KK, Detlie TE, Søberg T, Ricanek P, Jahnsen ME, Lerang F, Jahnsen J. Gastrointestinal bleeding due to peptic ulcers and erosions – a prospective observational study (BLUE study). Scandinavian Journal of Gastroenterology 2020;55:1139-45. [DOI: 10.1080/00365521.2020.1819405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
443 Wands DIF, El-Omar EM, Hansen R. Helicobacter pylori: getting to grips with the guidance. Frontline Gastroenterol 2021;12:650-5. [PMID: 34917323 DOI: 10.1136/flgastro-2020-101571] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
444 Khoury J, Geffen Y, Shaul R, Sholy H, Chowers Y, Saadi T. Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults. Journal of Global Antimicrobial Resistance 2017;10:182-5. [DOI: 10.1016/j.jgar.2017.05.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
445 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
446 Wauters L, Dickman R, Drug V, Mulak A, Serra J, Enck P, Tack J, Accarino A, Barbara G, Bor S, Coffin B, Corsetti M, De Schepper H, Dumitrascu D, Farmer A, Gourcerol G, Hauser G, Hausken T, Karamanolis G, Keszthelyi D, Malagelada C, Milosavljevic T, Muris J, O'Morain C, Papathanasopoulos A, Pohl D, Rumyantseva D, Sarnelli G, Savarino E, Schol J, Sheptulin A, Smet A, Stengel A, Storonova O, Storr M, Törnblom H, Vanuytsel T, Velosa M, Waluga M, Zarate N, Zerbib F; ESNM FD Consensus Group. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. Neurogastroenterol Motil 2021;33:e14238. [PMID: 34586707 DOI: 10.1111/nmo.14238] [Reference Citation Analysis]
447 Terasawa T, Hamashima C, Kato K, Miyashiro I, Yoshikawa T, Takaku R, Nishida H. Helicobacter pylori eradication treatment for gastric carcinoma prevention in asymptomatic or dyspeptic adults: systematic review and Bayesian meta-analysis of randomised controlled trials. BMJ Open 2019;9:e026002. [PMID: 31542733 DOI: 10.1136/bmjopen-2018-026002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
448 Pritchard DM, Bornschein J, Beales I, Beresniak A, Salhi H, Malfertheiner P. Cost-effectiveness modelling of use of urea breath test for the management of Helicobacter pylori-related dyspepsia and peptic ulcer in the UK. BMJ Open Gastroenterol 2021;8:e000685. [PMID: 34244244 DOI: 10.1136/bmjgast-2021-000685] [Reference Citation Analysis]
449 Fernández-Reyes M, Tamayo E, Rojas-Rengifo D, Fischer W, Carrasco-García E, Alonso M, Lizasoain J, Bujanda L, Cosme Á, Montes M. Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain. Eur J Clin Invest 2019;49:e13150. [PMID: 31192451 DOI: 10.1111/eci.13150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
450 Choe AR, Shim KN, Park Y, Song EM, Tae CH, Jung SA. Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients with Helicobacter pylori Infection. J Clin Med 2021;10:2619. [PMID: 34198677 DOI: 10.3390/jcm10122619] [Reference Citation Analysis]
451 Chen L, Cui H, Fan S, Li Z, Han S, Ma X, Luo S, Song X, Lv Q. Detection of Helicobacter pylori in dental plaque using a DNA biosensor for noninvasive diagnosis. RSC Adv 2018;8:21075-83. [DOI: 10.1039/c8ra03134g] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
452 Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Niv Y, Dickman R, Dotan I, Birkenfeld S. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol 2019;114:900-6. [PMID: 31095531 DOI: 10.14309/ajg.0000000000000223] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
453 Lee JW, Kim N, Nam RH, Jang JY, Choi Y, Lee DH. Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance. Helicobacter 2021;:e12844. [PMID: 34382277 DOI: 10.1111/hel.12844] [Reference Citation Analysis]
454 Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter. 2019;24:e12565. [PMID: 30698318 DOI: 10.1111/hel.12565] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
455 Zhao Y, Zhang J, Cheng ASL, Yu J, To KF, Kang W. Gastric cancer: genome damaged by bugs. Oncogene 2020;39:3427-42. [PMID: 32123313 DOI: 10.1038/s41388-020-1241-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
456 Ji CR, Liu J, Li YY, Qiao C, Qu JY, Hu JN, Lin MJ, Ji R, Li LX, Zuo XL, Li YQ. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. J Dig Dis 2020;21:549-57. [PMID: 32833285 DOI: 10.1111/1751-2980.12934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
457 Shinzaki S, Fujii T, Bamba S, Ogawa M, Kobayashi T, Oshita M, Tanaka H, Ozeki K, Takahashi S, Kitamoto H, Kani K, Nanjo S, Sugaya T, Sakakibara Y, Inokuchi T, Kakimoto K, Yamada A, Yasuhara H, Yokoyama Y, Yoshino T, Matsui A, Nakamura M, Tomizawa T, Sakemi R, Kamata N, Hibi T. Seven days triple therapy for eradication of Helicobacter pylori does not alter the disease activity of patients with inflammatory bowel disease. Intest Res 2018;16:609-18. [PMID: 30301329 DOI: 10.5217/ir.2018.00044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
458 Kayamba V, Shibemba A, Zyambo K, Heimburger DC, Morgan D, Kelly P. HIV related hypochlorhydria does not appear to respond to anti-retroviral therapy in Zambian adults: a case control study. Pan Afr Med J 2018;31:128. [PMID: 31037188 DOI: 10.11604/pamj.2018.31.128.11850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
459 Peng C, Sang S, Shen X, Zhang W, Yan J, Chen P, Jiang C, Yuan Y, Zhu W, Yao M. In vitro anti-Helicobacter pylori activity of Syzygium aromaticum and the preliminary mechanism of action. J Ethnopharmacol 2022;:114995. [PMID: 35032584 DOI: 10.1016/j.jep.2022.114995] [Reference Citation Analysis]
460 Zamani M, Zamani V, Derakhshan MH, Shokri-Shirvani J. The efficacy of first-line regimens for Helicobacter pylori eradication in different continents: A systematic review and network meta-analysis protocol. Medicine (Baltimore). 2018;97:e13682. [PMID: 30558078 DOI: 10.1097/md.0000000000013682] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
461 Crafa P, Franceschi M, Rodriguez Castro KI, Barchi A, Russo M, Franzoni L, Antico A, Baldassarre G, Panozzo MP, Di Mario F. Functional Dyspesia. Acta Biomed 2020;91:e2020069. [PMID: 32921764 DOI: 10.23750/abm.v91i3.10150] [Reference Citation Analysis]
462 Wang J, Cao Y, He W, Li X. Efficacy and safety of bismuth quadruple regimens containing tetracycline or furazolidone for initial eradication of Helicobacter pylori. Medicine (Baltimore) 2021;100:e28323. [PMID: 34941132 DOI: 10.1097/MD.0000000000028323] [Reference Citation Analysis]
463 Zhou B, Chen L, Li B, Wan L, Ai Y. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta‐analysis with trial sequential analysis. Helicobacter 2019;24. [DOI: 10.1111/hel.12651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
464 Yanyan S, Yanlei G, Ting Z, Shigang D. Hydrotalcite Can Prevent the Damaging Effects of Helicobacter Pylori on Gastric Epithelial Cells. Microsc Microanal 2018;24:277-83. [PMID: 29952282 DOI: 10.1017/S1431927618000314] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
465 Nouri D, Soleimanian Gj N, Ataei F, Mohammadi M. Effects of sex, age, size and location of perforation on the sensitivity of erect chest X-ray for gastroduodenal perforation. Radiography (Lond) 2021;27:1158-61. [PMID: 34247912 DOI: 10.1016/j.radi.2021.06.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Chen Q, Long X, Ji Y, Liang X, Li D, Gao H, Xu B, Liu M, Chen Y, Sun Y, Zhao Y, Xu G, Song Y, Yu L, Zhang W, Liu W, Graham DY, Lu H. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Aliment Pharmacol Ther. 2019;49:1385-1394. [PMID: 31020673 DOI: 10.1111/apt.15273] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
467 Bustamante-Rengifo JA, Astudillo-Hernández M, Del Pilar Crespo-Ortiz M. Effect of Helicobacter pylori and Helminth Coinfection on the Immune Response to Mycobacterium tuberculosis. Curr Microbiol 2021;78:3351-71. [PMID: 34251513 DOI: 10.1007/s00284-021-02604-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
468 Savarino V, Antonioli L, Fornai M, Marabotto E, Demarzo MG, Zingone F, Ghisa M, Barberio B, Zentilin P, Ribolsi M, Savarino E. An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 2021;:1-10. [PMID: 34550866 DOI: 10.1080/17474124.2021.1984878] [Reference Citation Analysis]
469 Hori T, Yamamoto H, Harada H, Yamamoto M, Yamada M, Yazawa T, Sasaki B, Tani M, Sato A, Katsura H, Kamada Y, Tani R, Aoyama R, Sasaki Y, Shintaku M, Iwasa Y, Zaima M. Multiple Gastric Carcinomas Associated with Epstein-Barr Virus and Helicobacter pylori: A Thought-Provoking Case. Am J Case Rep 2021;22:e931668. [PMID: 34158469 DOI: 10.12659/AJCR.931668] [Reference Citation Analysis]
470 Palamides P, Jolaiya T, Idowu A, Loell E, Onyekwere C, Ugiagbe R, Agbo I, Lesi O, Ndububa D, Adekanle O, Carranza M, Ally R, Njom H, Adeleye IA, Harrison U, Clarke A, Fischer W, Smith S, Haas R. Helicobacter pylori patient isolates from South Africa and Nigeria differ in virulence factor pathogenicity profile and associated gastric disease outcome. Sci Rep 2020;10:11409. [PMID: 32651394 DOI: 10.1038/s41598-020-66128-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
471 Lee YC, Lin JT. Screening and Treating Helicobacter pylori Infection for Gastric Cancer Prevention on the Population Level. J Gastroenterol Hepatol. 2017; Jan 14. [Epub ahead of print]. [PMID: 28087975 DOI: 10.1111/jgh.13726] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
472 Jin L, Li SY, Dai FL, Dai M, Xu WT. Efficacy and safety of Bifidobacterium combined with ilaprazole-containning quadruple therapy in rescue eradication of Helicobacter pyloriShijie Huaren Xiaohua Zazhi 2018; 26(4): 256-262 [DOI: 10.11569/wcjd.v26.i4.256] [Reference Citation Analysis]
473 Üçgül Atılgan C, Yozgat A, Kösekahya P, Çağlayan M, Şendul SY, Berker N, Altıparmak Z, Altıparmak E, Yılmazbaş P. The evaluation of the effect of Helicobacter pylori infection on choroidal thickness. Turk J Gastroenterol 2018;29:636-41. [PMID: 30289395 DOI: 10.5152/tjg.2018.17557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
474 Leja M, Grinberga-Derica I, Bilgilier C, Steininger C. Review: Epidemiology of Helicobacter pylori infection. Helicobacter. 2019;24 Suppl 1:e12635. [PMID: 31486242 DOI: 10.1111/hel.12635] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
475 Park CH, Yang DH, Kim JW, Kim JH, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. Clinical practice guideline for endoscopic resection of early gastrointestinal cancer. Intest Res 2021;19:127-57. [PMID: 33045799 DOI: 10.5217/ir.2020.00020] [Reference Citation Analysis]
476 Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication. Ann Clin Microbiol Antimicrob 2018;17:29. [PMID: 29950163 DOI: 10.1186/s12941-018-0281-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
477 Miraglia C, Moccia F, Russo M, Scida S, Franceschi M, Crafa P, Franzoni L, Nouvenne A, Meschi T, Leandro G, De' Angelis GL, Di Mario F. Non-invasive method for the assessment of gastric acid secretion. Acta Biomed 2018;89:53-7. [PMID: 30561418 DOI: 10.23750/abm.v89i8-S.7986] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
478 Chua EG, Debowski AW, Webberley KM, Peters F, Lamichhane B, Loke MF, Vadivelu J, Tay CY, Marshall BJ, Wise MJ. Analysis of core protein clusters identifies candidate variable sites conferring metronidazole resistance in Helicobacter pylori. Gastroenterol Rep (Oxf) 2019;7:42-9. [PMID: 30792865 DOI: 10.1093/gastro/goy048] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
479 Fonseca DR, Moura A, Leiro V, Silva-Carvalho R, Estevinho BN, Seabra CL, Henriques PC, Lucena M, Teixeira C, Gomes P, Parreira P, Martins MCL. Grafting MSI-78A onto chitosan microspheres enhances its antimicrobial activity. Acta Biomater 2021:S1742-7061(21)00638-3. [PMID: 34634508 DOI: 10.1016/j.actbio.2021.09.063] [Reference Citation Analysis]
480 Sue S, Sasaki T, Kaneko H, Irie K, Kondo M, Maeda S. Helicobacter pylori rescue treatment with vonoprazan, metronidazole, and sitafloxacin in the presence of penicillin allergy. JGH Open 2021;5:307-11. [PMID: 33553672 DOI: 10.1002/jgh3.12492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
481 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
482 Boulygina EA, Markelova MI, Khusnutdinova DR, Siniagina MN, Malanin SY, Abdulkhakov RA, Abdulkhakov SR, Chernov VM, Grigoryeva TV. Shotgun metagenomic data on the human stool samples to characterize shifts of the gut microbial profile after the Helicobacter pylori eradication therapy. Data Brief 2017;14:458-61. [PMID: 28831408 DOI: 10.1016/j.dib.2017.07.070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
483 Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-ge L, Yin W, Xie Y. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13. [DOI: 10.1007/s00228-017-2347-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
484 Walduck AK, Raghavan S. Immunity and Vaccine Development Against Helicobacter pylori. Adv Exp Med Biol 2019;1149:257-75. [PMID: 31016627 DOI: 10.1007/5584_2019_370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
485 Matsuzaki J, Tsugawa H, Suzuki H. Precision Medicine Approaches to Prevent Gastric Cancer. Gut Liver 2021;15:3-12. [PMID: 31893631 DOI: 10.5009/gnl19257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
486 Isaeva G, Isaeva R. Molecular methods for the detection of Helicobacter pylori. Minerva Biotecnol 2020;32. [DOI: 10.23736/s1120-4826.20.02665-8] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
487 Snir Y, Leibovitzh H, Leibovici-Weissman Y, Vilkin A, Cohen AD, Shochat T, Niv Y, Dotan I, Feldhamer I, Boltin D, Levi Z. Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients. United European Gastroenterol J 2021;9:343-53. [PMID: 32962566 DOI: 10.1177/2050640620951403] [Reference Citation Analysis]
488 Rodrigues JP, Pinho R, Silva J, Ponte A, Sousa M, Silva JC, Carvalho J. Appropriateness of the study of iron deficiency anemia prior to referral for small bowel evaluation at a tertiary center. World J Gastroenterol 2017; 23(24): 4444-4453 [PMID: 28706428 DOI: 10.3748/wjg.v23.i24.4444] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
489 Toh JWT, Wilson RB. Pathways of Gastric Carcinogenesis, Helicobacter pylori Virulence and Interactions with Antioxidant Systems, Vitamin C and Phytochemicals. Int J Mol Sci 2020;21:E6451. [PMID: 32899442 DOI: 10.3390/ijms21176451] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
490 Ke H, Li J, Lu B, Yang C, Wang J, Wang Z, Liu L, Chen Y. The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth-based quadruple therapy. Helicobacter 2021;26:e12768. [PMID: 33089598 DOI: 10.1111/hel.12768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
491 Gong L, El-Omar EM. Application of molecular techniques in Helicobacter pylori detection: limitations and improvements. Helicobacter 2021;:e12841. [PMID: 34333819 DOI: 10.1111/hel.12841] [Reference Citation Analysis]
492 Lok CH, Zhu D, Wang J, Ren YT, Jiang X, Li SJ, Zhao XY. Phenotype and Molecular Detection of Clarithromycin and Levofloxacin Resistance in Helicobacter pylori Clinical Isolates in Beijing. Infect Drug Resist 2020;13:2145-53. [PMID: 32753910 DOI: 10.2147/IDR.S249370] [Reference Citation Analysis]
493 A Castaneda C, Castillo M, Sanchez J, Casavilca S, Sanchez J, A Bernabe L, Suarez N, Chavez I, Ruiz E, Tello K, R Villa M, Zevallos R, Montenegro P, Dias-Neto E, Landa-Baella M, Taxa L. Detection of Helicobacter pylori in gastric cancer tissue through histopathology, immunohistochemistry and real-time reverse transcription-PCR. Future Microbiol 2020;15:1131-7. [PMID: 32954850 DOI: 10.2217/fmb-2019-0280] [Reference Citation Analysis]
494 Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14:697-710. [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117] [Cited by in Crossref: 96] [Cited by in F6Publishing: 72] [Article Influence: 19.2] [Reference Citation Analysis]
495 Spinzi G, Milano A, Brosolo P, Da Massa Carrara P, Labardi M, Merighi A, Riccardi L, Torresan F. The Italian Society for Digestive Endoscopy (SIED) accreditation and quality improving project based on international standards. Endosc Int Open 2020;8:E338-45. [PMID: 32140556 DOI: 10.1055/a-1096-0219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
496 Eisdorfer I, Shalev V, Goren S, Chodick G, Muhsen K. Sex differences in urea breath test results for the diagnosis of Helicobacter pylori infection: a large cross-sectional study. Biol Sex Differ 2018;9:1. [PMID: 29291751 DOI: 10.1186/s13293-017-0161-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
497 Sampaio PS, Calado CRC. Potential of FTIR-Spectroscopy for Drugs Screening against Helicobacter pylori. Antibiotics (Basel) 2020;9:E897. [PMID: 33322665 DOI: 10.3390/antibiotics9120897] [Reference Citation Analysis]
498 Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel) 2021;11:1305. [PMID: 34441240 DOI: 10.3390/diagnostics11081305] [Reference Citation Analysis]
499 Lee JW, Kim N, Nam RH, Yu JE, Son JH, Lee SM, Lee DH. Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori. Gut Liver 2021;15:53-60. [PMID: 33191308 DOI: 10.5009/gnl20247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
500 Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, Torres RC, Giono-Cerezo S, Escobar-Ogaz A, Torres J. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol 2020;10:539115. [PMID: 33643927 DOI: 10.3389/fcimb.2020.539115] [Reference Citation Analysis]
501 Muhsen K, Na'amnih W, Adler A, Carmeli Y, Cohen D. Clostridium difficile-associated disease and Helicobacter pylori seroprevalence: A case-control study. Helicobacter 2020;25:e12668. [PMID: 31721371 DOI: 10.1111/hel.12668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
502 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
503 Lyu T, Cheung KS, Ni L, Guo J, Mu P, Li Y, Yang Q, Yu X, Lyu Z, Wu J, Guo H, Leung WK, Seto WK. High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort study. J Antimicrob Chemother 2020;75:3391-4. [PMID: 32785699 DOI: 10.1093/jac/dkaa315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
504 Olmedo L, Azagra R, Aguyé A, Pascual M, Calvet X, Gené E. High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study. J Clin Med 2020;9:E2410. [PMID: 32731455 DOI: 10.3390/jcm9082410] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
505 Livzan MA, Gaus OV, Mozgovoi SI, Bordin DS. Chronic Autoimmune Gastritis: Modern Diagnostic Principles. Diagnostics (Basel) 2021;11:2113. [PMID: 34829460 DOI: 10.3390/diagnostics11112113] [Reference Citation Analysis]
506 Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut 2017;66:2043-6. [PMID: 28935677 DOI: 10.1136/gutjnl-2017-314744] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
507 Subsomwong P, Doohan D, Fauzia KA, Akada J, Matsumoto T, Yee TT, Htet K, Waskito LA, Tuan VP, Uchida T, Matsuhisa T, Yamaoka Y. Next-Generation Sequencing-Based Study of Helicobacter pylori Isolates from Myanmar and Their Susceptibility to Antibiotics. Microorganisms 2022;10:196. [DOI: 10.3390/microorganisms10010196] [Reference Citation Analysis]
508 Shah SC, Tepler A, Chung CP, Suarez G, Peek RM Jr, Hung A, Roumie C, Narula N. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology 2021:S0016-5085(21)03338-2. [PMID: 34358488 DOI: 10.1053/j.gastro.2021.07.043] [Reference Citation Analysis]
509 Muñoz AB, Stepanian J, Trespalacios AA, Vale FF. Bacteriophages of Helicobacter pylori. Front Microbiol 2020;11:549084. [PMID: 33281754 DOI: 10.3389/fmicb.2020.549084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
510 Ji W, Chen WQ, Tian X. Efficacy of compound Lactobacillus acidophilus tablets combined with quadruple therapy for Helicobacter pylori eradication and its correlation with pH value in the stomach: a study protocol of a randomised, assessor-blinded, single-centre study. BMJ Open 2018;8:e023131. [PMID: 30373781 DOI: 10.1136/bmjopen-2018-023131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
511 Dos Santos Viana I, Cordeiro Santos ML, Santos Marques H, Lima de Souza Gonçalves V, Bittencourt de Brito B, França da Silva FA, Oliveira E Silva N, Dantas Pinheiro F, Fernandes Teixeira A, Tanajura Costa D, Oliveira Souza B, Lima Souza C, Vasconcelos Oliveira M, Freire de Melo F. Vaccine development against Helicobacter pylori: from ideal antigens to the current landscape. Expert Rev Vaccines 2021;20:989-99. [PMID: 34139141 DOI: 10.1080/14760584.2021.1945450] [Reference Citation Analysis]
512 Schulz C, Schütte K, Mayerle J, Malfertheiner P. The role of the gastric bacterial microbiome in gastric cancer: Helicobacter pylori and beyond.Therap Adv Gastroenterol. 2019;12:1756284819894062. [PMID: 31897087 DOI: 10.1177/1756284819894062] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
513 Han Y, Dai W, Meng F, Gan X, Liu M, Deng X, Li Y, Wang G. Diagnosis of Helicobacter pylori infection in the elderly using an immunochromatographic assay-based stool antigen test. Microbiologyopen 2020;9:e1102. [PMID: 32666705 DOI: 10.1002/mbo3.1102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
514 Zhu Q, Wu X, Tang M, Wu L. Observation of tumor-associated macrophages expression in gastric cancer and its clinical pathological relationship. Medicine (Baltimore) 2020;99:e19839. [PMID: 32332633 DOI: 10.1097/MD.0000000000019839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
515 Rugge M, Savarino E, Sbaraglia M, Bricca L, Malfartheiner P. Gastritis: The clinico-pathological spectrum. Dig Liver Dis 2021:S1590-8658(21)00100-6. [PMID: 33785282 DOI: 10.1016/j.dld.2021.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
516 Jonaitis L, Pellicano R, Kupcinskas L. Helicobacter pylori and nonmalignant upper gastrointestinal diseases. Helicobacter. 2018;23 Suppl 1:e12522. [PMID: 30203583 DOI: 10.1111/hel.12522] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
517 Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, Gartner F, Touati E, Gomes J, Costa P, Martins MCL, Gonçalves IC. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta Biomater 2020;114:206-20. [PMID: 32622054 DOI: 10.1016/j.actbio.2020.06.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
518 Yin G, Bie S, Gu H, Shu X, Zheng W, Peng K, Zhao H, Li F, Chen B, Botchway BOA, Fang M, Jiang M. Application of gene chip technology in the diagnostic and drug resistance detection of Helicobacter pylori in children. J Gastroenterol Hepatol 2020;35:1331-9. [PMID: 31930581 DOI: 10.1111/jgh.14980] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
519 Arieira C, Boal Carvalho P, Dias de Castro F, Cotter J. Esophagogastroduodenoscopy Findings in Patients on the Waiting List for Bariatric Surgery. GE Port J Gastroenterol 2019;26:389-95. [PMID: 31832493 DOI: 10.1159/000495770] [Reference Citation Analysis]
520 Duda-Madej A, Kozłowska J, Krzyżek P, Anioł M, Seniuk A, Jermakow K, Dworniczek E. Antimicrobial O-Alkyl Derivatives of Naringenin and Their Oximes Against Multidrug-Resistant Bacteria. Molecules 2020;25:E3642. [PMID: 32785151 DOI: 10.3390/molecules25163642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
521 Jonaitis P, Kupcinskas J, Nyssen OP, Puig I, Gisbert JP, Jonaitis L. Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013-2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg). Medicina (Kaunas) 2021;57:642. [PMID: 34201428 DOI: 10.3390/medicina57070642] [Reference Citation Analysis]
522 Lahner E, Carabotti M, Annibale B. Treatment of Helicobacter pylori infection in atrophic gastritis. World J Gastroenterol 2018; 24(22): 2373-2380 [PMID: 29904244 DOI: 10.3748/wjg.v24.i22.2373] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
523 Jonaitis P, Kupcinskas L, Kupcinskas J. Molecular Alterations in Gastric Intestinal Metaplasia. Int J Mol Sci 2021;22:5758. [PMID: 34071181 DOI: 10.3390/ijms22115758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
524 Mestrovic A, Perkovic N, Bozic J, Pavicic Ivelja M, Vukovic J, Kardum G, Puljiz Z, Tonkic A. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLoS One 2020;15:e0244500. [PMID: 33378403 DOI: 10.1371/journal.pone.0244500] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
525 Lin T, Wu D, Tsay F, Tsai K, Tsai T, Peng N, Kao S, Chen W, Chen Y, Hsu P. Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection. Journal of the Chinese Medical Association 2020;83:233-7. [DOI: 10.1097/jcma.0000000000000256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
526 O'Connor A, Lamarque D, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017;22 Suppl 1. [PMID: 28891137 DOI: 10.1111/hel.12410] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
527 Mezmale L, Isajevs S, Bogdanova I, Polaka I, Krigere A, Rudzite D, Rudule A, Kikuste I, Parshutin S, Tazhedinov A, Mushinskiy D, Sametayev D, Belikhina T, Igissinov N, Park JY, Herrero R, Leja M. Prevalence of Atrophic Gastritis in Kazakhstan and the Accuracy of Pepsinogen Tests to Detect Gastric Mucosal Atrophy. Asian Pac J Cancer Prev 2019;20:3825-9. [PMID: 31870128 DOI: 10.31557/APJCP.2019.20.12.3825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
528 Pellicano R, Ribaldone DG, Caviglia GP. Strategies for Helicobacter pylori eradication in the year 2020. Saudi J Gastroenterol 2020;26:63-5. [PMID: 32295934 DOI: 10.4103/sjg.SJG_95_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
529 Wang L, Yao H, Tong T, Lau K, Leung SY, Ho JWK, Leung WK. Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies. Helicobacter. [DOI: 10.1111/hel.12871] [Reference Citation Analysis]
530 Fiorini G, Zullo A, Saracino IM, Pavoni M, Vaira D. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010–2016. Scandinavian Journal of Gastroenterology 2018;53:661-4. [DOI: 10.1080/00365521.2018.1464596] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
531 Valenzano M, Bisio A, Grassi G. Helicobacter pylori and diabetes mellitus: a controversial relationship. Minerva Endocrinol 2019;44:301-9. [PMID: 31304727 DOI: 10.23736/S0391-1977.19.03021-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
532 Scarpignato C, Gatta L. Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. In: Morice AH, Dettmar PW, editors. Reflux Aspiration and Lung Disease. Cham: Springer International Publishing; 2018. pp. 269-91. [DOI: 10.1007/978-3-319-90525-9_23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
533 Liyen Cartelle A, Uy PP, Koehler TE, Yap JEL. Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice. Cureus 2020;12:e12309. [PMID: 33520508 DOI: 10.7759/cureus.12309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
534 Yang J, Zhang Y, Fan L, Zhu YJ, Wang TY, Wang XW, Chen DF, Lan CH. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114:437-445. [PMID: 30807294 DOI: 10.14309/ajg.0000000000000132] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
535 Kotilea K, Kalach N, Homan M, Bontems P. Helicobacter pylori Infection in Pediatric Patients: Update on Diagnosis and Eradication Strategies. Pediatr Drugs 2018;20:337-51. [DOI: 10.1007/s40272-018-0296-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
536 Melenotte C, Mezouar S, Mège JL, Gorvel JP, Kroemer G, Raoult D. Bacterial infection and non-Hodgkin's lymphoma. Crit Rev Microbiol 2020;46:270-87. [PMID: 32412856 DOI: 10.1080/1040841X.2020.1760786] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
537 Mladenova I. Clinical Relevance of Helicobacter pylori Infection. J Clin Med 2021;10:3473. [PMID: 34441769 DOI: 10.3390/jcm10163473] [Reference Citation Analysis]
538 Suzuki H, Mori H. Single-capsule bismuth quadruple therapy: preferable at the moment, but what should be next? United European Gastroenterol J 2021;9:7-8. [PMID: 33210981 DOI: 10.1177/2050640620975357] [Reference Citation Analysis]
539 An Y, Wang Y, Wu S, Wang YH, Qian X, Li Z, Fu YJ, Xie Y. Fourth-generation quinolones in the treatment of Helicobacter pylori infection: A meta-analysis. World J Gastroenterol 2018; 24(29): 3302-3312 [PMID: 30090010 DOI: 10.3748/wjg.v24.i29.3302] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
540 Homolak J, Nikolić M, Potoč D, Živković M, Bakula D, Budimir I, Pavić I, Hrabar D, Ljubičić N, Vražić D. The onset of ulcerative colitis upon Helicobacter pylori eradication in a 72-year-old woman: report of a rare case with a 3-year follow-up. BMC Gastroenterol 2021;21:303. [PMID: 34332529 DOI: 10.1186/s12876-021-01876-5] [Reference Citation Analysis]
541 Pérez-arellano E, Rodriguez-garcia MI, Galera Rodenas AB, de la Morena-madrigal E. Erradicación de la infección por Helicobacter pylori con una nueva terapia cuádruple basada en bismuto en la práctica clínica. Gastroenterología y Hepatología 2018;41:145-52. [DOI: 10.1016/j.gastrohep.2017.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
542 Zagari RM, Rabitti S, Greenwood DC, Eusebi LH, Vestito A, Bazzoli F. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46:657-667. [PMID: 28782119 DOI: 10.1111/apt.14248] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 10.6] [Reference Citation Analysis]
543 Mcnicholl AG, Ducons J, Barrio J, Bujanda L, Forné-bardera M, Aparcero R, Ponce J, Rivera R, Dedeu-cuso JM, Garcia-iglesias P, Montoro M, Bejerano A, Ber-nieto Y, Madrigal B, Zapata E, Loras-alastruey C, Castro M, Nevarez A, Mendez I, Bory-ros F, Miquel-planas M, Vera I, Nyssen OP, Gisbert JP. Accuracy of the Ultra-Rapid Urease Test for diagnosis of Helicobacter pylori infection. Gastroenterología y Hepatología 2017;40:651-7. [DOI: 10.1016/j.gastrohep.2017.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
544 Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol 2019;1149:211-25. [PMID: 31016626 DOI: 10.1007/5584_2019_367] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
545 Lucero Y, George S, O'Ryan M. Indications for Helicobacter pylori Eradication: Do We Need to Consider to Screen and Treat Asymptomatic Children? J Pediatr Gastroenterol Nutr 2018;67:e86-7. [PMID: 29958254 DOI: 10.1097/MPG.0000000000002082] [Reference Citation Analysis]
546 Song C, Qian X, Zhu Y, Shu X, Song Y, Xiong Z, Ye J, Yu T, Ding L, Wang H, Lu N, Xie Y. Effectiveness and safety of furazolidone‐containing quadruple regimens in patients with Helicobacter pylori infection in real‐world practice. Helicobacter 2019. [DOI: 10.1111/hel.12591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
547 Fauzia KA, Miftahussurur M, Syam AF, Waskito LA, Doohan D, Rezkitha YAA, Matsumoto T, Tuan VP, Akada J, Yonezawa H, Kamiya S, Yamaoka Y. Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates. Toxins (Basel) 2020;12:E473. [PMID: 32722296 DOI: 10.3390/toxins12080473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
548 Rhie SY, Park JY, Shin TS, Kim JW, Kim BJ, Kim JG. Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. Antibiotics (Basel) 2020;9:E287. [PMID: 32471292 DOI: 10.3390/antibiotics9060287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
549 Deguchi H, Yamazaki H, Yamamoto Y, Fukuhara S. Association between parental history of Helicobacter pylori treatment failure and treatment failure in the offspring. Journal of Gastroenterology and Hepatology 2019;34:2112-7. [DOI: 10.1111/jgh.14774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
550 Kim TH, Park JM, Cheung DY, Oh JH. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. J Korean Med Sci 2020;35:e33. [PMID: 32030921 DOI: 10.3346/jkms.2020.35.e33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
551 Tariq H, Patel H, Kamal MU, Abbas N, Ameen M, Azam S, Kumar K, Ravi M, Vootla V, Shaikh D, Amanchi V, Hussain AN, Makker J. Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clin Exp Gastroenterol 2020;13:25-33. [PMID: 32158248 DOI: 10.2147/CEG.S239343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
552 Sverdén E, Agréus L, Dunn JM, Lagergren J. Peptic ulcer disease. BMJ 2019;367:l5495. [PMID: 31578179 DOI: 10.1136/bmj.l5495] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
553 Pellicano R. Similar Helicobacter pylori Eradication Rate in Obese Patients Undergoing Gastric Bypass Surgery and in General Population. Obes Surg 2018;28:553-4. [PMID: 29197049 DOI: 10.1007/s11695-017-3038-2] [Reference Citation Analysis]
554 Kim JJE, Kocsmár I, Buzás GM, Szirtes I, Rusz O, Diczházi C, Szijártó A, Hritz I, Schaff Z, Kiss A, Kocsmár É, Lotz G. Efficacy of Clarithromycin Depends on the Bacterial Density in Clarithromycin-Heteroresistant Helicobacter pylori Infections: An In Situ Detected Susceptibility and Quantitative Morphometry-Based Retrospective Study. Pathol Oncol Res 2021;27:1609863. [PMID: 34267605 DOI: 10.3389/pore.2021.1609863] [Reference Citation Analysis]
555 Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2018;41:272-80. [DOI: 10.1016/j.gastrohep.2017.12.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
556 Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M, ESPGHAN, NASPGHAN. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991-1003. [PMID: 28541262 DOI: 10.1097/mpg.0000000000001594] [Cited by in Crossref: 134] [Cited by in F6Publishing: 41] [Article Influence: 26.8] [Reference Citation Analysis]
557 Kocsmár É, Buzás GM, Szirtes I, Kocsmár I, Kramer Z, Szijártó A, Fadgyas-Freyler P, Szénás K, Rugge M, Fassan M, Kiss A, Schaff Z, Röst G, Lotz G. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nat Commun 2021;12:2255. [PMID: 33859206 DOI: 10.1038/s41467-021-22557-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
558 Buti L, Ruiz-Puig C, Sangberg D, Leissing TM, Brewer RC, Owen RP, Sgromo B, Royer C, Ebner D, Lu X. CagA-ASPP2 complex mediates loss of cell polarity and favors H. pylori colonization of human gastric organoids. Proc Natl Acad Sci U S A 2020;117:2645-55. [PMID: 31964836 DOI: 10.1073/pnas.1908787117] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
559 Zhou JJ, Shi X, Zheng SP, Tang D, Cai T, Yao Y, Wang F. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China. Helicobacter 2020;25:e12755. [PMID: 32914914 DOI: 10.1111/hel.12755] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
560 Yao X, Xiao S, Zhou L. Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication. Helicobacter 2021;26:e12846. [PMID: 34414638 DOI: 10.1111/hel.12846] [Reference Citation Analysis]
561 Wang X, Shu X, Li Q, Li Y, Chen Z, Wang Y, Pu K, Zheng Y, Ye Y, Liu M, Ma L, Zhang Z, Wu Z, Zhang F, Guo Q, Ji R, Zhou Y. Prevalence and risk factors of Helicobacter pylori infection in Wuwei, a high-risk area for gastric cancer in northwest China: An all-ages population-based cross-sectional study. Helicobacter 2021;26:e12810. [PMID: 33904635 DOI: 10.1111/hel.12810] [Reference Citation Analysis]
562 Parreira P, Martins MCL. The biophysics of bacterial infections: Adhesion events in the light of force spectroscopy. Cell Surf 2021;7:100048. [PMID: 33665520 DOI: 10.1016/j.tcsw.2021.100048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Hays C, Burucoa C, Lehours P, Tran CT, Leleu A, Raymond J. Molecular characterization of Helicobacter pylori resistance to rifamycins. Helicobacter 2018;23. [PMID: 29168600 DOI: 10.1111/hel.12451] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
564 Krzyżek P, Gościniak G, Fijałkowski K, Migdał P, Dziadas M, Owczarek A, Czajkowska J, Aniołek O, Junka A. Potential of Bacterial Cellulose Chemisorbed with Anti-Metabolites, 3-Bromopyruvate or Sertraline, to Fight against Helicobacter pylori Lawn Biofilm. Int J Mol Sci 2020;21:E9507. [PMID: 33327555 DOI: 10.3390/ijms21249507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
565 Long Parma D, Schmidt S, Muñoz E, Ramirez AG. Gastric adenocarcinoma burden and late-stage diagnosis in Latino and non-Latino populations in the United States and Texas, during 2004-2016: A multilevel analysis. Cancer Med 2021;10:6468-79. [PMID: 34409764 DOI: 10.1002/cam4.4175] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
566 Redondo JJ, Keller PM, Zbinden R, Wagner K. A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene. Diagn Microbiol Infect Dis. 2018;90:1-6. [PMID: 29111147 DOI: 10.1016/j.diagmicrobio.2017.09.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
567 Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Muñoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter 2018;23. [PMID: 29178562 DOI: 10.1111/hel.12452] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
568 Milivojevic V, Milosavljevic T. Burden of Gastroduodenal Diseases from the Global Perspective. Curr Treat Options Gastroenterol 2020. [PMID: 31993967 DOI: 10.1007/s11938-020-00277-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
569 Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of Helicobacter pylori in West Flanders - Belgium: an observational cross-sectional study. Acta Clin Belg 2021;:1-8. [PMID: 33502281 DOI: 10.1080/17843286.2021.1872307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
570 Blümel B, Goelz H, Kist M, Glocker E. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. Helicobacter 2018;23:e12494. [DOI: 10.1111/hel.12494] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
571 Zhang Y, Sun J, Dong Y, Shen X, Zhang Z. Vicenin-2 inhibits the Helicobacterium pylori infection associated gastric carcinogenic events through modulation of PI3K/AKT and Nrf2 signaling in GES-1 cells. J Biochem Mol Toxicol 2021;35:e22680. [PMID: 33325628 DOI: 10.1002/jbt.22680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
572 Zhou S, Marklund H, Blaha O, Desai M, Martin B, Bingham D, Berry GJ, Gomulia E, Ng AY, Shen J. Deep learning assistance for the histopathologic diagnosis of Helicobacter pylori. Intelligence-Based Medicine 2020;1-2:100004. [DOI: 10.1016/j.ibmed.2020.100004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
573 Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021;70:40-54. [PMID: 32958544 DOI: 10.1136/gutjnl-2020-321372] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
574 Vilaichone RK, Quach DT, Yamaoka Y, Sugano K, Mahachai V. Prevalence and Pattern of Antibiotic Resistant Strains of Helicobacter Pylori Infection in ASEAN. Asian Pac J Cancer Prev 2018;19:1411-3. [PMID: 29802708 DOI: 10.22034/APJCP.2018.19.5.1411] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
575 Yu M, Zhang R, Ni P, Chen S, Duan G. Helicobacter pylori Infection and Psoriasis: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2019;55. [PMID: 31561576 DOI: 10.3390/medicina55100645] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
576 Seo SI, Kang JG, Kim HS, Shin WG, Jang MK, Lee JH, Kim HY. Risk of Peptic Ulcer Bleeding Associated with Helicobacter pylori Infection, Nonsteroidal Anti-inflammatory Drugs, and Low-dose Aspirin Therapy in Peptic Ulcer Disease: A Case-control Study. Korean J Helicobacter Up Gastrointest Res 2019;19:42-7. [DOI: 10.7704/kjhugr.2019.19.1.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
577 Jiang X, Duan Y, Zhou B, Guo Q, Wang H, Hang X, Zeng L, Jia J, Bi H. The Cyclopropane Fatty Acid Synthase Mediates Antibiotic Resistance and Gastric Colonization of Helicobacter pylori. J Bacteriol 2019;201:e00374-19. [PMID: 31358615 DOI: 10.1128/JB.00374-19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
578 Brennan D, O’morain C, Mcnamara D, Smith SM. Molecular Detection of Antibiotic-Resistant Helicobacter pylori. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 29-36. [DOI: 10.1007/978-1-0716-1302-3_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
579 Liou J, Chen C, Fang Y, Chen P, Chang C, Chou C, Chen M, Tseng C, Lee J, Yang T, Chiu M, Yu J, Kuo C, Luo J, Hsu W, Hu W, Tsai M, Lin J, Shun C, Twu G, Lee Y, Bair M, Wu M, Liou J, Lee Y, Lin J, Wu C, Wu J, Chen C, Lin C, Fang Y, Bair M, Luo J, Wu M, Cheng T, Tseng P, Chiu H, Chang C, Yu C, Chiu M, Chen Y, Hu W, Chou C, Tai C, Lee C, Wang W, Chang W; Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial. Journal of Antimicrobial Chemotherapy 2018;73:2510-8. [DOI: 10.1093/jac/dky183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
580 Kocsmár É, Kocsmár I, Buzás GM, Szirtes I, Wacha J, Takáts A, Hritz I, Schaff Z, Rugge M, Fassan M, Kiss A, Lotz G. Helicobacter pylori heteroresistance to clarithromycin in adults-New data by in situ detection and improved concept. Helicobacter 2020;25:e12670. [PMID: 31701608 DOI: 10.1111/hel.12670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
581 Miehlke S, Frederking D, Günther T, Glocker E, Eisele B, Andresen V, Schröder S, Morgner A. Efficacy of three-in-one capsule bismuth quadruple therapy for Helicobacter pylori eradication in clinical practice in a multinational patient population. Helicobacter 2017;22:e12429. [DOI: 10.1111/hel.12429] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
582 Koletzko S, Jones N. No Screen and Treat in Children for Helicobacter pylori Infection. Journal of Pediatric Gastroenterology & Nutrition 2018;67:e87-8. [DOI: 10.1097/mpg.0000000000002121] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
583 Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018;16:679-687. [PMID: 30102559 DOI: 10.1080/14787210.2018.1511427] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
584 Yu L, Luo L, Long X, Liang X, Ji Y, Graham DY, Lu H. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019;24:e12596. [PMID: 31111580 DOI: 10.1111/hel.12596] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
585 Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter 2017;22:e12374. [DOI: 10.1111/hel.12374] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
586 Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K. Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J Clin Med 2020;9:E543. [PMID: 32079208 DOI: 10.3390/jcm9020543] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
587 Kong S, Chen H, Huang K, Jin D, Zhang G, Ye F. Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report. Medicine (Baltimore) 2021;100:e24915. [PMID: 33725850 DOI: 10.1097/MD.0000000000024915] [Reference Citation Analysis]
588 Ansari S, Yamaoka Y. Current understanding and management of Helicobacter pylori infection: an updated appraisal. F1000Res. 2018;7. [PMID: 29946428 DOI: 10.12688/f1000research.14149.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
589 Tran VH, Ha TMT, Le PTQ, Phan TN, Tran TNH. Characterisation of point mutations in domain V of the 23S rRNA gene of clinical Helicobacter pylori strains and clarithromycin-resistant phenotype in central Vietnam. Journal of Global Antimicrobial Resistance 2019;16:87-91. [DOI: 10.1016/j.jgar.2018.09.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
590 Song Y, Dou F, Zhou Z, Yang N, Zhong J, Pan J, Liu Q, Zhang J, Wang S. Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients. Biomed Res Int 2018;2018:2684836. [PMID: 30276203 DOI: 10.1155/2018/2684836] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
591 Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA, Bryant RV. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1450-6. [PMID: 33217029 DOI: 10.1111/jgh.15352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Abadi ATB. Resistance to clarithromycin and gastroenterologist’s persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. World J Gastroenterol 2017; 23(35): 6379-6384 [PMID: 29085187 DOI: 10.3748/wjg.v23.i35.6379] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
593 Link A, Bornschein J, Thon C. Helicobacter pylori induced gastric carcinogenesis - The best molecular model we have? Best Pract Res Clin Gastroenterol 2021;50-51:101743. [PMID: 33975683 DOI: 10.1016/j.bpg.2021.101743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
594 Galicia Poblet G, Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B, Botija Arcos G, Cilleruelo Pascual ML, González Martín LM, Hernández Hernández A, Martínez Escribano B, Ortola Castells X, Rizo Pascual J, Urruzuno Tellería P, Vegas Álvarez AM. Management of Helicobacter pylori infection in the pediatric age. An Pediatr (Engl Ed) 2021;95:383.e1-9. [PMID: 34642127 DOI: 10.1016/j.anpede.2021.05.004] [Reference Citation Analysis]
595 Ghosn Y, Hussein Kamareddine M, Tawk A, Bou-Ayash N, Bou-Ayash H, Mokamer N, Yared R, Aoun M, Khoury S, Cortas G, Jabbour G, Bedran K, Farhat S. Analysis of gastric and duodenal biopsy results in patients presenting with dyspepsia: a cross-sectional study in a middle eastern population. BMJ Open Gastroenterol 2019;6:e000330. [PMID: 31645989 DOI: 10.1136/bmjgast-2019-000330] [Reference Citation Analysis]
596 Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M, Kawai Y, Fujimiya T, Takeuchi H, Unezaki S, Kawai T. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front Pharmacol 2021;12:759249. [PMID: 34721043 DOI: 10.3389/fphar.2021.759249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
597 Kavitt RT, Lipowska AM, Anyane-yeboa A, Gralnek IM. Diagnosis and Treatment of Peptic Ulcer Disease. The American Journal of Medicine 2019;132:447-56. [DOI: 10.1016/j.amjmed.2018.12.009] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
598 Li H, Marceau M, Yang T, Liao T, Tang X, Hu R, Xie Y, Tang H, Tay A, Shi Y, Shen Y, Yang T, Pi X, Lamichhane B, Luo Y, Debowski AW, Nilsson HO, Haslam SM, Mulloy B, Dell A, Stubbs KA, Marshall BJ, Benghezal M. East-Asian Helicobacter pylori strains synthesize heptan-deficient lipopolysaccharide. PLoS Genet 2019;15:e1008497. [PMID: 31747390 DOI: 10.1371/journal.pgen.1008497] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
599 Han ML, Liou JM, Ser KH, Chen JC, Chen SC, Lee WJ. Changes of serum pepsinogen level and ABC classification after bariatric surgery. J Formos Med Assoc 2021;120:1377-85. [PMID: 33199102 DOI: 10.1016/j.jfma.2020.10.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
600 Dargenio C, Dargenio VN, Bizzoco F, Indrio F, Francavilla R, Cristofori F. Limosilactobacillus reuteri Strains as Adjuvants in the Management of Helicobacter pylori Infection. Medicina (Kaunas) 2021;57:733. [PMID: 34357014 DOI: 10.3390/medicina57070733] [Reference Citation Analysis]
601 Fiori-Duarte AT, Rodrigues RP, Kitagawa RR, Kawano DF. Insights into the Design of Inhibitors of the Urease Enzyme - A Major Target for the Treatment of Helicobacter pylori Infections. Curr Med Chem 2020;27:3967-82. [PMID: 30827224 DOI: 10.2174/0929867326666190301143549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
602 Ji R, Zhao X, Cao X, Zhang Y, Yang Y. Changes in gastric mucosal microbiota in gastric carcinogenesis: a systematic review protocol. BMJ Open 2021;11:e045810. [PMID: 33653765 DOI: 10.1136/bmjopen-2020-045810] [Reference Citation Analysis]
603 Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med 2021;112:281-7. [PMID: 32700868 DOI: 10.23736/S0026-4806.20.06810-X] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
604 Andreev DN, Maev IV. [Rebamipide: evidence base for use in gastroenterology]. Ter Arkh 2020;92:97-104. [PMID: 33720581 DOI: 10.26442/00403660.2020.12.200455] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
605 Pan J, Shi Z, Lin D, Yang N, Meng F, Lin L, Jin Z, Zhou Q, Wu J, Zhang J, Li Y. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Front Med 2020;14:43-50. [PMID: 31907860 DOI: 10.1007/s11684-019-0706-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
606 Gonzalez-Hormazabal P, Musleh M, Escandar S, Valladares H, Lanzarini E, Castro VG, Jara L, Berger Z. Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. BMC Gastroenterol 2018;18:91. [PMID: 29925321 DOI: 10.1186/s12876-018-0820-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
607 Salehi B, Sharopov F, Martorell M, Rajkovic J, Ademiluyi AO, Sharifi-Rad M, Fokou PVT, Martins N, Iriti M, Sharifi-Rad J. Phytochemicals in Helicobacter pylori Infections: What Are We Doing Now? Int J Mol Sci 2018;19:E2361. [PMID: 30103451 DOI: 10.3390/ijms19082361] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 12.5] [Reference Citation Analysis]
608 Xavier S, Magalhães J, Cotter J. Proton Pump Inhibitors: Are They a Real Threat to the Patient? GE Port J Gastroenterol 2018;25:243-52. [PMID: 30320163 DOI: 10.1159/000487154] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
609 Selgrad M, Bornschein J, Kandulski A, Weigt J, Roessner A, Wex T, Malfertheiner P. Combined Gastric and Colorectal Cancer Screening-A New Strategy. Int J Mol Sci 2018;19:E3854. [PMID: 30513960 DOI: 10.3390/ijms19123854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
610 Suzuki H. Helicobacter pylori-Associated Upper Gastrointestinal Symptoms: FD or HpD? Dig Dis Sci. 2017;62:1391-1393. [PMID: 28365919 DOI: 10.1007/s10620-017-4556-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
611 Park CH, Yang DH, Kim JW, Kim JH, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. [Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer]. Korean J Gastroenterol 2020;75:264-91. [PMID: 32448858 DOI: 10.4166/kjg.2020.75.5.264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
612 Huang HT, Wang HM, Yang SC, Tai WC, Liang CM, Wu KL, Lee CH, Chuah SK. Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication. Infect Drug Resist 2018;11:2073-80. [PMID: 30464550 DOI: 10.2147/IDR.S185511] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
613 Bair M, Chuang S, Lei W, Chen C, Tian H, Chiang T, Su WW, Lin C, Chung Lo Y, Jou Y, Wu C, Chia S, Wu M, Chen H, Chu C, Lee Y, Wang Y. Planning mass eradication of Helicobacter pylori infection for indigenous Taiwanese peoples to reduce gastric cancer. Journal of Gastroenterology and Hepatology 2020;35:609-16. [DOI: 10.1111/jgh.14898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
614 Shinozaki S, Osawa H, Hayashi Y, Miura Y, Yano T, Lefor AK, Yamamoto H. Predictors and timing for the development of symptomatic gastroesophageal reflux disease after successful Helicobactor pylori eradication therapy. Scand J Gastroenterol 2021;:1-6. [PMID: 34547219 DOI: 10.1080/00365521.2021.1975310] [Reference Citation Analysis]
615 Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14396. [PMID: 30762742 DOI: 10.1097/md.0000000000014396] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 6.7] [Reference Citation Analysis]
616 Suzuki H, Matsuzaki J. Helicobacter pylori eradication failure may have confounded the recent large-scale health database study that showed proton pump inhibitors increase gastric cancer risk. Gut. 2018;67:2071-2072. [PMID: 29247066 DOI: 10.1136/gutjnl-2017-315698] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
617 Galicia Poblet G, Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B, Botija Arcos G, Cilleruelo Pascual ML, González Martín LM, Hernández Hernández A, Martínez Escribano B, Ortola Castells X, Rizo Pascual J, Urruzuno Tellería P, Vegas Álvarez AM. [Management of Helicobacter pylori infection in the pediatric age]. An Pediatr (Barc) 2021:S1695-4033(21)00202-2. [PMID: 34183279 DOI: 10.1016/j.anpedi.2021.05.014] [Reference Citation Analysis]
618 Tang B, Tang L, Huang C, Tian C, Chen L, He Z, Yang G, Zuo L, Zhao G, Liu E, Wang S, Lin H, He J, Yang S. The Effect of Probiotics Supplementation on Gut Microbiota After Helicobacter pylori Eradication: A Multicenter Randomized Controlled Trial.Infect Dis Ther. 2021;10:317-333. [PMID: 33270205 DOI: 10.1007/s40121-020-00372-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
619 Wu SR, Liu J, Zhang LF, Wang N, Zhang LY, Wu Q, Liu JY, Shi YQ. Lamb’s tripe extract and vitamin B12 capsule plus celecoxib reverses intestinal metaplasia and atrophy: A retrospective cohort study. World J Clin Cases 2021; 9(34): 10472-10483 [PMID: 35004979 DOI: 10.12998/wjcc.v9.i34.10472] [Reference Citation Analysis]
620 Kim JL, Kim SG, Lee A, Choi J, Chung H, Cho SJ. Long-term natural history after endoscopic resection for gastric dysplasia. Surg Endosc 2021;35:5247-55. [PMID: 32989550 DOI: 10.1007/s00464-020-08023-3] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
621 Choi Y, Kim N, Yun CY, Choi YJ, Yoon H, Shin CM, Park YS, Ahn SH, Joong Park D, Lee HS, Kim JW, Kim JW, Lee KW, Chang W, Park JH, Lee YJ, Lee KH, Kim YH, Lee DH, Kim HH. Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years. Gastric Cancer 2020;23:1051-63. [PMID: 32361784 DOI: 10.1007/s10120-020-01076-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
622 Choi YI, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, Seo JY. Tailored eradication vs empirical bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication: A comparative, open trial. World J Gastroenterol 2019; 25(46): 6743-6751 [PMID: 31857776 DOI: 10.3748/wjg.v25.i46.6743] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
623 Lee H, Kim BJ, Kim SG, Kim JI, Choi IJ, Lee YC, Kim JG, Kim JJ; Korean College of Helicobacter and Upper Gastrointestinal Research. Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial. Trials. 2017;18:549. [PMID: 29149904 DOI: 10.1186/s13063-017-2281-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
624 Zamani M, Vahedi A, Tamaddoni A, Bijani A, Bagherzade M, Shokri-Shirvani J. Relationship between β-Thalassemia minor and Helicobacter pylori infection. Caspian J Intern Med 2018;9:54-9. [PMID: 29387320 DOI: 10.22088/cjim.9.1.54] [Reference Citation Analysis]
625 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
626 Engevik AC, Kaji I, Goldenring JR. The Physiology of the Gastric Parietal Cell. Physiol Rev 2020;100:573-602. [PMID: 31670611 DOI: 10.1152/physrev.00016.2019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
627 Jung YD, Kim Y, Chung WC. A Pilot Study of Helicobacter pylori Eradication Using a Polymerase Chain Reaction-based Test for Clarithromycin Resistance. Korean J Helicobacter Up Gastrointest Res 2017;17:200. [DOI: 10.7704/kjhugr.2017.17.4.200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
628 Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475. [PMID: 29512258 DOI: 10.1111/hel.12475] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 25.5] [Reference Citation Analysis]
629 Ciccaglione AF, Di Giulio M, Di Lodovico S, Di Campli E, Cellini L, Marzio L. Bovine lactoferrin enhances the efficacy of levofloxacin-based triple therapy as first-line treatment of Helicobacter pylori infection: an in vitro and in vivo study. J Antimicrob Chemother 2019;74:1069-77. [PMID: 30668729 DOI: 10.1093/jac/dky510] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
630 Tang X, Chen X, Shen Y, Yang T, Hu R, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Primary antibiotic resistance of Helicobacter pylori among a Chinese Tibetan population. Future Microbiol 2020;15:1353-61. [PMID: 32900223 DOI: 10.2217/fmb-2020-0206] [Reference Citation Analysis]
631 Zagari RM, Romiti A, Ierardi E, Gravina AG, Panarese A, Grande G, Savarino E, Maconi G, Stasi E, Eusebi LH, Farinati F, Conigliaro R, Bazzoli F, Romano M. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. Helicobacter. 2018;23:e12502. [PMID: 29924430 DOI: 10.1111/hel.12502] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
632 Bordin DS, Voynovan IN, Embutnieks YV, Nyssen OP, Megraud F, O`morain C, Perez-gisbert J. European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow. Terapevticheskii arkhiv 2020;92:12-8. [DOI: 10.26442/00403660.2020.02.000567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
633 Luo L, Huang Y, Liang X, Ji Y, Yu L, Lu H. Susceptibility‐guided therapy for Helicobacter pylori ‐infected penicillin‐allergic patients: A prospective clinical trial of first‐line and rescue therapies. Helicobacter 2020;25. [DOI: 10.1111/hel.12699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
634 Bartels L, Pedersen A, Kristensen N, Jepsen P, Vilstrup H, Stengaard-pedersen K, Dahlerup J. Helicobacter pylori infection is not associated with rheumatoid arthritis. Scandinavian Journal of Rheumatology 2019;48:24-31. [DOI: 10.1080/03009742.2018.1464205] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
635 Scida S, Russo M, Miraglia C, Leandro G, Franzoni L, Meschi T, De' Angelis GL, Di Mario F. Relationship between Helicobacter pylori infection and GERD. Acta Biomed 2018;89:40-3. [PMID: 30561416 DOI: 10.23750/abm.v89i8-S.7918] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
636 Annibale B, Esposito G, Lahner E. A current clinical overview of atrophic gastritis. Expert Review of Gastroenterology & Hepatology 2020;14:93-102. [DOI: 10.1080/17474124.2020.1718491] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
637 Jaka H, Rüttgerodt N, Bohne W, Mueller A, Gross U, Kasang C, Mshana SE. Helicobacter pylori Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania. Can J Gastroenterol Hepatol 2019;2019:8481375. [PMID: 31355162 DOI: 10.1155/2019/8481375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
638 Sugimoto M, Murata M, Iwata E, Nagata N, Itoi T, Kawai T. Risk of Reflux-Related Symptoms and Reflux Esophagitis after Helicobacter pylori Eradication Treatment in the Japanese Population. J Clin Med 2021;10:1434. [PMID: 33916067 DOI: 10.3390/jcm10071434] [Reference Citation Analysis]
639 Nayebi A, Navashenaq JG, Soleimani D, Nachvak SM. Probiotic supplementation: A prospective approach in the treatment of COVID-19. Nutr Health 2021;:2601060211049631. [PMID: 34747257 DOI: 10.1177/02601060211049631] [Reference Citation Analysis]
640 Gidlöf S. Is the scalpel the greatest proof of the failure of medicine? Acta Obstet Gynecol Scand 2021;100:1755. [PMID: 34528712 DOI: 10.1111/aogs.14257] [Reference Citation Analysis]
641 Liu F, Yu J, Zhang YX, Li F, Liu Q, Zhou Y, Huang S, Fang H, Xiao Z, Liao L, Xu J, Wu XY, Wu F. High-throughput tandem-microwell assay for ammonia repositions FDA-Approved drugs to inhibit Helicobacter pylori urease. FASEB J 2021;35:e21967. [PMID: 34613630 DOI: 10.1096/fj.202100465RR] [Reference Citation Analysis]
642 Leja M, Camargo MC, Polaka I, Isajevs S, Liepniece-Karele I, Janciauskas D, Rudzite D, Kikuste I, Vanags A, Kojalo I, Folkmanis V, Kirsners A, Tolmanis I, Rabkin CS. Detection of gastric atrophy by circulating pepsinogens: A comparison of three assays. Helicobacter 2017;22. [PMID: 28557128 DOI: 10.1111/hel.12393] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
643 Chiang TH, Chiu SY, Chen SL, Yen AM, Fann JC, Liu CY, Chou CK, Chiu HM, Shun CT, Wu MS, Lin JT, Lee YC, Chen TH, Lin MW. Serum Pepsinogen as a Predictor for Gastric Cancer Death: A 16-Year Community-based Cohort Study. J Clin Gastroenterol. 2019;53:e186-e193. [PMID: 29369241 DOI: 10.1097/mcg.0000000000000992] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
644 Bluemel B, Goelz H, Goldmann B, Grüger J, Hamel H, Loley K, Ludolph T, Meyer J, Miehlke S, Mohr A, Tüffers K, Usadel H, Wagner S, Wenzel H, Wiemer L, Vorreiter J, Eisele B, Hofreuter D, Glocker EO. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect 2020;26:235-9. [PMID: 31212078 DOI: 10.1016/j.cmi.2019.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
645 Kim YM, Lee KH, Kim JH, Park SY, Song YG, Jeon SY, Park H. Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics (Basel) 2020;9:E589. [PMID: 32916937 DOI: 10.3390/antibiotics9090589] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
646 Debraekeleer A, Remaut H. Future perspective for potential Helicobacter pylori eradication therapies. Future Microbiology 2018;13:671-87. [DOI: 10.2217/fmb-2017-0115] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
647 Smith S, Jolaiya T, Fowora M, Palamides P, Ngoka F, Bamidele M, Lesi O, Onyekwere C, Ugiagbe R, Agbo I, Ndububa D, Adekanle O, Adedeji A, Adeleye I, Harrison U. Clinical and Socio- Demographic Risk Factors for Acquisition of Helicobacter pylori Infection in Nigeria. Asian Pac J Cancer Prev. 2018;19:1851-1857. [PMID: 30049197 DOI: 10.22034/apjcp.2018.19.7.1851] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
648 Fitzgerald R, Smith SM. An Overview of Helicobacter pylori Infection. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 1-14. [DOI: 10.1007/978-1-0716-1302-3_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
649 Pichon M, Burucoa C. Impact of the Gastro-Intestinal Bacterial Microbiome on Helicobacter-Associated Diseases. Healthcare (Basel). 2019;7. [PMID: 30813360 DOI: 10.3390/healthcare7010034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
650 Tshibangu-Kabamba E, Ngoma-Kisoko PJ, Tuan VP, Matsumoto T, Akada J, Kido Y, Tshimpi-Wola A, Tshiamala-Kashala P, Ahuka-Mundeke S, Ngoy DM, Disashi-Tumba G, Yamaoka Y. Next-Generation Sequencing of the Whole Bacterial Genome for Tracking Molecular Insight into the Broad-Spectrum Antimicrobial Resistance of Helicobacter pylori Clinical Isolates from the Democratic Republic of Congo. Microorganisms 2020;8:E887. [PMID: 32545318 DOI: 10.3390/microorganisms8060887] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
651 Cao Y, Zhang J, Liu Y, Zhang L, Wang L, Wang J, Qi Y, Lv H, Liu J, Huo L, Wei X, Shi Y. The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial. Medicine (Baltimore) 2021;100:e27923. [PMID: 34918639 DOI: 10.1097/MD.0000000000027923] [Reference Citation Analysis]
652 Gunnarsdottir AI, Gudjonsson H, Hardardottir H, Jonsdottir KD, Bjornsson ES. Antibiotic susceptibility of Helicobacter pylori in Iceland. Infect Dis (Lond) 2017;49:647-54. [PMID: 28440099 DOI: 10.1080/23744235.2017.1317359] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
653 Jeong SJ, Lee KH, Kim JH, Park SY, Song YG. Efficacy and Gut Dysbiosis of Gentamicin-Intercalated Smectite as a New Therapeutic Agent against Helicobacter pylori in a Mouse Model. Antibiotics (Basel) 2020;9:E502. [PMID: 32785101 DOI: 10.3390/antibiotics9080502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
654 Richter V, Gonzalez JO, Hazan S, Gottlieb G, Friedenberg K, Gatof D, Ganeshappa R, Delgado JS, Abramowitz D, Hardi R, Coates A, Haq M, Mehta N, Jones BA, Moss SF, Shirin H. The validity of breath collection bags method in detecting Helicobacter pylori using the novel BreathID ® Hp Lab System: a multicenter clinical study in 257 subjects. Ther Adv Gastrointest Endosc 2019;12:2631774519843401. [PMID: 31192315 DOI: 10.1177/2631774519843401] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
655 Dore MP, Cipolli A, Ruggiu MW, Manca A, Bassotti G, Pes GM. Helicobacter pylori eradication may influence timing of endoscopic surveillance for gastric cancer in patients with gastric precancerous lesions: A retrospective study. Medicine (Baltimore) 2018;97:e9734. [PMID: 29369216 DOI: 10.1097/MD.0000000000009734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
656 Rahim MAA, Johani FH, Shah SA, Hassan MR, Manaf MRA. 13 C-Urea Breath Test Accuracy for helicobacter pylori Infection in the Asian Population: A Meta-Analysis. Ann Glob Health. 2019;85:110. [PMID: 31348624 DOI: 10.5334/aogh.2570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
657 Boyanova L, Hadzhiyski P, Markovska R, Yaneva P, Yordanov D, Gergova G, Mitov I. Prevalence of Helicobacter pylori is still high among symptomatic Bulgarian children. AMicr 2018;66:255-60. [DOI: 10.1556/030.65.2018.053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
658 Komarov AL, Shahmatova OO, Korobkova VV, Kurilina EV, Shuleshova AG, Panchenko EP. Gastric mucosa condition in patients with coronary artery disease and high risk of gastrointestinal bleeding (register REGATTA-1). Terapevticheskii arkhiv 2022;93:1457-62. [DOI: 10.26442/00403660.2021.12.201224] [Reference Citation Analysis]
659 Xie Y, Zhang Z, Hong J, Liu W, Lu H, Du Y, Wang W, Xu J, Wang X, Huo L, Zhang G, Lan C, Li X, Li Y, Wang H, Zhang G, Zhu Y, Shu X, Chen Y, Wang J, Lu N; the Chinese Society of Gastroenterology Chinese Study Group on Helicobacter pylori. Furazolidone‐containing triple and quadruple eradication therapy for initial treatment for Helicobacter pylori infection: A multicenter randomized controlled trial in China. Helicobacter 2018;23:e12496. [DOI: 10.1111/hel.12496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
660 Canil AM, Iossa A, Termine P, Caporilli D, Petrozza V, Silecchia G. Histopathology Findings in Patients Undergoing Laparoscopic Sleeve Gastrectomy. Obes Surg 2018;28:1760-5. [PMID: 29305814 DOI: 10.1007/s11695-017-3092-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
661 Chautard R, Malka D, Samaha E, Tougeron D, Barbereau D, Caron O, Rahmi G, Barrioz T, Cellier C, Feau S, Lecomte T. Upper Gastrointestinal Lesions during Endoscopy Surveillance in Patients with Lynch Syndrome: A Multicentre Cohort Study. Cancers (Basel) 2021;13:1657. [PMID: 33916129 DOI: 10.3390/cancers13071657] [Reference Citation Analysis]
662 Nyssen OP, Pérez-Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Brglez Jurecic N, Huguet JM, Alcaide N, Voynovan I, María Botargues Bote J, Modolell I, Pérez Lasala J, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Marcos Pinto R, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, Shvets O, Venerito M, Bytzer P, Goldis A, Simsek I, Lamy V, Przytulski K, Kunovský L, Capelle L, Milosavljevic T, Caldas M, Garre A, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg). Helicobacter 2020;25:e12686. [PMID: 32173974 DOI: 10.1111/hel.12686] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
663 Hofreuter D, Behrendt J, Franz A, Meyer J, Jansen A, Bluemel B, Eisele B, Koken M, Glocker EO. Antimicrobial resistance of Helicobacter pylori in an eastern German region. Helicobacter 2021;26:e12765. [PMID: 33067911 DOI: 10.1111/hel.12765] [Reference Citation Analysis]
664 Brusselaers N, Engstrand L, Lagergren J. PPI use and oesophageal cancer: What if the results are true? Cancer Epidemiology 2018;54:139-40. [DOI: 10.1016/j.canep.2018.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
665 Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol 2020;55:1054-61. [PMID: 32930864 DOI: 10.1007/s00535-020-01723-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
666 Yuan Z, Xiao S, Li S, Suo B, Wang Y, Meng L, Liu Z, Yin Z, Xue Y, Zhou L. The impact of Helicobacter pylori infection, eradication therapy, and probiotics intervention on gastric microbiota in young adults. Helicobacter 2021;26:e12848. [PMID: 34448282 DOI: 10.1111/hel.12848] [Reference Citation Analysis]
667 Teufel A, Quante M, Kandulski A, Hirth M, Zhan T, Eckardt M, Thieme R, Kusnik A, Yesmembetov K, Wiest I, Riemann JF, Schlitt HJ, Gockel I, Malfertheiner P, Ebert MP. [Prevention of gastrointestinal cancer]. Z Gastroenterol 2021;59:964-82. [PMID: 34507375 DOI: 10.1055/a-1540-7539] [Reference Citation Analysis]
668 Chen HY, Hu Y, Lu NH, Zhu Y. Caudal type homeoboxes as a driving force in Helicobacter pylori infection-induced gastric intestinal metaplasia. Gut Microbes 2020;12:1-12. [PMID: 33031021 DOI: 10.1080/19490976.2020.1809331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
669 Graham DY, Dore MP. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology 2018;154:462-6. [DOI: 10.1053/j.gastro.2018.01.018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 10.8] [Reference Citation Analysis]
670 Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: The efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106-114. [PMID: 28497487 DOI: 10.1111/apt.14130] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 11.8] [Reference Citation Analysis]
671 Miftahussurur M, Doohan D, Syam AF, Nusi IA, Subsomwong P, Waskito LA, Maulahela H, Akil F, Uwan WB, Siregar G, Fauzia KA, Rezkitha YAA, Rahman A, Wibawa IDN, Saudale AMJ, Richardo M, Sugihartono T, Chomariyati A, Bramantoro T, Uchida T, Yamaoka Y. CYP2C19 Polymorphisms in Indonesia: Comparison among Ethnicities and the Association with Clinical Outcomes. Biology (Basel) 2021;10:300. [PMID: 33917299 DOI: 10.3390/biology10040300] [Reference Citation Analysis]
672 Doulberis M, Papaefthymiou A, Polyzos SA, Bargiotas P, Liatsos C, Srivastava DS, Zavos C, Katsinelos P, Kountouras J. Association between Active Helicobacter pylori Infection and Glaucoma: A Systematic Review and Meta-Analysis. Microorganisms 2020;8:E894. [PMID: 32545826 DOI: 10.3390/microorganisms8060894] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
673 Di J, Zhang J, Cao L, Huang TT, Zhang JX, Mi YN, Xiao X, Yan PP, Wu ML, Yao T, Liu DZ, Liu J, Cao YX. Hydrogen Peroxide-Mediated Oxygen Enrichment Eradicates Helicobacter pylori In Vitro and In Vivo. Antimicrob Agents Chemother 2020;64:e02192-19. [PMID: 32071054 DOI: 10.1128/AAC.02192-19] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
674 Contreras M, Benejat L, Mujica H, Peña J, García-amado M, Michelangeli F, Lehours P. Real-time PCR detection of a 16S rRNA single mutation of Helicobacter pylori isolates associated with reduced susceptibility and resistance to tetracycline in the gastroesophageal mucosa of individual hosts. Journal of Medical Microbiology 2019;68:1287-91. [DOI: 10.1099/jmm.0.001051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
675 Fukui H, Xu X, Miwa H. Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders. J Neurogastroenterol Motil 2018;24:367-86. [PMID: 29969855 DOI: 10.5056/jnm18071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
676 Kornoukhova LA, Emanuel VL, Denisov NL, Nikonov EL. Helicobacter pylori infection: place of serological and cultural diagnostics in clinical guidelines. Klin Lab Diagn 2021;66:496-501. [PMID: 34388321 DOI: 10.51620/0869-2084-2021-66-8-496-501] [Reference Citation Analysis]
677 Miftahussurur M, Doohan D, Nusi IA, Adi P, Rezkitha YAA, Waskito LA, Fauzia KA, Bramantoro T, Maimunah U, Thamrin H, Masithah SI, Sukadiono S, Uchida T, Lusida MI, Yamaoka Y. Gastroesophageal reflux disease in an area with low Helicobacter pylori infection prevalence. PLoS One 2018;13:e0205644. [PMID: 30427843 DOI: 10.1371/journal.pone.0205644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
678 Grad C, Pop A, Gaborean E, Grad S, Dumitrascu D. Value of GastroPanel in the diagnosis of atrophic gastritis. Exp Ther Med 2021;22:1347. [PMID: 34630701 DOI: 10.3892/etm.2021.10782] [Reference Citation Analysis]
679 Ribaldone DG, Astegiano M, Pellicano R. Helicobacter pylori eradication: poor medical compliance from East to West of the world. Scand J Gastroenterol 2018;53:265. [PMID: 29383955 DOI: 10.1080/00365521.2018.1433231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
680 Kumar S, Sangitha R, Nachamkin I, Metz DC. Resistance patterns of refractory H. pylori infection in a referral center in the Delaware Valley. GastroHep 2020;2:6-12. [PMID: 32377173 DOI: 10.1002/ygh2.382] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
681 Leja M, Park JY, Murillo R, Liepniece-Karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R. Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. BMJ Open 2017;7:e016999. [PMID: 28801429 DOI: 10.1136/bmjopen-2017-016999] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
682 Toyoshima O, Nishizawa T, Sakitani K, Yamakawa T, Takahashi Y, Kinoshita K, Torii A, Yamada A, Suzuki H, Koike K. Helicobacter pylori eradication improved the Kyoto classification score on endoscopy. JGH Open. 2020;4:909-914. [PMID: 33102763 DOI: 10.1002/jgh3.12360] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
683 Negovan A, Iancu M, Mocan S, Banescu C. Immunohistochemistry as confirmatory test for current Helicobacter pylori infection in patients treated with proton pump inhibitors. Eur J Intern Med 2018;50:e31-2. [PMID: 29203056 DOI: 10.1016/j.ejim.2017.11.013] [Reference Citation Analysis]
684 Baroni MR, Bucci P, Giani RN, Giusti A, Tedeschi FA, Salvatierra E, Barbaglia Y, Jimenez F, Zalazar FE. Usefulness of rapid urease test samples for molecular analysis of clarithromycin resistance in Helicobacter pylori. Revista Argentina de Microbiología 2018;50:359-64. [DOI: 10.1016/j.ram.2017.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
685 Arismendi Sosa AC, Salinas Ibáñez AG, Pérez Chaca MV, Penissi AB, Gómez NN, Vega AE. Inflammatory response induced by Helicobacter pylori infection in lung. Microb Pathog 2020;142:104103. [PMID: 32112810 DOI: 10.1016/j.micpath.2020.104103] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
686 Hall M, Wenner J, Scherman P, Öberg S. Intestinal metaplasia at the gastroesophageal junction is associated with gastroesophageal reflux but not with Helicobacter pylori infection. Scandinavian Journal of Gastroenterology 2018;53:1179-85. [DOI: 10.1080/00365521.2018.1526967] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
687 de Korwin JD. [Helicobacter pylori: When to look for an infection and treat it in adults?]. Rev Med Interne 2021;42:482-91. [PMID: 33648778 DOI: 10.1016/j.revmed.2020.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
688 Sugimoto M, Murata M, Mizuno H, Iwata E, Nagata N, Itoi T, Kawai T. Endoscopic Reflux Esophagitis and Reflux-Related Symptoms after Helicobacter pylori Eradication Therapy: Meta-Analysis. J Clin Med 2020;9:E3007. [PMID: 32961949 DOI: 10.3390/jcm9093007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
689 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Reference Citation Analysis]
690 Ribaldone DG, Astegiano M. Comment #2 on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin". Gastroenterol Res Pract 2018;2018:5260358. [PMID: 30647734 DOI: 10.1155/2018/5260358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
691 Nestegard O, Johnsen KM, Sørbye SW, Halvorsen FA, Tønnessen T, Paulssen EJ, Melby KK, Goll R, Florholmen J. Clinical characterization of Helicobacter pylori infected patients 15 years after unsuccessful eradication. PLoS One 2020;15:e0238944. [PMID: 32966303 DOI: 10.1371/journal.pone.0238944] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
692 Zhang L, Liu J, Meng F, Guan Y, Wang Y, Zhu S, Liu Y, Xie Q, Yu J, Zhang S. Pharmacokinetics of Bismuth following Oral Administration of Wei Bi Mei in Healthy Chinese Volunteers. Evid Based Complement Alternat Med 2020;2020:2679034. [PMID: 32855646 DOI: 10.1155/2020/2679034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
693 Puig I, Sanabria E, Feu F, Couto I, Blanco M, Alonso P, Gisbert JP, McNicholl AG, Seoane A, Bory F, Polo F, Orivé V, Ponce J, Borda F, Hervás A, Pérez-Aisa Á, Rivera R, Quintero E, Nicolás-Pérez D, Bujanda L, Rodrigo L, Calvet X; Spanish Gastroenterological Association Gastroduodenal Diseases Study Group. Heterogeneity of clinical management of low-grade gastric lymphoma of mucosa-associated lymphoid tissue. An audit of 198 patients in Spain. Gastroenterol Hepatol 2020;43:79-86. [PMID: 31787375 DOI: 10.1016/j.gastrohep.2019.08.012] [Reference Citation Analysis]
694 Chapelle N, Péron M, Quénéhervé L, Bourget A, Leroy M, Touchefeu Y, Cauchin E, Coron E, Mosnier JF, Matysiak-Budnik T. Long-Term Follow-up of Gastric Precancerous Lesions in a Low GC Incidence Area. Clin Transl Gastroenterol 2020;11:e00237. [PMID: 33512802 DOI: 10.14309/ctg.0000000000000237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
695 Shin SP, Bang CS, Lee JJ, Baik GH. Helicobacter pylori Infection in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Gut Liver 2019;13:628-41. [PMID: 30970438 DOI: 10.5009/gnl18517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
696 Alsohaibani F, Alquaiz M, Alkahtani K, Alashgar H, Peedikayil M, AlFadda A, Almadi M. Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia. Saudi J Gastroenterol 2020;26:84-8. [PMID: 32295933 DOI: 10.4103/sjg.SJG_626_19] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
697 Wang LM, Shang XJ. Therapeutic efficacy of pretreatment with compound Acidophilus lactob-acillus tablets followed by quadruple therapy in gastric ulcer patients with Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2018; 26(33): 1953-1958 [DOI: 10.11569/wcjd.v26.i33.1953] [Reference Citation Analysis]
698 Adriani A, Saracco GM, Pellicano R. Helicobacter pylori infection and dermatologic diseases: time to turn the page? G Ital Dermatol Venereol 2020;155:709-10. [PMID: 33228342 DOI: 10.23736/S0392-0488.20.06855-8] [Reference Citation Analysis]
699 Quach DT, Vilaichone RK, Vu KV, Yamaoka Y, Sugano K, Mahachai V. Helicobacter pylori Infection and Related Gastrointestinal Diseases in Southeast Asian Countries: An Expert Opinion Survey. Asian Pac J Cancer Prev. 2018;19:3565-3569. [PMID: 30583684 DOI: 10.31557/apjcp.2018.19.12.3565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
700 Toyoshima O, Nishizawa T, Sekiba K, Matsuno T, Kondo R, Watanabe H, Suzuki H, Tanikawa C, Koike K, Matsuda K. A single nucleotide polymorphism in Prostate Stem Cell Antigen is associated with endoscopic grading in Kyoto classification of gastritis. J Clin Biochem Nutr. 2020;. [PMID: 33536715 DOI: 10.3164/jcbn.20-67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
701 Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
702 Yang L, Zhang J, Xu J, Wei X, Yang J, Liu Y, Li H, Zhao C, Wang Y, Zhang L, Gai Z. Helicobacter pylori Infection Aggravates Dysbiosis of Gut Microbiome in Children With Gastritis. Front Cell Infect Microbiol 2019;9:375. [PMID: 31781514 DOI: 10.3389/fcimb.2019.00375] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
703 Cosme A, Torrente Iranzo S, Montes Ros M, Fernández-reyes Silvestre M, Alonso Galán H, Lizasoain J, Bujanda L. Helicobacterpylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies: XXXX. Helicobacter 2019;24:e12557. [DOI: 10.1111/hel.12557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
704 Miftahussurur M, Fauzia KA, Nusi IA, Setiawan PB, Syam AF, Waskito LA, Doohan D, Ratnasari N, Khomsan A, Adnyana IK, Akada J, Yamaoka Y. E-test versus agar dilution for antibiotic susceptibility testing of Helicobacter pylori: a comparison study. BMC Res Notes 2020;13:22. [PMID: 31924273 DOI: 10.1186/s13104-019-4877-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
705 Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology 2021;161:495-507.e4. [PMID: 33839101 DOI: 10.1053/j.gastro.2021.04.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
706 Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, Kao JY, Dai N, Si JM. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol 2018; 24(40): 4596-4605 [PMID: 30386109 DOI: 10.3748/wjg.v24.i40.4596] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
707 Gemilyan M, Hakobyan G, Benejat L, Allushi B, Melik-Nubaryan D, Mangoyan H, Laur A, Daguerre E, Grigoryan E, Megraud F. Prevalence of Helicobacter pylori infection and antibiotic resistance profile in Armenia. Gut Pathog 2019;11:28. [PMID: 31182977 DOI: 10.1186/s13099-019-0310-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
708 Mi M, Wu F, Zhu J, Liu F, Cui G, Wen X, Hu Y, Deng Z, Wu X, Zhang Z, Qi T, Chen Z. Heterogeneity of Helicobacter pylori Strains Isolated from Patients with Gastric Disorders in Guiyang, China. Infect Drug Resist 2021;14:535-45. [PMID: 33603417 DOI: 10.2147/IDR.S287631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
709 Rodríguez Gómez ER, Otero Regino W, Monterrey PA, Trespalacios Rangel AA. cagA gene EPIYA motif genetic characterization from Colombian Helicobacter pylori isolates: Standardization of a molecular test for rapid clinical laboratory detection. PLoS One 2020;15:e0227275. [PMID: 31923209 DOI: 10.1371/journal.pone.0227275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
710 Xie Y, Song C, Cheng H, Xu C, Zhang Z, Wang J, Huo L, Du Q, Xu J, Chen Y, Zhang X, Zhang G, Yang G, Zuo X, Guo T, Lu Y, Wang F, Wang X, Zhuang K, Chen S, Liu W, Lu N; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Long-term follow-up of Helicobacter pylori reinfection and its risk factors after initial eradication: a large-scale multicentre, prospective open cohort, observational study. Emerg Microbes Infect 2020;9:548-57. [PMID: 32160805 DOI: 10.1080/22221751.2020.1737579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
711 Choi JH, Yang YJ, Bang CS, Lee JJ, Baik GH. Current Status of the Third-Line Helicobacter pylori Eradication. Gastroenterol Res Pract 2018;2018:6523653. [PMID: 29853863 DOI: 10.1155/2018/6523653] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
712 Mao LQ, Zhou YL, Wang SS, Chen L, Hu Y, Yu LM, Xu JM, Lyu B. Impact of Helicobacter pylori eradication on the gastric microbiome. Gut Pathog 2021;13:60. [PMID: 34645495 DOI: 10.1186/s13099-021-00460-2] [Reference Citation Analysis]
713 Tepeš B, Malfertheiner P, Labenz J, Aygen S. Modified Helicobacter test using a new test meal and a 13C-urea breath test in Helicobacter pylori positive and negative dyspepsia patients on proton pump inhibitors. World J Gastroenterol 2017; 23(32): 5954-5961 [PMID: 28932087 DOI: 10.3748/wjg.v23.i32.5954] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]